<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7918405</article-id><article-id pub-id-type="doi">10.3390/ph14020157</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-14-00157</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Status and Challenges of Plant-Anticancer Compounds in Cancer Treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4058-3709</contrib-id><name><surname>Garcia-Oliveira</surname><given-names>Paula</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00157">1</xref><xref ref-type="aff" rid="af2-pharmaceuticals-14-00157">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5164-3004</contrib-id><name><surname>Otero</surname><given-names>Paz</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00157">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4095-7857</contrib-id><name><surname>Pereira</surname><given-names>Antia Gonzalez</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00157">1</xref><xref ref-type="aff" rid="af2-pharmaceuticals-14-00157">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2930-2531</contrib-id><name><surname>Chamorro</surname><given-names>Franklin</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00157">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4819-7856</contrib-id><name><surname>Carpena</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00157">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1994-0436</contrib-id><name><surname>Echave</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00157">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5663-9239</contrib-id><name><surname>Fraga-Corral</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00157">1</xref><xref ref-type="aff" rid="af2-pharmaceuticals-14-00157">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9215-9737</contrib-id><name><surname>Simal-Gandara</surname><given-names>Jesus</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00157">1</xref><xref rid="c1-pharmaceuticals-14-00157" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3513-0054</contrib-id><name><surname>Prieto</surname><given-names>Miguel Angel</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00157">1</xref><xref rid="c1-pharmaceuticals-14-00157" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Santos</surname><given-names>Paulo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-14-00157"><label>1</label>Nutrition and Bromatology Group, Analytical and Food Chemistry Department, Faculty of Food Science and Technology, University of Vigo, Ourense Campus, E-32004 Ourense, Spain; <email>paula.garcia.oliveira@uvigo.es</email> (P.G.-O.); <email>pazoterofuertes@gmail.com</email> (P.O.); <email>antia.gonzalez.pereira@uvigo.es</email> (A.G.P.); <email>chamorro1984@gmail.com</email> (F.C.); <email>maria.carpena.rodriguez@uvigo.es</email> (M.C.); <email>ecalja@outlook.es</email> (J.E.); <email>mfraga@uvigo.es</email> (M.F.-C.)</aff><aff id="af2-pharmaceuticals-14-00157"><label>2</label>Centro de Investiga&#x000e7;&#x000e3;o de Montanha (CIMO), Campus de Santa Apolonia, Instituto Polit&#x000e9;cnico de Bragan&#x000e7;a, 5300-253 Bragan&#x000e7;a, Portugal</aff><author-notes><corresp id="c1-pharmaceuticals-14-00157"><label>*</label>Correspondence: <email>jsimal@uvigo.es</email> (J.S.-G.); <email>mprieto@uvigo.es</email> (M.A.P.)</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>2</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2021</year></pub-date><volume>14</volume><issue>2</issue><elocation-id>157</elocation-id><history><date date-type="received"><day>31</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>06</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Nowadays, cancer is one of the deadliest diseases in the world, which has been estimated to cause 9.9 million deaths in 2020. Conventional treatments for cancer commonly involve mono-chemotherapy or a combination of radiotherapy and mono-chemotherapy. However, the negative side effects of these approaches have been extensively reported and have prompted the search of new therapeutic drugs. In this context, scientific community started to look for innovative sources of anticancer compounds in natural sources, including traditional plants. Currently, numerous studies have evaluated the anticancer properties of natural compounds derived from plants, both in vitro and in vivo. In pre-clinical stages, some promising compounds could be mentioned, such as the sulforaphane or different phenolic compounds. On the other hand, some phytochemicals obtained positive results in clinical stages and were further approved for cancer treatment, such as vinca alkaloids or the paclitaxel. Nevertheless, these compounds are not exempt of limitations, such as low solubility, restricted effect on their own, negative side-effects, etc. This review aims to compile the information about the current phytochemicals used for cancer treatment and also promising candidates, main action mechanisms and also reported limitations. In this sense, some strategies to face the limitations have been considered, such as nano-based formulations to improve solubility or chemical modification to reduce toxicity. In conclusion, although more research is still necessary to develop more efficient and safe phytochemical drugs, more of these compounds might be used in future cancer therapies.</p></abstract><kwd-group><kwd>natural compounds</kwd><kwd>traditional plants</kwd><kwd>anticancer</kwd><kwd>clinical/pre-clinical studies</kwd><kwd>challenges</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-14-00157"><title>1. Introduction </title><p>Cancer is one of the deadliest diseases globally and especially in western countries. According to the International Cancer Observatory, roughly 9.9 million people have died in 2020 as a result of developing cancer [<xref rid="B1-pharmaceuticals-14-00157" ref-type="bibr">1</xref>]. Cancer is a complex disease, generally defined as an uncontrolled proliferation and development of cells in tissues forming an amalgamation and microenvironment (tumor) that may potentially expand to a whole organ or systemically to other tissues (metastasis) [<xref rid="B2-pharmaceuticals-14-00157" ref-type="bibr">2</xref>]. This abnormal cell behavior may be the result of hereditary genetics, or an epigenetic-driven alteration of key genes (oncogenes) related to the cell cycle and regulation of cell death (apoptosis) [<xref rid="B3-pharmaceuticals-14-00157" ref-type="bibr">3</xref>]. Cancerous cells are also characterized by dysregulation of programmed apoptosis and aberrant behavior of microtubules, as they are involved in the mitotic process [<xref rid="B3-pharmaceuticals-14-00157" ref-type="bibr">3</xref>]. The World Health Organization identifies as main causes behind the development of cancer random somatic mutations, ionizing radiation, reactive oxidative species as well as several chemical and biological agents [<xref rid="B4-pharmaceuticals-14-00157" ref-type="bibr">4</xref>]. Except for random mutations, these are widely recognized exogenous carcinogens. Ionizing radiation is able to disrupt the hydrogen bonds between nucleic acids as well as altering their chemical conformation, which may yield alterations in normal DNA expression regulation [<xref rid="B5-pharmaceuticals-14-00157" ref-type="bibr">5</xref>]. Infectious diseases caused by bacteria, fungi or viruses have also been significantly correlated with developing cancer afterward in the same affected tissues. Well-established associations between infections and cancer are viruses like human papillomavirus to cervix cancer, <italic>Herpesvirus</italic> to Kaposi&#x02019;s sarcoma or Hepatitis B and C to liver cancer. In the same sense, bacterial infections by <italic>Helycobacter pylori</italic> are linked to gastric cancer or the genus <italic>Salmonella</italic> to colon or gallbladder cancer development post-infection [<xref rid="B6-pharmaceuticals-14-00157" ref-type="bibr">6</xref>]. Viruses that integrate their genetic material into the host may alter normal expression of genes related to cell division or even induce expression of oncogenes that could derive into oncogenesis. Some examples of these are the integration of Hepatitis B virus into telomeres, as well as genes coding for proteins X and S, which induce inflammation and neoplasia; or Human Papilomavirus integration in oncogenes E6 and E7 in the cell genome, which suppress the p53 anti-tumor gene and promote cell proliferation while simultaneously alters cell-to-cell adhesion [<xref rid="B7-pharmaceuticals-14-00157" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-14-00157" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceuticals-14-00157" ref-type="bibr">9</xref>]. These oncogenes have been related to increased release of inflammatory mediators like necrosis factor kappaB (Nf-&#x003ba;B) or Activator protein-1 (AP-1) [<xref rid="B8-pharmaceuticals-14-00157" ref-type="bibr">8</xref>]. Conversely, bacterial infections may elicit the release of toxins with cytotoxic activity and the disruption of the tissue cell matrix. Known examples are enteric toxins from <italic>S. typhi</italic> or CagA and vacuolating toxins of <italic>H. pylori</italic>, which may induce cell death, neoplasia, and also alterations in the normal cell metabolism [<xref rid="B10-pharmaceuticals-14-00157" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceuticals-14-00157" ref-type="bibr">11</xref>]. Other infectious pathogens like fungi and parasitic helminths that produce direct or toxin-mediated tissular damage are also accounted as oncogenic agents [<xref rid="B12-pharmaceuticals-14-00157" ref-type="bibr">12</xref>]. Aside from specific genetic alterations, the main recognized tumor-inducing mechanism of biological agents is tissue inflammation as a result of cell damage and subsequent neoplasia which, if unchecked, can result in potential chronic inflammation of the affected tissues (e.g., hepatic cirrhosis by Hepatitis virus) [<xref rid="B7-pharmaceuticals-14-00157" ref-type="bibr">7</xref>,<xref rid="B13-pharmaceuticals-14-00157" ref-type="bibr">13</xref>]. Regarding reactive oxygen species, like hydroxide peroxide or hydroxyl radical, which are normal metabolic products but also arise from contact with oxygen, they are described to provoke damage and alterations of the cell membranes, lipids or DNA [<xref rid="B14-pharmaceuticals-14-00157" ref-type="bibr">14</xref>]. Indeed, reactive oxygen species have been identified to increase in tumorous cells, enhancing their proliferation and survivability [<xref rid="B15-pharmaceuticals-14-00157" ref-type="bibr">15</xref>]. Nonetheless, the common factor besides possible genetic alterations by oxidative stress, infections and ultraviolet radiation is the associated inflammatory response [<xref rid="B12-pharmaceuticals-14-00157" ref-type="bibr">12</xref>,<xref rid="B14-pharmaceuticals-14-00157" ref-type="bibr">14</xref>]. On this matter, chronic inflammation is considered both cause and symptom of other ailments, but particularly of cancer, as tumorous cells secrete several pro-inflammatory molecules [<xref rid="B16-pharmaceuticals-14-00157" ref-type="bibr">16</xref>]. For example, it is well known that the pro-inflammatory mediator cyclooxygenase-2 (COX-2) is overexpressed in several types of cancer. As such, pro-inflammatory mediators are markers of cancer and could be also a possible target for anticancer therapies [<xref rid="B17-pharmaceuticals-14-00157" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-14-00157" ref-type="bibr">18</xref>]. Considering chemical carcinogens aside from potential hazardous substances, the main carcinogens originate in diet. Major chemical carcinogens include polycyclic aromatic hydrocarbons (PAHs), N-nitroso compounds, heterocyclic amines (HCAs) and alcohol. PAHs like anthracene appear in combustion reactions, and are reported in grilled or smoked foods, as well as being part of urban air pollution. They are linked to lung and digestive tract cancer [<xref rid="B19-pharmaceuticals-14-00157" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceuticals-14-00157" ref-type="bibr">20</xref>]. Closely related in their effects and occurrence, HCAs like 2-Amino-1-methyl-6-phenylimidazo [4,5-b]pyridine are the result of pyrolysis of proteins and amino acids in meat or fish foods [<xref rid="B21-pharmaceuticals-14-00157" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-14-00157" ref-type="bibr">22</xref>]. It is worth mentioning that tobacco is reported to contain high levels of PAHs and HCAs, linking them to the pro-carcinogen effects of tobacco consumption [<xref rid="B23-pharmaceuticals-14-00157" ref-type="bibr">23</xref>]. N-nitroso compounds are additives in processed meats and include nitrites and nitrosamines like N-nitrosedimethylamine that have been correlated to gastric cancer development [<xref rid="B24-pharmaceuticals-14-00157" ref-type="bibr">24</xref>]. Ethanol as well as other alcohols present in beverages and spirits induce many metabolic and endocrine disorders along with being highly cytotoxic chemicals and attributed to cause many types of cancers [<xref rid="B25-pharmaceuticals-14-00157" ref-type="bibr">25</xref>]. Altogether, it should be considered that a variety of exogenous carcinogens from different sources can heavily prompt cancer development (<xref ref-type="fig" rid="pharmaceuticals-14-00157-f001">Figure 1</xref>).</p><p>Cancer not only displays heterogeneous cell and tissue-specific behavior, depending on the onset, inducer and individual genetic profile, but also an unpredictable and diverse evolution that hinders its treatment [<xref rid="B26-pharmaceuticals-14-00157" ref-type="bibr">26</xref>]. Conventional cancer treatment approach commonly involves chemotherapy, radiotherapy and surgery [<xref rid="B27-pharmaceuticals-14-00157" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-14-00157" ref-type="bibr">28</xref>]. Regarding chemotherapeutics, their effect is cytostatic, acting through shifting the expression of cell cycle mediators, disruption of microtubules, or inducers of apoptosis. However, as radiotherapy and chemotherapy do not discriminate between normal and cancer cells, their application is paired with certain side effects, ranging from mild gastrointestinal alterations and nausea to severe gut mucosa dysfunction, cardiovascular toxicity or immunity disorders [<xref rid="B29-pharmaceuticals-14-00157" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceuticals-14-00157" ref-type="bibr">30</xref>]. These side effects, which can linger for long periods after treatment, pose a major issue when selecting and applying therapeutics.</p><p>The ever-growing interest in the search of new therapeutic compounds against cancer has pushed researchers to look for innovative sources of anticancer compounds in natural sources, including plants [<xref rid="B31-pharmaceuticals-14-00157" ref-type="bibr">31</xref>]. Traditionally, plants have been used in all cultures for healing diverse diseases and improve well-being [<xref rid="B32-pharmaceuticals-14-00157" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceuticals-14-00157" ref-type="bibr">33</xref>]. Further research demonstrated that traditional-used plants contain bioactive compounds, which administered in sufficient doses, have positive effects on health. These effects are attributed to the biological properties of the compounds, such as antioxidant, anti-inflammatory, antimicrobial and also anticancer. Nowadays, the potential of plants as sources of anticancer compounds is both well recorded in traditional medicine and experimental findings [<xref rid="B34-pharmaceuticals-14-00157" ref-type="bibr">34</xref>]. In several cases, phytochemical compounds have been directly employed or chemically modified to develop chemicals used in modern medicine, including anticancer drugs. According with the Food and Drug Administration (FDA), more than the 60% of the drugs employed in cancer treatment are obtained from natural resources [<xref rid="B32-pharmaceuticals-14-00157" ref-type="bibr">32</xref>]. In <xref ref-type="fig" rid="pharmaceuticals-14-00157-f002">Figure 2</xref>, a schematic process for the development of anticancer drugs based on phytochemical compounds is presented. Briefly, this process starts with the extraction from plants and the testing of the extracts to evaluate their anticancer potential. Bioactive compounds of the extract are identified, purified and tested in pre-clinical studies, (both in vitro cell cultures and in vivo animal models) and later clinical trials in humans [<xref rid="B35-pharmaceuticals-14-00157" ref-type="bibr">35</xref>]. In these studies, some factors such efficacy, induced tumorigenic changes, possible side effects and toxicity factors must be deeply characterized [<xref rid="B30-pharmaceuticals-14-00157" ref-type="bibr">30</xref>]. Vinka alkaloids, taxanes, and camptothecin are some examples of compounds that are currently clinically employed.</p><p>In general, plant-anticancer compounds have been considered a possible option to develop new chemotherapeutics and also to enhance the effectivity of the conventional ones [<xref rid="B36-pharmaceuticals-14-00157" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceuticals-14-00157" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-14-00157" ref-type="bibr">38</xref>]. Nevertheless, these compounds present many drawbacks, such as low stability or solubility, difficulty to be extracted from natural sources and even negative side effects [<xref rid="B39-pharmaceuticals-14-00157" ref-type="bibr">39</xref>]. Thus, the application of these compounds still has to face several challenges and further research is necessary. In this review, current information about phytochemical compounds currently employed clinically in cancer treatment and also promising compounds in pre-clinical and clinical level will be addressed. In addition, the main challenges lying facing the use of these compounds as therapeutic agents and possible strategies to solve them will be described.</p></sec><sec id="sec2-pharmaceuticals-14-00157"><title>2. Phytochemicals Currently Used in Cancer Therapy</title><p>Along the last decade, many works have compiled ethnomedicinal and ethnopharmacological uses of very different plant species. Numerous experimental works based on the evaluation through in vitro and in vivo assays have confirmed the therapeutic application of many natural compounds, which have been later included as part of approved treatments, including in anticancer agents (<xref ref-type="fig" rid="pharmaceuticals-14-00157-f003">Figure 3</xref>) [<xref rid="B40-pharmaceuticals-14-00157" ref-type="bibr">40</xref>].</p><p>This section summarizes current available information regarding the clinical status of the main plant compounds proposed for cancer treatment. Vinka alkaloids, taxanes, camptothecin derivatives, podophyllotoxin and derivatives and roscovitine are the most used in clinical studies. <xref rid="pharmaceuticals-14-00157-t001" ref-type="table">Table 1</xref> collects an overview of the data supporting the development of plant compounds as anticancer agents, including clinical trials and clinical uses.</p><sec><title>2.1. Vinca Alkaloids</title><p>The vinca alkaloids is a large group of about 130 terpenoid indole alkaloids, naturally found in <italic>Catharanthus roseus</italic> leaves [<xref rid="B31-pharmaceuticals-14-00157" ref-type="bibr">31</xref>]. These compounds were one of the first plant alkaloids used in the development of anticancer drugs. Currently, several vinca alkaloids are in clinical use for cancer treatment: vinblastine, vincristine and also semi-synthetic derivatives, such as vinorelbine, vindesine, or vinflunine [<xref rid="B45-pharmaceuticals-14-00157" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceuticals-14-00157" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceuticals-14-00157" ref-type="bibr">47</xref>]. These compounds are considered small tubulin-binding molecules. The interaction with the tubulin proteins in the mitotic spindle avoids its polymerization into microtubules, inhibiting the cell mitosis. Thus, the cells remain in a prolonged arrest phase and finally die [<xref rid="B48-pharmaceuticals-14-00157" ref-type="bibr">48</xref>]. Vincristine has been demonstrated to possess highest affinity for tubulin than vinblastine, and even than the vinca derivatives vindesine and vinorelbine [<xref rid="B47-pharmaceuticals-14-00157" ref-type="bibr">47</xref>,<xref rid="B49-pharmaceuticals-14-00157" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceuticals-14-00157" ref-type="bibr">50</xref>]. The dimeric nature of these alkaloids has been described to act through two ways. Vindoline moiety has been proposed to bind the &#x003b2;-subunit of tubulin heterodimers, which ultimately inhibits mitosis and leads to apoptosis. Catharanthine moiety has less potent effect on &#x003b1;/&#x003b2;-tubulin polymerization. However, different genes have been demonstrated to be sensitive to this molecule, such as those related with cell-to-cell signaling and interaction, which may be related with its capacity to induce cytotoxic effects [<xref rid="B51-pharmaceuticals-14-00157" ref-type="bibr">51</xref>].</p><p>In the 60s, Food and Drug Administration (FDA) approved the clinical application of vinblastine and vincristine, becoming very incipient plant-derived anticancer agents [<xref rid="B40-pharmaceuticals-14-00157" ref-type="bibr">40</xref>], usually combined with other compounds [<xref rid="B52-pharmaceuticals-14-00157" ref-type="bibr">52</xref>]. Vinblastine has been used in for the treatment of Hodgkin&#x02019;s disease, apart from testicular carcinoma, breast cancer and germ cell tumors [<xref rid="B53-pharmaceuticals-14-00157" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceuticals-14-00157" ref-type="bibr">54</xref>]. In a small phase II study of thalidomide and vinblastine in chemotherapy- refractory Hodgkin&#x02019;s Lymphoma, both drugs demonstrated encouraging activity with some durable responses and acceptable toxicity [<xref rid="B55-pharmaceuticals-14-00157" ref-type="bibr">55</xref>]. In another phase II study carried out from 2001 to 2003 with patients posing advanced solid tumors, it was observed that the combination of daily cyclophosphamide and weekly vinblastine, administered concurrently with daily rofecoxib, provided moderate anticancer activity [<xref rid="B56-pharmaceuticals-14-00157" ref-type="bibr">56</xref>]. Moreover, the use of neoadjuvant chemotherapy with cisplatin, methotrexate, and vinblastine in patients with muscle-invasive urothelial bladder cancer treated by cystectomy and/or radiotherapy has been internationally investigated with 966 patients in the early 1990s [<xref rid="B57-pharmaceuticals-14-00157" ref-type="bibr">57</xref>]. The results showed that chemotherapy with cisplatin, methotrexate, and vinblastine improves outcome as first-line adjunctive treatment for invasive bladder cancer. Vinblastine was approved in Europe in 2009 for second-line treatment of metastatic and advanced urothelial cancer after failure of therapy with platin. Since then, the medicine was used in some clinical trials with successful results [<xref rid="B58-pharmaceuticals-14-00157" ref-type="bibr">58</xref>]. Vincristine has been used in chemotherapy in adults and children for treating acute leukemia but it has been also applied to treat rhabdomyosarcoma, neuroblastoma, Wilm&#x02019;s tumor, Hodgkin&#x02019;s disease and other lymphomas. Besides, it represents a treatment for non-malignant hematologic disorders like autoimmune and thrombotic thrombocytopenia, and hemolytic uremic syndrome.</p></sec><sec id="sec2dot2-pharmaceuticals-14-00157"><title>2.2. Paclitaxel</title><p>In this group of molecules, the most recognized compound is paclitaxel, one of the most effective and promising therapeutic drugs available against a wide range of cancers. This compound has been identified in different species of the genus <italic>Taxus</italic> such as <italic>Taxus brevifolia</italic>, <italic>T. baccata</italic>, <italic>T. media</italic> or <italic>T. cuspidate</italic> [<xref rid="B59-pharmaceuticals-14-00157" ref-type="bibr">59</xref>]. It is an anti-neoplastic agent which acts as a microtubule&#x02019;s stabilizer and mitosis inhibitor. Its main antitumor effect is derived from the compound binding the &#x003b2;-sub-unit of tubulin, which inhibits the microtubule depolymerization into tubulin and stops the cell cycle in the G2/M phase, leading to cell death [<xref rid="B60-pharmaceuticals-14-00157" ref-type="bibr">60</xref>].</p><p>FDA first approved Taxol<sup>&#x000ae;</sup> for the treatment of ovarian cancer in 1992. Nowadays, the human prescription indications and uses of this drug comprise Kaposi&#x02019;s Sarcoma, breast cancer, ovarian cancer, microcytic lung malignant neoplasm. In addition, it is often used to treat several cancers including oesophageal, bladder, prostate, cervical, gastric, head, neck and testicular cancers [<xref rid="B61-pharmaceuticals-14-00157" ref-type="bibr">61</xref>]. Nevertheless, paclitaxel has few drawbacks, such as low hydrosolubility, present side-effect and patients can develop resistance to the drug. Among them, the development of multidrug resistance that has limited its therapeutic efficacy has been not totally explained, although few potential mechanisms have been suggested, like &#x003b1;-/&#x003b2;-tubulin mutations and/or alterations in the binding regions [<xref rid="B54-pharmaceuticals-14-00157" ref-type="bibr">54</xref>].</p></sec><sec id="sec2dot3-pharmaceuticals-14-00157"><title>2.3. Camptothecin and Irinotecan</title><p>Camptothecin is a natural compound with potent antitumor activity, isolated in 1966 from the bark of Camptothecin acuminata. This molecule binds to the TOP1 cleavage complex, leading to an accumulation of DNA strand breaks during replication, causing apoptosis in the S phase of the cell cycle [<xref rid="B62-pharmaceuticals-14-00157" ref-type="bibr">62</xref>]. The use of camptothecin in clinical applications has shown some limitations derived from its poor solubility and stability [<xref rid="B63-pharmaceuticals-14-00157" ref-type="bibr">63</xref>]. For this reason, several stable derivatives are currently under study in clinical trials, from which only two can be used in clinical studies by the US Federal Drug Administration. One of them is irinotecan, approved in 1996 as a therapy agent for refractory colorectal carcinoma [<xref rid="B64-pharmaceuticals-14-00157" ref-type="bibr">64</xref>]. This compound is now widely used to treat other types of cancer, including lung, although the dose limiting toxicity of this antitumor agent includes diarrhea, neutropenia and severe leukopenia [<xref rid="B65-pharmaceuticals-14-00157" ref-type="bibr">65</xref>]. The second compound is Topotecan, approved in 2007 as a secondary agent for therapy of ovarian cancer or small cell lung cancer [<xref rid="B66-pharmaceuticals-14-00157" ref-type="bibr">66</xref>]. However, some studies have revealed that therapeutic use of irinotecan is limited due to its hydrophobicity, low stability at physiologic pH, and side effects.</p></sec><sec id="sec2dot4-pharmaceuticals-14-00157"><title>2.4. Podophyllotoxin and Analogues</title><p>Podophyllotoxin is an important plant-derived natural product isolated from <italic>Podophyllum peltatum</italic> and <italic>Podophyllum emodi</italic> [<xref rid="B35-pharmaceuticals-14-00157" ref-type="bibr">35</xref>]. It has a lignan as interesting molecule, which can be semisynthesized commercially, showing antitumor activity against different types of cancers, such as cervical carcinoma, osteosarcoma, nasopharyngeal carcinoma, colon cancer, breast cancer, prostate cancer, small cell lung cancer and testicular carcinoma [<xref rid="B67-pharmaceuticals-14-00157" ref-type="bibr">67</xref>]. The mechanism of action of podophyllotoxin is related to the blockage of cell division in the metaphase of mitosis due to the inhibition of microtubule assembly in the mitotic apparatus [<xref rid="B35-pharmaceuticals-14-00157" ref-type="bibr">35</xref>]. However, their derivatives etoposide and teniposide are not inhibitors of microtubule assembly, but act via interaction with DNA and inhibition of DNA topoisomerase II [<xref rid="B35-pharmaceuticals-14-00157" ref-type="bibr">35</xref>].</p><p>The initially clinical use of podophyllotoxin was declined rapidly, due to its unacceptable side effects, including nausea, vomiting, and damage to normal tissues [<xref rid="B68-pharmaceuticals-14-00157" ref-type="bibr">68</xref>]. However, due to its remarkable inhibitory effect on tumor cell growth and extensive use in traditional medicine, podophyllotoxin has constituted an important starting point in the development of three of the most highly prescribed anticancer agents worldwide: etoposide, teniposide, and the water-soluble prodrug etoposide phosphate [<xref rid="B68-pharmaceuticals-14-00157" ref-type="bibr">68</xref>]. The podophyllotoxin derivatives are gaining attention for clinically trials having wider use of podophyllotoxin scaffolds in medicine. In a randomized clinical trial, the effects of podophyllotoxin on anogenital warts with imiquimod 5% cream were compared. The study led to the conclusion of a strong inhibitory effect on warts growth in patients treated with podophyllotoxin versus patients treated with imiquimod cream [<xref rid="B69-pharmaceuticals-14-00157" ref-type="bibr">69</xref>].</p></sec><sec id="sec2dot5-pharmaceuticals-14-00157"><title>2.5. Roscovitine</title><p>The agent Roscovitine (generic name Seliciclib) is a purine-based anticancer compound, isolated from the cotyledons of <italic>Raphanus sativus</italic> L. (Brassicaceae) [<xref rid="B31-pharmaceuticals-14-00157" ref-type="bibr">31</xref>]. This compound is a potent inhibitor of cyclin-dependent kinases (CDK) CDK1, CDK2, CDK5, CDK7, CDK9 and CDK12, through direct competition at the ATP-binding site [<xref rid="B70-pharmaceuticals-14-00157" ref-type="bibr">70</xref>,<xref rid="B71-pharmaceuticals-14-00157" ref-type="bibr">71</xref>]. As an inhibitor of the CDK family, roscovitine has an important impact upon several fundamental processes in cells [<xref rid="B72-pharmaceuticals-14-00157" ref-type="bibr">72</xref>]. CDK1 and 2 are involved in the control of the initiation and progression of cellular division. Then, the inhibition of these kinases leads to the reduction of the cell proliferation. The inhibition of CDK7, CDK9 and CDK12 results in downregulation of a large number of genes [<xref rid="B71-pharmaceuticals-14-00157" ref-type="bibr">71</xref>]. This compound has been tested in several phase I and II clinical trials showing its anticancer activity. Roscovitine was used in phase I clinical trial against glomerulonephritis, in phase II clinical testing against lung and breast cancer and currently, it is in a phase II clinical trial in patients with Cushing disease [<xref rid="B73-pharmaceuticals-14-00157" ref-type="bibr">73</xref>]. Roscovitine has also been tested in a phase I trial in combination with gemcitabine and cisplatin in non-small cell lung cancer patients and the results revealed that the 70% of the patients with nasopharyngeal tumors showed stable disease during the study [<xref rid="B72-pharmaceuticals-14-00157" ref-type="bibr">72</xref>]. Another example supporting the anticancer activity of this molecule is a phase I trial study in which roscovitine was orally administrated to patients with refractory solid tumors. In this case, although no tumor reductions were observed, roscovitine induced a stable disease in some patients [<xref rid="B72-pharmaceuticals-14-00157" ref-type="bibr">72</xref>]. Other studies in vivo revealed that roscovitine causes significant selective DNA damage in head and neck cancer cells and in human papilloma virus-positive (but not in human papilloma virus-negative) [<xref rid="B74-pharmaceuticals-14-00157" ref-type="bibr">74</xref>]. These results support the potential of roscovitine as a drug against human papilloma virus and head and neck squamous cell carcinoma. However, a phase II trial performed with almost 200 patients suffering with non-small cell lung cancer has failed. The study has met the primary endpoint of improving progression free survival, although patients administered with roscovitine did show longer median survival [<xref rid="B72-pharmaceuticals-14-00157" ref-type="bibr">72</xref>].</p></sec></sec><sec id="sec3-pharmaceuticals-14-00157"><title>3. Compounds in Pre-Clinical and Clinical Stages</title><p>Numerous phytochemical compounds have demonstrated to exert significant anticancer activity in pre-clinical studies (both in vitro and in vivo). These positive results led to their evaluation in further clinical trials, to estimate the suitability (preliminary efficacy, toxicity, pharmacokinetics, safety data, etc.) of the compounds as possible agents in new strategies for cancer therapy (several examples have been compiled in <xref rid="pharmaceuticals-14-00157-t002" ref-type="table">Table 2</xref>). In this section, some of these compounds will be described, including colchicine derivatives, sulphoraphane and dietary phenolic compounds, such as resveratrol, curcumin, quercetin, gingerol and kaempferol. Nowadays, several pre-clinical and clinical studies have been conducted with these compounds, but more clinical trials are still necessary before their further application.</p><sec id="sec3dot1-pharmaceuticals-14-00157"><title>3.1. Colchicine Derivates</title><p>Colchicine is a natural alkaloid that was initially isolated from plants that belong to the genus <italic>Colchicum</italic> such as <italic>Colchicum autumnale</italic>. Later, its presence was also confirmed in other vegetal species like those from genera <italic>Gloriosa</italic> and <italic>Sandersonia</italic>. This compound is considered a tubulin poison because it suppresses microtubule dynamics, which ultimately disrupts the formation of the mitotic spindle. Colchicine, through its specific colchicine domain-binding, gets bound to tubulin between both &#x003b1; and &#x003b2; subunits which subsequently stimulates the depolymerization of tubulin complexes. This destabilization of microtubules is capable of arresting cell cycle at different phases leading to a final induction of the cell apoptosis [<xref rid="B90-pharmaceuticals-14-00157" ref-type="bibr">90</xref>]. Colchicine was initially evaluated as cancer therapy, but it presents few drawbacks: it possesses high toxicity and shows low specificity for tumor cells that lead it to target normal cells. Hence, colchicine has a limited medical application in cancer therapy. Nevertheless, semisynthetic derivatives that present lower toxicity have been developed and successfully applied on in vitro studies. Colchicinamide, deacetylcolchicine or valyl colchicine and other synthetic derivatives have been tested in different in vitro human cancer cell lines such as colorectal, chronic granulocytic leukemia, melanoma, central nervous system and breast cancers [<xref rid="B36-pharmaceuticals-14-00157" ref-type="bibr">36</xref>,<xref rid="B91-pharmaceuticals-14-00157" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceuticals-14-00157" ref-type="bibr">92</xref>,<xref rid="B93-pharmaceuticals-14-00157" ref-type="bibr">93</xref>]. It seems that deacetylcolchicine has been employed in clinical trials, due to its effectiveness against melanoma, Hodgkin&#x02019;s lymphoma, and chronic granulocytic leukemia [<xref rid="B94-pharmaceuticals-14-00157" ref-type="bibr">94</xref>], but, to our knowledge, no other clinical trials with colchicine derivatives have been reported. Most of the studies evaluating colchicine derivatives have been carried out in vitro. Some of these compounds have been considered more active and selective, compared to colchicine [<xref rid="B92-pharmaceuticals-14-00157" ref-type="bibr">92</xref>,<xref rid="B93-pharmaceuticals-14-00157" ref-type="bibr">93</xref>], but more pre-clinical and clinical trials are still necessary to assess the efficacy, pharmacokinetics, limitations and safety issues of these compounds, before considering them possible candidates for future cancer treatment.</p></sec><sec id="sec3dot2-pharmaceuticals-14-00157"><title>3.2. Sulforaphane</title><p>Sulforaphane (1-isothiocyanate-4-methyl-sulfinylbutane) (SFN) is the best-known compound of the isothiocyanate group [<xref rid="B95-pharmaceuticals-14-00157" ref-type="bibr">95</xref>]. It is a redox-active natural molecule isolated for the first time in 1958 from the leaves of hoary cress (<italic>Lepidium draba</italic>). Afterwards, in 1992, it was found in plants from the Brassicaceae family. Today, this compound is well known to be found in foods and specifically in cruciferous vegetables like broccoli sprouts [<xref rid="B96-pharmaceuticals-14-00157" ref-type="bibr">96</xref>]. In fact, some studies show that extracts from broccoli can induce the phase II detoxification enzymes and the antioxidant enzymes in mammalian cells [<xref rid="B97-pharmaceuticals-14-00157" ref-type="bibr">97</xref>]. SFN has been tested for cancer prevention, cancer therapy and also in other chronic disease prevention and treatment bioassays [<xref rid="B98-pharmaceuticals-14-00157" ref-type="bibr">98</xref>]. This compound has regulatory effects on the tumor cell cycle, apoptosis, and angiogenesis by modulation of the related signaling pathways and genes [<xref rid="B99-pharmaceuticals-14-00157" ref-type="bibr">99</xref>]. In the analysis of the cell cycle, it was observed that SFN causes G2/M phase arrest, leading to inhibition of tumor proliferation/growth, which is associated with downregulation of cyclin B1 and cyclin D1 genes (related with the progression of the cell cycle), as well as increased protein levels of cyclin/CDK inhibitor p21 (related with cellular senescence). SFN also increased the expression of the pro-apoptotic protein Bax and decreased expression of the anti-apoptotic protein Bcl-x, inducing apoptosis in cancer cells [<xref rid="B99-pharmaceuticals-14-00157" ref-type="bibr">99</xref>].</p><p>In the last years, the anticancer properties of this compound have been demonstrated in vitro and in vivo, and a few clinical trials have been carried out tenting the suitability of oral-supplementation of SFN for cancer chemoprevention and also in combination with other anticancer drugs [<xref rid="B100-pharmaceuticals-14-00157" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceuticals-14-00157" ref-type="bibr">101</xref>]. Clinical trials have been performed on prostate and breast cancer patients. In a double-blinded, randomized, placebo-controlled trial, the oral administration of SFN lead to the significant reduction of prostate-specific antigen in prostate cancer patients after radical prostatectomy [<xref rid="B75-pharmaceuticals-14-00157" ref-type="bibr">75</xref>]. In a phase II clinical trial on prostate cancer patients with biochemical recurrence after prostatectomy, patients who received oral administration of SFN showed a lengthening of the on-treatment prostate-specific antigen doubling time, compared to pre-treatment [<xref rid="B76-pharmaceuticals-14-00157" ref-type="bibr">76</xref>]. In a recent phase II clinical trial, the results showed that the administration of SFN as adjuvant enhanced the efficacy of doxorubicin against in vivo breast cancer [<xref rid="B77-pharmaceuticals-14-00157" ref-type="bibr">77</xref>]. More studies about clinical uses of SFN in humans seems warranted, due to the high availability and tolerability of this compound, and its effectiveness as a chemoprevention agent in preclinical models of carcinogen-induced cancer [<xref rid="B102-pharmaceuticals-14-00157" ref-type="bibr">102</xref>].</p></sec><sec id="sec3dot3-pharmaceuticals-14-00157"><title>3.3. Phenolic Compounds</title><p>Some of the most promising compounds that may be in the development of new drugs are phenolic compounds. These compounds are secondary metabolites from plants (an also some algae), which could be divided into phenolic acids, flavonoids, lignans, stilbenes and other compounds [<xref rid="B103-pharmaceuticals-14-00157" ref-type="bibr">103</xref>]. Nowadays, these compounds have attracted the attention of scientific community due to their large range of biological properties, such as antioxidant, anti-inflammatory, antibacterial and also anticancer [<xref rid="B104-pharmaceuticals-14-00157" ref-type="bibr">104</xref>,<xref rid="B105-pharmaceuticals-14-00157" ref-type="bibr">105</xref>,<xref rid="B106-pharmaceuticals-14-00157" ref-type="bibr">106</xref>,<xref rid="B107-pharmaceuticals-14-00157" ref-type="bibr">107</xref>]. Due to their beneficial effects on health, the interest of the consumption of phenolic compounds has increased [<xref rid="B108-pharmaceuticals-14-00157" ref-type="bibr">108</xref>]. Regarding anticancer activity, it has been described that these compounds may interfere with the initiation, growth and progression of cancer by modulating different enzymes and also diverse signaling pathways related with cell-proliferation [<xref rid="B105-pharmaceuticals-14-00157" ref-type="bibr">105</xref>]. Several examples of phenolic compounds employed in pre-clinical and clinical studies have been described below.</p><sec id="sec3dot3dot1-pharmaceuticals-14-00157"><title>3.3.1. Resveratrol</title><p>Resveratrol is a phenolic compound present in some fruits, such as grapes, peanuts, blueberries and blackberries. Numerous studies have evaluated the anticancer properties of this compound. Several action mechanisms of resveratrol have been described: positive regulation of p53 and BAX proteins (related with pro-apoptotic pathways) and negative regulation of NF-&#x003ba;B, AP-1, hypoxia-inducible factor 1-alpha (HIF-1&#x003b1;), matrix metalloproteases, Bcl-2 protein, COX-2, cytokines and CDK [<xref rid="B109-pharmaceuticals-14-00157" ref-type="bibr">109</xref>]. Some pre-clinical studies performed in vitro demonstrated that resveratrol was able to suppress the cell proliferation through cell cycle arrest, induce apoptosis and modulate autophagy in different cancer cell lines, including ovarian cancer cell line, resistant human leukemia cells, non-small-cell lung cancer and human lung adenocarcinoma [<xref rid="B110-pharmaceuticals-14-00157" ref-type="bibr">110</xref>,<xref rid="B111-pharmaceuticals-14-00157" ref-type="bibr">111</xref>,<xref rid="B112-pharmaceuticals-14-00157" ref-type="bibr">112</xref>]. Regarding in vivo studies, the anticancer properties of this compounds were also significant. For example, in an in vivo study, resveratrol was administered to mice, leading to a 60% reduction in the appearance of sporadic colorectal cancer. Similarly, resveratrol inhibited cell proliferation, induced the apoptosis and suppressed the angiogenesis and metastasis in bladder cancer mice-models [<xref rid="B113-pharmaceuticals-14-00157" ref-type="bibr">113</xref>]. Resveratrol has been also reported to enhance the efficacy of traditional chemotherapeutic drugs, including temozolomide, doxorubicin and paclitaxel in mice models [<xref rid="B114-pharmaceuticals-14-00157" ref-type="bibr">114</xref>,<xref rid="B115-pharmaceuticals-14-00157" ref-type="bibr">115</xref>,<xref rid="B116-pharmaceuticals-14-00157" ref-type="bibr">116</xref>].</p><p>The positive results obtained at pre-clinical level led to the development of clinical studies using this compound. For example, in 2011, a phase I study conducted with colorectal cancer patients with hepatic metastasis reported that the administration of microparticular-formulated resveratrol (5 g/day, 14 days) increased the apoptosis of malignant cells in the hepatic tissue, compared with placebo [<xref rid="B78-pharmaceuticals-14-00157" ref-type="bibr">78</xref>]. In colorectal adenocarcinoma, resveratrol reduced the expression of COX-2 and M<sub>1</sub>G (NCT00433576). In another study, the results showed that trans-resveratrol (100 mg/day, 12 weeks) reduced the DNA methylation of RASSF-1&#x003b1;, a gene related with breast-cancer, and also reduced the cancer promoting prostaglandin E2 expression in the breast [<xref rid="B79-pharmaceuticals-14-00157" ref-type="bibr">79</xref>]. A phase I study conducted with recurrent prostate cancer patients with elevated prostate-specific antigen levels evaluated the effects of the administration of pulverized muscadine grape skin extract containing resveratrol (4000 mg). The results showed a significant reduction of the recurrence of the cancer by more than 5 months, compared with placebo [<xref rid="B80-pharmaceuticals-14-00157" ref-type="bibr">80</xref>]. A further 12-month study reported similar results using two different doses, 500 and 4000 mg of resveratrol [<xref rid="B81-pharmaceuticals-14-00157" ref-type="bibr">81</xref>]. Regarding these clinical trials, the use of resveratrol may be promising in cancer treatment. However, one of the main drawbacks of resveratrol is its low water-solubility, which limits its clinical use. To overcome this limitation, some strategies have been considered such as synthesis of novel derivatives and analogues [<xref rid="B116-pharmaceuticals-14-00157" ref-type="bibr">116</xref>], micro-formulation [<xref rid="B78-pharmaceuticals-14-00157" ref-type="bibr">78</xref>] or nano-delivery systems [<xref rid="B117-pharmaceuticals-14-00157" ref-type="bibr">117</xref>].</p></sec><sec id="sec3dot3dot2-pharmaceuticals-14-00157"><title>3.3.2. Curcumin</title><p>Curcumin is a natural pigment of phenolic nature extracted from <italic>Curcuma longa.</italic> This compound has been extensively studied due to their immunomodulatory and anticancer properties, among others [<xref rid="B118-pharmaceuticals-14-00157" ref-type="bibr">118</xref>]. Numerous biological targets of curcumin have been described, such as proteins involved in the antioxidant-response, apoptosis, cell-cycle regulation and cancer progression [<xref rid="B119-pharmaceuticals-14-00157" ref-type="bibr">119</xref>]. Numerous pre-clinical studies have demonstrated that curcumin is an effective chemopreventive agent and also acts as a beneficial adjuvant [<xref rid="B120-pharmaceuticals-14-00157" ref-type="bibr">120</xref>]. To cite some examples, in vitro assays reported that curcumin exerted anticancer effects (reduction of cell proliferation, cell cycle arrest, apoptosis, autophagy, etc.) in different cells lines, such as human endometrial, malignant glioma, malignant mesothelioma, breast adenocarcinoma, melanoma, chronic myelogenous leukemia or gastric cancer cell lines [<xref rid="B116-pharmaceuticals-14-00157" ref-type="bibr">116</xref>,<xref rid="B121-pharmaceuticals-14-00157" ref-type="bibr">121</xref>,<xref rid="B122-pharmaceuticals-14-00157" ref-type="bibr">122</xref>,<xref rid="B123-pharmaceuticals-14-00157" ref-type="bibr">123</xref>,<xref rid="B124-pharmaceuticals-14-00157" ref-type="bibr">124</xref>]. In vivo studies have reported similar results, for example, in chronic myeloid leukemia [<xref rid="B123-pharmaceuticals-14-00157" ref-type="bibr">123</xref>], pancreatic cancer [<xref rid="B125-pharmaceuticals-14-00157" ref-type="bibr">125</xref>] or breast cancer mice models [<xref rid="B126-pharmaceuticals-14-00157" ref-type="bibr">126</xref>]. Curcumin has been also reported to enhance the effects of conventional drugs, such as cisplatin, doxorubicin, paclitaxel or irinotecan [<xref rid="B127-pharmaceuticals-14-00157" ref-type="bibr">127</xref>,<xref rid="B128-pharmaceuticals-14-00157" ref-type="bibr">128</xref>]. Nevertheless, this compound present low bio-availability, due to its low solubility, which limits its clinic applications. In this sense, nanoparticles-based drugs or derivative compounds have been reported to be suitable options to developed curcumin treatments [<xref rid="B119-pharmaceuticals-14-00157" ref-type="bibr">119</xref>,<xref rid="B126-pharmaceuticals-14-00157" ref-type="bibr">126</xref>].</p><p>Despite bioavailability limitations, to date, several clinical studies have evaluated the potential of curcumin against different cancers: breast, prostate, pancreatic, colorectal and hematological [<xref rid="B35-pharmaceuticals-14-00157" ref-type="bibr">35</xref>,<xref rid="B116-pharmaceuticals-14-00157" ref-type="bibr">116</xref>]. More recently, a study assessed the efficacy of curcumin complexed with phospholipids as complementary treatment of gemcitabine on pancreatic cancer patients. The results showed that the administration of the product (2000 mg/day) increased the efficacy of gemcitabine, without any observed toxicity [<xref rid="B82-pharmaceuticals-14-00157" ref-type="bibr">82</xref>]. Similar effects were observed in a II phase study, where curcumin was tested as complementary treatment of paclitaxel in metastatic and advanced breast cancer. The treatment with both compounds was more efficient compared with paclitaxel-placebo and no toxic effects were observed [<xref rid="B83-pharmaceuticals-14-00157" ref-type="bibr">83</xref>]. As a function of these results, it seems guaranteed that curcumin could be used in combination with the conventional drugs to enhance their efficacy in the future.</p></sec><sec id="sec3dot3dot3-pharmaceuticals-14-00157"><title>3.3.3. Quercetin</title><p>Quercetin is a flavonoid commonly found in berries, onions and leafy vegetables, to which anticancer properties are attributed [<xref rid="B129-pharmaceuticals-14-00157" ref-type="bibr">129</xref>]. In this sense, numerous studies in vitro and in vivo pre-clinical studies have showed positive results. Regarding its action mechanisms, quercetin has been demonstrated to induce cell cycle arrest by regulating cyclin D1 and p53-related pathways; apoptosis trough the induction of pro-apoptotic factors and the decrease of anti-apoptotic ones; induces autophagy and inhibits proliferation, angiogenesis and metastasis [<xref rid="B130-pharmaceuticals-14-00157" ref-type="bibr">130</xref>,<xref rid="B131-pharmaceuticals-14-00157" ref-type="bibr">131</xref>]. These effects have been observed in different in vitro cell lines, including breast, ovarian, lung and colon cancer cells, among many others [<xref rid="B130-pharmaceuticals-14-00157" ref-type="bibr">130</xref>,<xref rid="B132-pharmaceuticals-14-00157" ref-type="bibr">132</xref>,<xref rid="B133-pharmaceuticals-14-00157" ref-type="bibr">133</xref>], and also in different in vivo mice models [<xref rid="B134-pharmaceuticals-14-00157" ref-type="bibr">134</xref>,<xref rid="B135-pharmaceuticals-14-00157" ref-type="bibr">135</xref>,<xref rid="B136-pharmaceuticals-14-00157" ref-type="bibr">136</xref>]. Furthermore, quercetin has been reported to enhance the efficacy of chemotherapeutic drugs [<xref rid="B137-pharmaceuticals-14-00157" ref-type="bibr">137</xref>,<xref rid="B138-pharmaceuticals-14-00157" ref-type="bibr">138</xref>].</p><p>Regarding clinical trials, several have evaluated the suitability of quercetin as anticancer drug. For example, a study conducted on humans reported that a high intake of quercetin in the diet is inversely related to the risk of gastric adenocarcinoma [<xref rid="B84-pharmaceuticals-14-00157" ref-type="bibr">84</xref>]. Another study evaluated the use of quercetin to prevent and treat oral mucositis induced by chemotherapy. The results showed a significant reduction of oral mucositis incidence in the quercetin treated group, which may suggest that this compound could be used to palliate chemotherapy side-effects [<xref rid="B139-pharmaceuticals-14-00157" ref-type="bibr">139</xref>]. Nowadays, some clinical trials are ongoing in prostate (NCT01912820), squamous cell carcinoma (NCT03476330) and lung cancer (NCT04267874). However, in some cases, the results are limited due to the low solubility and bioavailability of this compound. To overcome these drawbacks, several delivery systems have been proposed for instance, lipids, nanoparticles, nanoemulsions, liposomes or micelles [<xref rid="B131-pharmaceuticals-14-00157" ref-type="bibr">131</xref>].</p></sec><sec id="sec3dot3dot4-pharmaceuticals-14-00157"><title>3.3.4. Gingerol</title><p>Gingerol is another phenolic compound with significant anticancer properties, extracted from the fresh rhizome of <italic>Zingiber officinale</italic>. The action mechanisms attributed to gingerol include reduction of inflammation (decrease of NF&#x003ba;B and COX-2), induction of phase II detoxification enzymes (Nrf2), genomic instability (tubulin interactions), and altered gene expression (increased expression of pro-apoptotic molecules and decreased expression of anti-apoptotic factors), among others [<xref rid="B140-pharmaceuticals-14-00157" ref-type="bibr">140</xref>]. These effects have been corroborated in different in vitro cultures, such as neuroblastoma, sarcoma, human myeloid leukemia, breast Caco-2 cancer cells, and also in breast cancer-animal models [<xref rid="B141-pharmaceuticals-14-00157" ref-type="bibr">141</xref>,<xref rid="B142-pharmaceuticals-14-00157" ref-type="bibr">142</xref>,<xref rid="B143-pharmaceuticals-14-00157" ref-type="bibr">143</xref>,<xref rid="B144-pharmaceuticals-14-00157" ref-type="bibr">144</xref>,<xref rid="B145-pharmaceuticals-14-00157" ref-type="bibr">145</xref>]. Recently, studies have demonstrated that gingerol may be used in combination with cisplatin [<xref rid="B146-pharmaceuticals-14-00157" ref-type="bibr">146</xref>] or doxorubicin [<xref rid="B145-pharmaceuticals-14-00157" ref-type="bibr">145</xref>], to improve their efficacy.</p><p>Several clinical trials have employed ginger root extracts, containing gingerol, to determinate its ability to prevent cancer development. In a pilot study, patients at increased risk for colorectal cancer received 2 g of ginger (standardized to 5% of gingerol). The results suggested that ginger supplementation might be effective to prevent the apparition of cancer [<xref rid="B85-pharmaceuticals-14-00157" ref-type="bibr">85</xref>]. In other pilot study, newly diagnosed cancer patients received a ginger extract (standardized 6-gingerol 20 mg/day) as chemotherapeutic adjuvant, starting 3 days prior to the first cycle of chemotherapy till the fourth cycle. The results obtained showed that the antioxidant status was increased and oxidative markers were reduced in the ginger group, suggesting that daily supplementation could reduce the negative effects of chemotherapy [<xref rid="B86-pharmaceuticals-14-00157" ref-type="bibr">86</xref>]. Recently, a phase II, randomized, double-blind, placebo-controlled study confirmed that 6-gingerol significantly improved the overall complete response rate in chemotherapy-induced nausea and vomiting, appetite, and quality of life in cancer patients receiving chemotherapy [<xref rid="B87-pharmaceuticals-14-00157" ref-type="bibr">87</xref>]. It has been described that gingerol has low solubility in water, leading to low bioavailability and limited applications. Several strategies may be employed to overcome these drawbacks, such as proliposomes [<xref rid="B147-pharmaceuticals-14-00157" ref-type="bibr">147</xref>], nanostructured lipid carriers [<xref rid="B148-pharmaceuticals-14-00157" ref-type="bibr">148</xref>] or microemulsion [<xref rid="B149-pharmaceuticals-14-00157" ref-type="bibr">149</xref>], achieving higher bioavailability and activity, compared to free gingerol.</p></sec><sec id="sec3dot3dot5-pharmaceuticals-14-00157"><title>3.3.5. Kaempferol</title><p>Kaempferol is one of the most common flavonoids, found in diverse fruits and vegetables. Many studies have described the beneficial effects of dietary kaempferol in reducing the risk of chronic diseases, especially cancer [<xref rid="B150-pharmaceuticals-14-00157" ref-type="bibr">150</xref>]. Kaempferol increases the body&#x02019;s antioxidant defense against free radicals, which have been demonstrated to be one of the main causes involved in cancer development. At molecular level, kaempferol has been reported to modulate several key elements in cellular signal transduction pathways linked to apoptosis, cell-cycle arrest, angiogenesis, inflammation and metastasis [<xref rid="B150-pharmaceuticals-14-00157" ref-type="bibr">150</xref>,<xref rid="B151-pharmaceuticals-14-00157" ref-type="bibr">151</xref>]. Nowadays, several pre-clinical in vitro and in vivo studies have reported the anticancer properties of this flavonoid against different types of cancers, including breast, prostate, ovarian, lung, colon or kidney [<xref rid="B152-pharmaceuticals-14-00157" ref-type="bibr">152</xref>].</p><p>Several clinical studies have evaluated the relation between the intake of dietary flavonoids (including kaempferol) and cancer, showing variable results. Many studies have reported no significant relation between oral intake of kaempferol and risk of cancer development [<xref rid="B153-pharmaceuticals-14-00157" ref-type="bibr">153</xref>], ovarian [<xref rid="B154-pharmaceuticals-14-00157" ref-type="bibr">154</xref>] or breast cancer [<xref rid="B155-pharmaceuticals-14-00157" ref-type="bibr">155</xref>]. On the other hand, some clinical studies have reported significant reduction in ovarian cancer [<xref rid="B88-pharmaceuticals-14-00157" ref-type="bibr">88</xref>] and the risk of pancreatic cancer development in smokers [<xref rid="B89-pharmaceuticals-14-00157" ref-type="bibr">89</xref>]. Considering these results, it would be necessary to perform more clinical studies with larger groups. In addition, like other phenolic compounds, the clinical applications of this compound are limited by its poor bioavailability. In this sense, nano-formulations, phospholipids or metallic complex could be strategies to enhance the bioavailability of these compounds and thus, their bioactivity [<xref rid="B152-pharmaceuticals-14-00157" ref-type="bibr">152</xref>,<xref rid="B156-pharmaceuticals-14-00157" ref-type="bibr">156</xref>].</p></sec></sec><sec id="sec3dot4-pharmaceuticals-14-00157"><title>3.4. Other Plant Derived Compounds</title><p>Other plant-derived compounds that have demonstrated anticancer properties both on in vitro and in vivo studies have been compiled in <xref rid="pharmaceuticals-14-00157-t003" ref-type="table">Table 3</xref>. The results obtained in pre-clinical stage could led to the development of more clinical studies and the design of new chemotherapeutics.</p></sec></sec><sec id="sec4-pharmaceuticals-14-00157"><title>4. Current Challenges of Anticancer Phytochemicals</title><p>The development of phytochemical anticancer agents requires substantial evidence of efficacy derived from adequate clinical trials before their approval for use in patients. Although the mentioned compounds present significant anticancer properties, they also have limitations that should be overcome before its further clinical application, in the case of compounds in clinical stage, or to enhance their characteristics, in the case of drugs currently used in cancer treatment. In this sense, poor aqueous solubility, poor penetration to enter in targeted cells, absorption by normal cells, limited therapeutic potential and toxic side effects are still the major concern of the application of phytochemical compounds in cancer treatment [<xref rid="B35-pharmaceuticals-14-00157" ref-type="bibr">35</xref>,<xref rid="B211-pharmaceuticals-14-00157" ref-type="bibr">211</xref>]. For example, compounds like colchicine, camptothecin and podophyllotoxin derivatives have showed limited use due to the side effects. In some cases, compounds such as SFN or vinca alkaloids present limited effect and they are used in combination with other agents. In this section, several challenges and strategies proposed to solve the drawbacks of these compounds will be discussed. Apart from these challenges, the discovery and development of possible phytochemical compounds employed clinically also has to face other challenges related to the extraction synthesis, optimization and characterization of phytochemicals anticancer compounds. Thus, new advances in analytical technology and computational methodologies, to facilitate the identification of new phytochemicals, optimize their extraction and/or opt for its chemical synthesis or modifications are expected.</p><sec id="sec4dot1-pharmaceuticals-14-00157"><title>4.1. Limited Solubility and Poor Absortion</title><p>As mentioned in previous sections, some compounds present low availability, which is one of the main reasons of the limited potential of phytochemicals. To solve bioavailability limitations related to stability, absorption and metabolism, lipid-based formulations (such as microencapsulation, liposomes, nano-emulsion, etc.) and nanotechnology have been considered as a suitable approach to enhance aqueous solubility, stability, target specific to cancerous cells and even reduce the quantity of the phytochemical compound to achieve secure therapeutic levels [<xref rid="B211-pharmaceuticals-14-00157" ref-type="bibr">211</xref>,<xref rid="B212-pharmaceuticals-14-00157" ref-type="bibr">212</xref>]. For example, the administration of the vinca alkaloids has been further improved by including them into micro- or nano-capsules, such as liposomes or micelles (&#x0201c;Liposome-encapsulated vinca alkaloids and their use in combating tumors&#x0201d; patent no. US4952408A; &#x0201c;Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids&#x0201d; patent no. US8765181B2). The encapsulation of core ingredients permits a controlled release and protects the bioactivity from external factors that may affect the performance. Among them, liposomes named after Marqibo<sup>&#x000ae;</sup>, have been approved by FDA to treat adult leukemia [<xref rid="B54-pharmaceuticals-14-00157" ref-type="bibr">54</xref>]. Similar efforts have been conducted to improve the solubility of paclitaxel, and several nano-technological platforms have been developed including polymeric nanoparticles (Abraxane<sup>&#x000ae;</sup>), polymeric conjugates (Xyotax), polymeric micelles (Genexol-PM, NK 105) and liposomes (LEP-ETU). However, although a large number of nano-medicines has been investigated in the last decades, only few nano-formulations have achieved their use in clinical trials, with even fewer being approved for clinical application. For example, the hydroxypropyl-methacrylamide copolymer&#x02013;PTX developed by the pharmaceutical Pfizer has stopped in Phase I due to the high neurotoxicity in rats during the study. Poly (L-glutamic acid)-paclitaxel (PG-TXL) belongs to the few formulations that reached phase III clinical trials. Unfortunately, the development of PG-TXL stopped in 2016 due to the inability to show significant improvement over current standard care [<xref rid="B213-pharmaceuticals-14-00157" ref-type="bibr">213</xref>]. In the case of irinotecan, some studies have revealed that its therapeutic use is limited due to its hydrophobicity, low stability at physiologic pH, and side effects. These issues could be solved by new drug formulations containing nanoparticles, polymer conjugates, dendrimers, peptides, and carbohydrates [<xref rid="B64-pharmaceuticals-14-00157" ref-type="bibr">64</xref>].</p><p>Regarding compounds in clinical studies, as previously mentioned, low solubility and availability are some of the main limitations that hinder their possible use for cancer treatment. For example, it has been reported that resveratrol has a circulation half-life of several minutes, while quercetin is generally present at low micromolar concentrations in blood, insufficient for a potent anticancer activity [<xref rid="B214-pharmaceuticals-14-00157" ref-type="bibr">214</xref>]. Thus, numerous studies have evaluated innovative strategies to enhance their availability, including nano-formulations, liposomes, nanoparticles, etc. For example, gingerol formulated in proliposomes showed a higher inhibition of HepG2 cancer cells in vitro and also a higher oral bioavailability in vivo [<xref rid="B147-pharmaceuticals-14-00157" ref-type="bibr">147</xref>]. In other study, gold-coated iron oxide nanoparticles improved significantly the stability and activity of SFN against human breast cancer cells [<xref rid="B215-pharmaceuticals-14-00157" ref-type="bibr">215</xref>]. Recently, mesoporous silica nanoparticles conjugated with hyaluronic acid were employed as a drug delivery system of curcumin, and the anticancer activity was measured in vitro and in vivo. The results showed that the delivery system enhanced the anticancer activity in both assays, which may attributed to a higher bioavailability [<xref rid="B216-pharmaceuticals-14-00157" ref-type="bibr">216</xref>].</p><p>Nowadays, several clinical trials have been performed using innovative strategies to enhance the bioavailability of chemotherapeutic drugs, as recorded in other reviews [<xref rid="B212-pharmaceuticals-14-00157" ref-type="bibr">212</xref>,<xref rid="B214-pharmaceuticals-14-00157" ref-type="bibr">214</xref>]. However, these studies are few compared with the numerous works published evaluating novel strategies. Therefore, it is expected that more clinical trials will be conducted in the future.</p></sec><sec id="sec4dot2-pharmaceuticals-14-00157"><title>4.2. Combination of Phytochemicals with Conventional Chemotherapeutics</title><p>Some authors have pointed out that cancer treatment with a single-target chemical agent is not entirely effective since it is difficult to achieve optimal cytotoxic effects in cancer cells due to their rapid molecular adaptations. In addition, some phytochemicals currently in clinical evaluation present limited effects on their own [<xref rid="B217-pharmaceuticals-14-00157" ref-type="bibr">217</xref>]. Therefore, a combinatorial approach of these compounds with conventional chemotherapeutics may achieve a synergistic effect that increases toxicity in cancer cells (associated to the sensitization of the cancer cells to the drugs, attributed to the phytochemicals), reduces therapeutic doses and also toxicity concerns [<xref rid="B214-pharmaceuticals-14-00157" ref-type="bibr">214</xref>,<xref rid="B217-pharmaceuticals-14-00157" ref-type="bibr">217</xref>,<xref rid="B218-pharmaceuticals-14-00157" ref-type="bibr">218</xref>]. In this sense, numerous studies have evaluated the efficiency of this combination and have been compiled extensively in recent reviews [<xref rid="B116-pharmaceuticals-14-00157" ref-type="bibr">116</xref>,<xref rid="B219-pharmaceuticals-14-00157" ref-type="bibr">219</xref>]. For example, resveratrol has been successfully used as adjuvant of several conventional chemotherapeutic drugs, such as temozolomide, doxorubicin and paclitaxel on in vitro assays and mice models [<xref rid="B114-pharmaceuticals-14-00157" ref-type="bibr">114</xref>,<xref rid="B115-pharmaceuticals-14-00157" ref-type="bibr">115</xref>,<xref rid="B116-pharmaceuticals-14-00157" ref-type="bibr">116</xref>]. Other compound commonly employed as chemosensitizing agent is curcumin. For example, when combining curcumin with docetaxel, a decrease in drug resistance was observed in breast cancer cells [<xref rid="B220-pharmaceuticals-14-00157" ref-type="bibr">220</xref>]. Similar results were also observed combined with vincristine, paclitaxel, irinotecan and cisplatin, enhancing the efficacy of these drugs, compared to single treatment [<xref rid="B127-pharmaceuticals-14-00157" ref-type="bibr">127</xref>,<xref rid="B128-pharmaceuticals-14-00157" ref-type="bibr">128</xref>,<xref rid="B221-pharmaceuticals-14-00157" ref-type="bibr">221</xref>,<xref rid="B222-pharmaceuticals-14-00157" ref-type="bibr">222</xref>]. Recently, gingerol has been found to enhance the sensitivity of in vitro gastric cancer cells to cisplatin [<xref rid="B146-pharmaceuticals-14-00157" ref-type="bibr">146</xref>], and the sensitivity of liver cancer cells to doxorubicin [<xref rid="B145-pharmaceuticals-14-00157" ref-type="bibr">145</xref>]. Other compounds that have been employed in combinatory assays appeared in <xref rid="pharmaceuticals-14-00157-t003" ref-type="table">Table 3</xref>, like apigenin, betulinic acid and berberine. In addition, as could be observed in <xref rid="pharmaceuticals-14-00157-t002" ref-type="table">Table 2</xref>, the combination strategy has been also assessed in clinical trials. Thus, although more studies are still necessary, it seems that the use of phytochemicals as chemosensitizing may be beneficial in cancer therapy.</p></sec></sec><sec id="sec5-pharmaceuticals-14-00157"><title>5. Conclusions</title><p>Traditional plants have been historically considered as an endless source of new compounds for the development of new pharmaceuticals and drugs. Therefore, nowadays researchers have at their complete disposal, plenty of ethnomedicinal and ethnopharmacological information of very different plant species which is a tool for selecting candidates and lead the research to those plants more promising. As a result of this knowledge, different examples of phytochemicals with medicinal properties against different diseases can be found throughout the literature.</p><p>Cancer is a complex disease that every year costs several millions of human lives. The uncontrolled proliferation of cells causes the incorrect functioning of the body, with a long list of symptoms and finally, death. So, given the health and social important of this disease, but also its economic impact on the health system, new therapeutic alternatives are being continuously investigated. For this purpose, it is essential to consider some factors such as clinical trials, efficacy, the induced tumorigenic changes, possible side effects and toxicity of the pharmaceuticals. In this context, a variety of phytochemicals obtained from plants have been discovered and are currently used in cancer therapies. In the present review, some examples such as vinca alkaloids, paclitaxel or irinotecan, that have demonstrated to exert anticancer effects on clinical trials and have been approved for clinical use are collected. Nevertheless, these compounds are not exempt of limitations, such as low solubility, restricted effect on their own, negative side-effects, etc. This article also highlights some compounds that are being investigated in pre-clinical and clinical stages, such as SFN and different phenolic compounds, which have shown interesting results. However, more clinical trials are still necessary before their further safe application.</p><p>At last, after a brief discussion of the information collected on the manuscript, an attempt has been made to identify which are the main challenges of anticancer phytochemicals, current needs and future research lines. Low availability is a target challenge for this area, which is now focused on the development and improvement of drug delivery systems, such as nano-based formulations. Moreover, many of these compounds have been demonstrated to be effective chemosensitizing agents, so they could be used combined with conventional chemotherapeutics. In this sense, more clinical trials evaluating the efficacy of the systems to enhance availability and combinatory trials should be performed before considering a compound for its use alone or in combination with other drugs.</p><p>The manuscript brings to light the need for more large-scale clinical trials and standardization procedures to validate phytochemicals in anticancer therapy. Thus, it is essential the coordinate work of interdisciplinary areas like medicinal chemistry, pharmacology, biochemistry and biology to deeply understand the availability, efficacy, safety, mechanism of action and synergistic effects of these new drugs. Therefore, to address all the limitations and needs of this research area, this review aimed at compiling the information about the current phytochemicals used for cancer treatment, promising candidates and to identify those fundamental challenges for the development of new alternatives.</p></sec></body><back><ack><title>Acknowledgments</title><p>The research leading to these results was supported by: MICINN supporting the Ram&#x000f3;n&#x00026;Cajal grant for M.A. Prieto (RYC-2017-22891), the project UP4HEALTH for supporting the researcher P. Otero, the Xunta de Galicia and University of Vigo supporting the post-doctoral grant for M. Fraga-Corral (ED481B-2019/096) and the pre-doctoral grants for P. Garc&#x000ed;a-Oliveira (ED481A-2019/295) and A.G. Pereira (ED481A-2019/0228).</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, M.A.P. and J.S.-G.; methodology, P.G.-O., P.O., A.G.P., F.C., M.C., J.E., M.F.-C., J.S.-G. and M.A.P.; formal analysis, P.G.-O., P.O., A.G.P., F.C., M.C., J.E., M.F.-C., J.S.-G. and M.A.P.; investigation, P.G.-O., P.O., A.G.P., F.C., M.C., J.E., M.F.-C., J.S.-G. and M.A.P.; writing&#x02014;original draft preparation, P.G.-O., P.O., A.G.P., F.C., M.C., J.E., M.F.-C., J.S.-G. and M.A.P.; writing&#x02014;review and editing, M.A.P. and J.S.-G.; supervision, M.A.P. and J.S.-G.; project administration, M.A.P. and J.S.-G. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>The research leading to these results was supported by FEDER under the program Interreg V-A Spain-Portugal (POPTEC) 2014-2020 ref. 0377_IBERPHENOL_6_E and ref. 0181_NANOEATERS_01_E; by Xunta de Galicia supporting the program EXCELEN-CIA-ED431F 2020/12; by EcoChestnut Project (Erasmus+ KA202) that supports the work of M. Carpena; by Ibero-American Program on Science and Technology (CYTED - AQ-UA-CIBUS, P317RT0003) and by the Bio Based Industries Joint Undertaking (JU) under grant agreement No 888003 UP4HEALTH Project (H2020-BBI-JTI-2019), the JU receives support from the European Union&#x02019;s Horizon 2020 research and innovation program and the Bio Based Industries Consortium.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-14-00157"><label>1.</label><element-citation publication-type="web"><article-title>International Agency for Research on Cancer Global Cancer Observatory</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://gco.iarc.fr/today">https://gco.iarc.fr/today</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-12-31">(accessed on 31 December 2020)</date-in-citation></element-citation></ref><ref id="B2-pharmaceuticals-14-00157"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valent</surname><given-names>P.</given-names></name><name><surname>Bonnet</surname><given-names>D.</given-names></name><name><surname>De Maria</surname><given-names>R.</given-names></name><name><surname>Lapidot</surname><given-names>T.</given-names></name><name><surname>Copland</surname><given-names>M.</given-names></name><name><surname>Melo</surname><given-names>J.V.</given-names></name><name><surname>Chomienne</surname><given-names>C.</given-names></name><name><surname>Ishikawa</surname><given-names>F.</given-names></name><name><surname>Schuringa</surname><given-names>J.J.</given-names></name><name><surname>Stassi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Cancer stem cell definitions and terminology: The devil is in the details</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>767</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1038/nrc3368</pub-id><pub-id pub-id-type="pmid">23051844</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-14-00157"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernald</surname><given-names>K.</given-names></name><name><surname>Kurokawa</surname><given-names>M.</given-names></name></person-group><article-title>Evading apoptosis in cancer</article-title><source>Trends Cell Biol.</source><year>2013</year><volume>23</volume><fpage>620</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2013.07.006</pub-id><pub-id pub-id-type="pmid">23958396</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-14-00157"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>B.W.</given-names></name><name><surname>Wild</surname><given-names>C.P.</given-names></name></person-group><source>World Cancer Report 2014</source><comment>WHO Press</comment><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2014</year><isbn>978-92-832-0443-5</isbn></element-citation></ref><ref id="B5-pharmaceuticals-14-00157"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>D.L.</given-names></name><name><surname>Saladi</surname><given-names>R.N.</given-names></name><name><surname>Fox</surname><given-names>J.L.</given-names></name></person-group><article-title>Ultraviolet radiation and skin cancer</article-title><source>Int. J. Dermatol.</source><year>2010</year><volume>49</volume><fpage>978</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1111/j.1365-4632.2010.04474.x</pub-id><?supplied-pmid 20883261?><pub-id pub-id-type="pmid">20883261</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-14-00157"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>International Agency for Research on Cancer</collab></person-group><source>Biological Agents, Volume 100B: A Review on Human Carcinogens</source><publisher-name>IARC</publisher-name><publisher-loc>Lyon, France</publisher-loc><year>2012</year></element-citation></ref><ref id="B7-pharmaceuticals-14-00157"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L.H.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>H.X.</given-names></name><name><surname>Li</surname><given-names>W.Y.</given-names></name><name><surname>Zeng</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>S.P.</given-names></name><name><surname>Zhuang</surname><given-names>X.H.</given-names></name><name><surname>Lin</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/ncomms12992</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-14-00157"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>D.</given-names></name><name><surname>Gutkind</surname><given-names>J.S.</given-names></name></person-group><article-title>Human tumor-associated viruses and new insights into the molecular mechanisms of cancer</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>S31</fpage><lpage>S42</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.351</pub-id><?supplied-pmid 19956178?><pub-id pub-id-type="pmid">19956178</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-14-00157"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>A.</given-names></name><name><surname>Henderson</surname><given-names>S.</given-names></name><name><surname>Lagos</surname><given-names>D.</given-names></name><name><surname>Nikitenko</surname><given-names>L.</given-names></name><name><surname>Coulter</surname><given-names>E.</given-names></name><name><surname>Roberts</surname><given-names>S.</given-names></name><name><surname>Gratrix</surname><given-names>F.</given-names></name><name><surname>Plaisance</surname><given-names>K.</given-names></name><name><surname>Renne</surname><given-names>R.</given-names></name><name><surname>Bower</surname><given-names>M.</given-names></name><etal/></person-group><article-title>KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming</article-title><source>Genes Dev.</source><year>2010</year><volume>24</volume><fpage>195</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1101/gad.553410</pub-id><pub-id pub-id-type="pmid">20080955</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-14-00157"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>S.</given-names></name><name><surname>Moss</surname><given-names>S.F.</given-names></name></person-group><article-title>Helicobacter pylori virulence factors in gastric carcinogenesis</article-title><source>Cancer Lett.</source><year>2009</year><volume>282</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.11.016</pub-id><?supplied-pmid 19111390?><pub-id pub-id-type="pmid">19111390</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-14-00157"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scanu</surname><given-names>T.</given-names></name><name><surname>Spaapen</surname><given-names>R.M.</given-names></name><name><surname>Bakker</surname><given-names>J.M.</given-names></name><name><surname>Pratap</surname><given-names>C.B.</given-names></name><name><surname>Wu</surname><given-names>L.E.</given-names></name><name><surname>Hofland</surname><given-names>I.</given-names></name><name><surname>Broeks</surname><given-names>A.</given-names></name><name><surname>Shukla</surname><given-names>V.K.</given-names></name><name><surname>Kumar</surname><given-names>M.</given-names></name><name><surname>Janssen</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Salmonella Manipulation of Host Signaling Pathways Provokes Cellular Transformation Associated with Gallbladder Carcinoma</article-title><source>Cell Host Microbe</source><year>2015</year><volume>17</volume><fpage>763</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2015.05.002</pub-id><?supplied-pmid 26028364?><pub-id pub-id-type="pmid">26028364</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-14-00157"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsland</surname><given-names>D.</given-names></name><name><surname>Neefjes</surname><given-names>J.</given-names></name></person-group><article-title>Bacterial infections and cancer</article-title><source>EMBO Rep.</source><year>2018</year><volume>19</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.15252/embr.201846632</pub-id><?supplied-pmid 30348892?><pub-id pub-id-type="pmid">29247079</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-14-00157"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesri</surname><given-names>E.A.</given-names></name><name><surname>Cesarman</surname><given-names>E.</given-names></name><name><surname>Boshoff</surname><given-names>C.</given-names></name></person-group><article-title>Kaposi&#x02019;s sarcoma and its associated herpesvirus</article-title><source>Nat. Rev. Cancer</source><year>2010</year><volume>10</volume><fpage>707</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1038/nrc2888</pub-id><pub-id pub-id-type="pmid">20865011</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-14-00157"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuter</surname><given-names>S.</given-names></name><name><surname>Gupta</surname><given-names>S.C.</given-names></name><name><surname>Chaturvedi</surname><given-names>M.M.</given-names></name><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Oxidative stress, inflammation, and cancer: How are they linked?</article-title><source>Free Radic. Biol. Med.</source><year>2010</year><volume>49</volume><fpage>1603</fpage><lpage>1616</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2010.09.006</pub-id><pub-id pub-id-type="pmid">20840865</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-14-00157"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moloney</surname><given-names>J.N.</given-names></name><name><surname>Cotter</surname><given-names>T.G.</given-names></name></person-group><article-title>ROS signalling in the biology of cancer</article-title><source>Semin. Cell Dev. Biol.</source><year>2018</year><volume>80</volume><fpage>50</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2017.05.023</pub-id><pub-id pub-id-type="pmid">28587975</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-14-00157"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crusz</surname><given-names>S.M.</given-names></name><name><surname>Balkwill</surname><given-names>F.R.</given-names></name></person-group><article-title>Inflammation and cancer: Advances and new agents</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2015</year><volume>12</volume><fpage>584</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2015.105</pub-id><?supplied-pmid 26122183?><pub-id pub-id-type="pmid">26122183</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-14-00157"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masferrer</surname><given-names>J.L.</given-names></name><name><surname>Leahy</surname><given-names>K.M.</given-names></name><name><surname>Koki</surname><given-names>A.T.</given-names></name><name><surname>Zweifel</surname><given-names>B.S.</given-names></name><name><surname>Settle</surname><given-names>S.L.</given-names></name><name><surname>Woerner</surname><given-names>B.M.</given-names></name><name><surname>Edwards</surname><given-names>D.A.</given-names></name><name><surname>Flickinger</surname><given-names>A.G.</given-names></name><name><surname>Moore</surname><given-names>R.J.</given-names></name><name><surname>Seibert</surname><given-names>K.</given-names></name></person-group><article-title>Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors</article-title><source>Cancer Res.</source><year>2000</year><volume>60</volume><fpage>1306</fpage><lpage>1311</lpage><?supplied-pmid 10728691?><pub-id pub-id-type="pmid">10728691</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-14-00157"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>X.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Hua</surname><given-names>S.</given-names></name></person-group><article-title>Immunological approaches towards cancer and inflammation: A cross talk</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><pub-id pub-id-type="doi">10.3389/fimmu.2018.00563</pub-id><?supplied-pmid 29662489?><pub-id pub-id-type="pmid">29662489</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-14-00157"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Tao</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Su</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Global lung cancer risk from PAH exposure highly depends on emission sources and individual susceptibility</article-title><source>Sci. Rep.</source><year>2014</year><volume>4</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/srep06561</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-14-00157"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>V.</given-names></name><name><surname>Kim</surname><given-names>K.H.</given-names></name></person-group><article-title>Review of PAH contamination in food products and their health hazards</article-title><source>Environ. Int.</source><year>2015</year><volume>84</volume><fpage>26</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.envint.2015.06.016</pub-id><?supplied-pmid 26203892?><pub-id pub-id-type="pmid">26203892</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-14-00157"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugimura</surname><given-names>T.</given-names></name><name><surname>Wakabayashi</surname><given-names>K.</given-names></name><name><surname>Nakagama</surname><given-names>H.</given-names></name><name><surname>Nagao</surname><given-names>M.</given-names></name></person-group><article-title>Heterocyclic amines: Mutagens/carcinogens produced during cooking of meat and fish</article-title><source>Gann Monogr. Cancer Res.</source><year>2004</year><volume>52</volume><fpage>71</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2004.tb03205.x</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-14-00157"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puangsombat</surname><given-names>K.</given-names></name><name><surname>Gadgil</surname><given-names>P.</given-names></name><name><surname>Houser</surname><given-names>T.A.</given-names></name><name><surname>Hunt</surname><given-names>M.C.</given-names></name><name><surname>Smith</surname><given-names>J.S.</given-names></name></person-group><article-title>Occurrence of heterocyclic amines in cooked meat products</article-title><source>Meat Sci.</source><year>2012</year><volume>90</volume><fpage>739</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/j.meatsci.2011.11.005</pub-id><?supplied-pmid 22129588?><pub-id pub-id-type="pmid">22129588</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-14-00157"><label>23.</label><element-citation publication-type="book"><source>WHO Report on the Global Tobacco Epidemic, 2011: Warning About the Dangers of Tobacco</source><edition>3rd ed.</edition><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2011</year></element-citation></ref><ref id="B24-pharmaceuticals-14-00157"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>P.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Guan</surname><given-names>W.</given-names></name></person-group><article-title>Dietary nitrates, nitrites, and nitrosamines intake and the risk of gastric cancer: A meta-analysis</article-title><source>Nutrients</source><year>2015</year><volume>7</volume><elocation-id>9872</elocation-id><pub-id pub-id-type="doi">10.3390/nu7125505</pub-id><pub-id pub-id-type="pmid">26633477</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-14-00157"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Praud</surname><given-names>D.</given-names></name><name><surname>Rota</surname><given-names>M.</given-names></name><name><surname>Rehm</surname><given-names>J.</given-names></name><name><surname>Shield</surname><given-names>K.</given-names></name><name><surname>Zato&#x00144;ski</surname><given-names>W.</given-names></name><name><surname>Hashibe</surname><given-names>M.</given-names></name><name><surname>La Vecchia</surname><given-names>C.</given-names></name><name><surname>Boffetta</surname><given-names>P.</given-names></name></person-group><article-title>Cancer incidence and mortality attributable to alcohol consumption</article-title><source>Int. J. Cancer</source><year>2016</year><volume>138</volume><fpage>1380</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1002/ijc.29890</pub-id><?supplied-pmid 26455822?><pub-id pub-id-type="pmid">26455822</pub-id></element-citation></ref><ref id="B26-pharmaceuticals-14-00157"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litzenburger</surname><given-names>U.M.</given-names></name><name><surname>Buenrostro</surname><given-names>J.D.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Sheffield</surname><given-names>N.C.</given-names></name><name><surname>Kathiria</surname><given-names>A.</given-names></name><name><surname>Greenleaf</surname><given-names>W.J.</given-names></name><name><surname>Chang</surname><given-names>H.Y.</given-names></name></person-group><article-title>Single-cell epigenomic variability reveals functional cancer heterogeneity</article-title><source>Genome Biol.</source><year>2017</year><volume>18</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s13059-016-1133-7</pub-id><?supplied-pmid 28118844?><pub-id pub-id-type="pmid">28077169</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-14-00157"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>S.Y.</given-names></name><name><surname>Cheng</surname><given-names>Y.J.</given-names></name><name><surname>Lei</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>A.Q.</given-names></name><name><surname>Zhang</surname><given-names>X.Z.</given-names></name></person-group><article-title>Combinational strategy for high-performance cancer chemotherapy</article-title><source>Biomaterials</source><year>2018</year><volume>171</volume><fpage>178</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.04.027</pub-id><?supplied-pmid 29698868?><pub-id pub-id-type="pmid">29698868</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-14-00157"><label>28.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gautam</surname><given-names>L.</given-names></name><name><surname>Jain</surname><given-names>A.</given-names></name><name><surname>Shrivastava</surname><given-names>P.</given-names></name><name><surname>Vyas</surname><given-names>S.</given-names></name><name><surname>Vyas</surname><given-names>S.P.</given-names></name></person-group><article-title>Emergence of novel targeting systems and conventional therapies for effective cancer treatment</article-title><source>Nano Drug Delivery Strategies for the Treatment of Cancers</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, the Netherlands</publisher-loc><year>2021</year><fpage>1</fpage><lpage>35</lpage></element-citation></ref><ref id="B29-pharmaceuticals-14-00157"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurgali</surname><given-names>K.</given-names></name><name><surname>Jagoe</surname><given-names>R.T.</given-names></name><name><surname>Abalo</surname><given-names>R.</given-names></name></person-group><article-title>Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.3389/fphar.2018.00245</pub-id><pub-id pub-id-type="pmid">29387012</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-14-00157"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>C.K.</given-names></name><name><surname>Mitchell</surname><given-names>R.N.</given-names></name></person-group><article-title>Winning the battle, but losing the war: Mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity</article-title><source>Cardiovasc. Pathol.</source><year>2017</year><volume>30</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.carpath.2017.06.009</pub-id><pub-id pub-id-type="pmid">28759820</pub-id></element-citation></ref><ref id="B31-pharmaceuticals-14-00157"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichota</surname><given-names>A.</given-names></name><name><surname>Gwozdzinski</surname><given-names>K.</given-names></name></person-group><article-title>Anticancer Activity of Natural Compounds from Plant and Marine Environment</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>3533</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19113533</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-14-00157"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babaei</surname><given-names>G.</given-names></name><name><surname>Aliarab</surname><given-names>A.</given-names></name><name><surname>Abroon</surname><given-names>S.</given-names></name><name><surname>Rasmi</surname><given-names>Y.</given-names></name><name><surname>Aziz</surname><given-names>S.G.G.</given-names></name></person-group><article-title>Application of sesquiterpene lactone: A new promising way for cancer therapy based on anticancer activity</article-title><source>Biomed. Pharmacother.</source><year>2018</year><volume>106</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.06.131</pub-id><pub-id pub-id-type="pmid">29966966</pub-id></element-citation></ref><ref id="B33-pharmaceuticals-14-00157"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Oliveira</surname><given-names>P.</given-names></name><name><surname>Fraga-Corral</surname><given-names>M.</given-names></name><name><surname>Pereira</surname><given-names>A.G.</given-names></name><name><surname>Louren&#x000e7;o-Lopes</surname><given-names>C.</given-names></name><name><surname>Jimenez-Lopez</surname><given-names>C.</given-names></name><name><surname>Prieto</surname><given-names>M.A.</given-names></name><name><surname>Simal-Gandara</surname><given-names>J.</given-names></name></person-group><article-title>Scientific basis for the industrialization of traditionally used plants of the Rosaceae family</article-title><source>Food Chem.</source><year>2020</year><volume>330</volume><fpage>127197</fpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2020.127197</pub-id><pub-id pub-id-type="pmid">32540521</pub-id></element-citation></ref><ref id="B34-pharmaceuticals-14-00157"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopes</surname><given-names>C.M.</given-names></name><name><surname>Dourado</surname><given-names>A.</given-names></name><name><surname>Oliveira</surname><given-names>R.</given-names></name></person-group><article-title>Phytotherapy and Nutritional Supplements on Breast Cancer</article-title><source>Biomed Res. Int.</source><year>2017</year><volume>2017</volume><fpage>1</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1155/2017/7207983</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-14-00157"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhari</surname><given-names>A.S.</given-names></name><name><surname>Mandave</surname><given-names>P.C.</given-names></name><name><surname>Deshpande</surname><given-names>M.</given-names></name><name><surname>Ranjekar</surname><given-names>P.</given-names></name><name><surname>Prakash</surname><given-names>O.</given-names></name></person-group><article-title>Phytochemicals in cancer treatment: From preclinical studies to clinical practice</article-title><source>Front. Pharmacol.</source><year>2020</year><volume>10</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.3389/fphar.2019.01614</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-14-00157"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>J.</given-names></name><name><surname>Abbasi</surname><given-names>B.A.</given-names></name><name><surname>Mahmood</surname><given-names>T.</given-names></name><name><surname>Kanwal</surname><given-names>S.</given-names></name><name><surname>Ali</surname><given-names>B.</given-names></name><name><surname>Shah</surname><given-names>S.A.</given-names></name><name><surname>Khalil</surname><given-names>A.T.</given-names></name></person-group><article-title>Plant-derived anticancer agents: A green anticancer approach</article-title><source>Asian Pac. J. Trop. Biomed.</source><year>2017</year><volume>7</volume><fpage>1129</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1016/j.apjtb.2017.10.016</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-14-00157"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Q.Q.</given-names></name><name><surname>Xu</surname><given-names>X.Y.</given-names></name><name><surname>Shang</surname><given-names>A.</given-names></name><name><surname>Gan</surname><given-names>R.Y.</given-names></name><name><surname>Wu</surname><given-names>D.T.</given-names></name><name><surname>Atanasov</surname><given-names>A.G.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>Bin Phytochemicals for the prevention and treatment of gastric cancer: Effects and mechanisms</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>570</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21020570</pub-id><?supplied-pmid 31963129?><pub-id pub-id-type="pmid">31963129</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-14-00157"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redondo-Blanco</surname><given-names>S.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>J.</given-names></name><name><surname>Guti&#x000e9;rrez-del-R&#x000ed;o</surname><given-names>I.</given-names></name><name><surname>Villar</surname><given-names>C.J.</given-names></name><name><surname>Lomb&#x000f3;</surname><given-names>F.</given-names></name></person-group><article-title>New insights toward colorectal cancer chemotherapy using natural bioactive compounds</article-title><source>Front. Pharmacol.</source><year>2017</year><volume>8</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.3389/fphar.2017.00109</pub-id><?supplied-pmid 28352231?><pub-id pub-id-type="pmid">28149278</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-14-00157"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clardy</surname><given-names>J.</given-names></name><name><surname>Walsh</surname><given-names>C.</given-names></name></person-group><article-title>Lessons from natural molecules</article-title><source>Nature</source><year>2004</year><volume>432</volume><fpage>829</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1038/nature03194</pub-id><pub-id pub-id-type="pmid">15602548</pub-id></element-citation></ref><ref id="B40-pharmaceuticals-14-00157"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>D.J.</given-names></name><name><surname>Cragg</surname><given-names>G.M.</given-names></name></person-group><article-title>Natural Products as Sources of New Drugs from 1981 to 2014</article-title><source>J. Nat. Prod.</source><year>2016</year><volume>79</volume><fpage>629</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.5b01055</pub-id><pub-id pub-id-type="pmid">26852623</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-14-00157"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>A.</given-names></name><name><surname>Qazi</surname><given-names>G.</given-names></name><name><surname>Ganju</surname><given-names>R.</given-names></name><name><surname>El-Tamer</surname><given-names>M.</given-names></name><name><surname>Singh</surname><given-names>J.</given-names></name><name><surname>Saxena</surname><given-names>A.</given-names></name><name><surname>Bedi</surname><given-names>Y.</given-names></name><name><surname>Taneja</surname><given-names>S.</given-names></name><name><surname>Bhat</surname><given-names>H.</given-names></name></person-group><article-title>Medicinal Plants and Cancer Chemoprevention</article-title><source>Curr. Drug Metab.</source><year>2008</year><volume>9</volume><fpage>581</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.2174/138920008785821657</pub-id><pub-id pub-id-type="pmid">18781909</pub-id></element-citation></ref><ref id="B42-pharmaceuticals-14-00157"><label>42.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Moraes</surname><given-names>D.F.C.</given-names></name><name><surname>de Mesquita</surname><given-names>L.S.S.</given-names></name><name><surname>do Amaral</surname><given-names>F.M.M.</given-names></name><name><surname>de Sousa Ribeiro</surname><given-names>M.N.</given-names></name><name><surname>Malik</surname><given-names>S.</given-names></name></person-group><article-title>Anticancer drugs from plants</article-title><source>Biotechnology and Production of Anti-Cancer Compounds</source><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2017</year><fpage>121</fpage><lpage>142</lpage></element-citation></ref><ref id="B43-pharmaceuticals-14-00157"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwell</surname><given-names>M.</given-names></name><name><surname>Rahman</surname><given-names>P.K.S.</given-names></name></person-group><article-title>Medicinal Plants: Their Use in Anticancer Treatment</article-title><source>Int. J. Pharm. Sci. Res.</source><year>2015</year><volume>6</volume><fpage>4103</fpage><lpage>4112</lpage><pub-id pub-id-type="doi">10.13040/IJPSR.0975-8232.6(10).4103-12.Medicinal</pub-id><pub-id pub-id-type="pmid">26594645</pub-id></element-citation></ref><ref id="B44-pharmaceuticals-14-00157"><label>44.</label><element-citation publication-type="gov"><article-title>FDA Food and Drud Administration Approved Drug Products&#x02014;Orange Book</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm">https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-12-31">(accessed on 31 December 2020)</date-in-citation></element-citation></ref><ref id="B45-pharmaceuticals-14-00157"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>I.-H.</given-names></name><name><surname>Bodnar</surname><given-names>J.A.</given-names></name><name><surname>Bowman</surname><given-names>R.N.</given-names></name><name><surname>White</surname><given-names>E.L.</given-names></name></person-group><article-title>Determination of Vincristine and Vinblastine in <italic>Catharanthus roseus</italic> Plants by High Performance Liquid Chromatography/Electrospray Ionization Mass Spectrometry</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>1997</year><volume>20</volume><fpage>1159</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1080/10826079708010966</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-14-00157"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.-T.</given-names></name><name><surname>Huang</surname><given-names>Y.-W.</given-names></name><name><surname>Yang</surname><given-names>C.-H.</given-names></name><name><surname>Huang</surname><given-names>K.-S.</given-names></name></person-group><article-title>Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids</article-title><source>Curr. Top. Med. Chem.</source><year>2015</year><volume>15</volume><fpage>1491</fpage><lpage>1500</lpage><pub-id pub-id-type="doi">10.2174/1568026615666150414120547</pub-id><?supplied-pmid 25877096?><pub-id pub-id-type="pmid">25877096</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-14-00157"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>H.</given-names></name><name><surname>Colby</surname><given-names>D.A.</given-names></name><name><surname>Seto</surname><given-names>S.</given-names></name><name><surname>Va</surname><given-names>P.</given-names></name><name><surname>Tam</surname><given-names>A.</given-names></name><name><surname>Kakei</surname><given-names>H.</given-names></name><name><surname>Rayl</surname><given-names>T.J.</given-names></name><name><surname>Hwang</surname><given-names>I.</given-names></name><name><surname>Boger</surname><given-names>D.L.</given-names></name></person-group><article-title>Total synthesis of vinblastine, vincristine, related natural products, and key structural analogues</article-title><source>J. Am. Chem. Soc.</source><year>2009</year><volume>131</volume><fpage>4904</fpage><lpage>4916</lpage><pub-id pub-id-type="doi">10.1021/ja809842b</pub-id><?supplied-pmid 19292450?><pub-id pub-id-type="pmid">19292450</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-14-00157"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martino</surname><given-names>E.</given-names></name><name><surname>Casamassima</surname><given-names>G.</given-names></name><name><surname>Castiglione</surname><given-names>S.</given-names></name><name><surname>Cellupica</surname><given-names>E.</given-names></name><name><surname>Pantalone</surname><given-names>S.</given-names></name><name><surname>Papagni</surname><given-names>F.</given-names></name><name><surname>Rui</surname><given-names>M.</given-names></name><name><surname>Siciliano</surname><given-names>A.M.</given-names></name><name><surname>Collina</surname><given-names>S.</given-names></name></person-group><article-title>Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2018</year><volume>28</volume><fpage>2816</fpage><lpage>2826</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2018.06.044</pub-id><?supplied-pmid 30122223?><pub-id pub-id-type="pmid">30122223</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-14-00157"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>M.A.</given-names></name><name><surname>Himes</surname><given-names>R.H.</given-names></name><name><surname>Wilson</surname><given-names>L.</given-names></name></person-group><article-title>Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro</article-title><source>Cancer Res.</source><year>1985</year><volume>45</volume><fpage>2741</fpage><lpage>2747</lpage><pub-id pub-id-type="pmid">3986806</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-14-00157"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobert</surname><given-names>S.</given-names></name><name><surname>Vulevic</surname><given-names>B.</given-names></name><name><surname>Correia</surname><given-names>J.J.</given-names></name></person-group><article-title>Interaction of Vinca Alkaloids with Tubulin: A Comparison of Vinblastine, Vincristine, and Vinorelbine</article-title><source>Biochemistry</source><year>1996</year><volume>35</volume><fpage>6806</fpage><lpage>6814</lpage><pub-id pub-id-type="doi">10.1021/bi953037i</pub-id><pub-id pub-id-type="pmid">8639632</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-14-00157"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sertel</surname><given-names>S.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Zu</surname><given-names>Y.</given-names></name><name><surname>Rebacz</surname><given-names>B.</given-names></name><name><surname>Konkimalla</surname><given-names>B.</given-names></name><name><surname>Plinkert</surname><given-names>P.K.</given-names></name><name><surname>Kr&#x000e4;mer</surname><given-names>A.</given-names></name><name><surname>Gertsch</surname><given-names>J.</given-names></name><name><surname>Efferth</surname><given-names>T.</given-names></name></person-group><article-title>Molecular docking and pharmacogenomics of Vinca alkaloids and their monomeric precursors, vindoline and catharanthine</article-title><source>Biochem. Pharmacol.</source><year>2011</year><volume>81</volume><fpage>723</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2010.12.026</pub-id><?supplied-pmid 21219884?><pub-id pub-id-type="pmid">21219884</pub-id></element-citation></ref><ref id="B52-pharmaceuticals-14-00157"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taher</surname><given-names>M.A.</given-names></name><name><surname>Foundation</surname><given-names>I.B.</given-names></name></person-group><article-title>Vinca alkaloid&#x02014;The second most used alkaloid for cancer treatment&#x02014;A review</article-title><source>Int. J. Physiol. Nutr. Phys. Educ.</source><year>2017</year><volume>2</volume><fpage>723</fpage><lpage>727</lpage></element-citation></ref><ref id="B53-pharmaceuticals-14-00157"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almagro</surname><given-names>L.</given-names></name><name><surname>Fern&#x000e1;ndez-P&#x000e9;rez</surname><given-names>F.</given-names></name><name><surname>Pedre&#x000f1;o</surname><given-names>M.A.</given-names></name></person-group><article-title>Indole Alkaloids from Catharanthus roseus: Bioproduction and Their Effect on Human Health</article-title><source>Molecules</source><year>2015</year><volume>20</volume><fpage>2973</fpage><lpage>3000</lpage><pub-id pub-id-type="doi">10.3390/molecules20022973</pub-id><?supplied-pmid 25685907?><pub-id pub-id-type="pmid">25685907</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-14-00157"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seca</surname><given-names>A.M.L.</given-names></name><name><surname>Pinto</surname><given-names>D.C.G.A.</given-names></name></person-group><article-title>Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>263</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19010263</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-14-00157"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuruvilla</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>K.</given-names></name><name><surname>Mollee</surname><given-names>P.</given-names></name><name><surname>Panzarella</surname><given-names>T.</given-names></name><name><surname>McCrae</surname><given-names>J.</given-names></name><name><surname>Nagy</surname><given-names>T.</given-names></name><name><surname>Crump</surname><given-names>M.</given-names></name><name><surname>Keating</surname><given-names>A.</given-names></name></person-group><article-title>A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin&#x02019;s lymphoma</article-title><source>Hematology</source><year>2006</year><volume>11</volume><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1080/10245330500276592</pub-id><?supplied-pmid 16522545?><pub-id pub-id-type="pmid">16522545</pub-id></element-citation></ref><ref id="B56-pharmaceuticals-14-00157"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>S.D.</given-names></name><name><surname>Whissell</surname><given-names>M.</given-names></name><name><surname>Noble</surname><given-names>J.C.S.</given-names></name><name><surname>Cano</surname><given-names>P.O.</given-names></name><name><surname>Lopez</surname><given-names>P.G.</given-names></name><name><surname>Germond</surname><given-names>C.J.</given-names></name></person-group><article-title>Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors</article-title><source>Clin. Cancer Res.</source><year>2006</year><volume>12</volume><fpage>3092</fpage><lpage>3098</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2255</pub-id><?supplied-pmid 16707607?><pub-id pub-id-type="pmid">16707607</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-14-00157"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitamura</surname><given-names>H.</given-names></name><name><surname>Tsukamoto</surname><given-names>T.</given-names></name><name><surname>Shibata</surname><given-names>T.</given-names></name><name><surname>Masumori</surname><given-names>N.</given-names></name><name><surname>Fujimoto</surname><given-names>H.</given-names></name><name><surname>Hirao</surname><given-names>Y.</given-names></name><name><surname>Fujimoto</surname><given-names>K.</given-names></name><name><surname>Kitamura</surname><given-names>Y.</given-names></name><name><surname>Tomita</surname><given-names>Y.</given-names></name><name><surname>Tobisu</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study</article-title><source>Ann. Oncol.</source><year>2014</year><volume>25</volume><fpage>1192</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu126</pub-id><pub-id pub-id-type="pmid">24669010</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-14-00157"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerullis</surname><given-names>H.</given-names></name><name><surname>Wawroschek</surname><given-names>F.</given-names></name><name><surname>K&#x000f6;hne</surname><given-names>C.H.</given-names></name><name><surname>Ecke</surname><given-names>T.H.</given-names></name></person-group><article-title>Vinflunine in the treatment of advanced urothelial cancer: Clinical evidence and experience</article-title><source>Ther. Adv. Urol.</source><year>2017</year><volume>9</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1177/1756287216677903</pub-id><pub-id pub-id-type="pmid">28042310</pub-id></element-citation></ref><ref id="B59-pharmaceuticals-14-00157"><label>59.</label><element-citation publication-type="gov"><article-title>PubChem Compound Summary for CID 16760674, Taxol<sup>&#x000ae;</sup></article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/16760674">https://pubchem.ncbi.nlm.nih.gov/compound/16760674</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-12-30">(accessed on 30 December 2020)</date-in-citation></element-citation></ref><ref id="B60-pharmaceuticals-14-00157"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergman</surname><given-names>M.E.</given-names></name><name><surname>Davis</surname><given-names>B.</given-names></name><name><surname>Phillips</surname><given-names>M.A.</given-names></name></person-group><article-title>Medically useful plant terpenoids: Biosynthesis, occurrence, and mechanism of action</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>3961</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24213961</pub-id></element-citation></ref><ref id="B61-pharmaceuticals-14-00157"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernabeu</surname><given-names>E.</given-names></name><name><surname>Cagel</surname><given-names>M.</given-names></name><name><surname>Lagomarsino</surname><given-names>E.</given-names></name><name><surname>Moretton</surname><given-names>M.</given-names></name><name><surname>Chiappetta</surname><given-names>D.A.</given-names></name></person-group><article-title>Paclitaxel: What has been done and the challenges remain ahead</article-title><source>Int. J. Pharm.</source><year>2017</year><volume>526</volume><fpage>474</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.05.016</pub-id><pub-id pub-id-type="pmid">28501439</pub-id></element-citation></ref><ref id="B62-pharmaceuticals-14-00157"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Jiang</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Ling</surname><given-names>X.</given-names></name></person-group><article-title>Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer?</article-title><source>Am. J. Cancer Res.</source><year>2017</year><volume>7</volume><fpage>2350</fpage><lpage>2394</lpage><pub-id pub-id-type="pmid">29312794</pub-id></element-citation></ref><ref id="B63-pharmaceuticals-14-00157"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>R.</given-names></name></person-group><article-title>Cancer therapies utilizing the camptothecins: A Review of the in vivo literature</article-title><source>Mol. Pharm.</source><year>2010</year><volume>7</volume><fpage>307</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1021/mp900243b</pub-id><pub-id pub-id-type="pmid">20108971</pub-id></element-citation></ref><ref id="B64-pharmaceuticals-14-00157"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kciuk</surname><given-names>M.</given-names></name><name><surname>Marciniak</surname><given-names>B.</given-names></name><name><surname>Kontek</surname><given-names>R.</given-names></name></person-group><article-title>Irinotecan&#x02014;Still an important player in cancer chemotherapy: A comprehensive overview</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>4919</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21144919</pub-id><?supplied-pmid 32664667?><pub-id pub-id-type="pmid">32664667</pub-id></element-citation></ref><ref id="B65-pharmaceuticals-14-00157"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>K.I.</given-names></name><name><surname>Sasaki</surname><given-names>Y.</given-names></name></person-group><article-title>Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: From patients enrolled in clinical trials to those in the &#x0201c;real world&#x0201d;</article-title><source>Drug Metab. Pharmacokinet.</source><year>2014</year><volume>29</volume><fpage>20</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.2133/dmpk.DMPK-13-RV-103</pub-id><pub-id pub-id-type="pmid">24256625</pub-id></element-citation></ref><ref id="B66-pharmaceuticals-14-00157"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahid</surname><given-names>M.</given-names></name></person-group><article-title>Camptothecin and its analogs antitumor activity by poisoning topoisomerase I, their structure activity relationship and clinical development perspective of analogs</article-title><source>J. App. Pharm.</source><year>2016</year><volume>6</volume><fpage>286</fpage><lpage>295</lpage></element-citation></ref><ref id="B67-pharmaceuticals-14-00157"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Rakesh</surname><given-names>K.P.</given-names></name><name><surname>Shantharam</surname><given-names>C.S.</given-names></name><name><surname>Manukumar</surname><given-names>H.M.</given-names></name><name><surname>Asiri</surname><given-names>A.M.</given-names></name><name><surname>Marwani</surname><given-names>H.M.</given-names></name><name><surname>Qin</surname><given-names>H.</given-names></name></person-group><article-title>Bioorganic &#x00026; Medicinal Chemistry Podophyllotoxin derivatives as an excellent anticancer aspirant for future chemotherapy: A key current imminent needs</article-title><source>Bioorg. Med. Chem.</source><year>2018</year><volume>26</volume><fpage>340</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2017.11.026</pub-id><?supplied-pmid 29269253?><pub-id pub-id-type="pmid">29269253</pub-id></element-citation></ref><ref id="B68-pharmaceuticals-14-00157"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carolina</surname><given-names>N.</given-names></name><name><surname>Hill</surname><given-names>C.</given-names></name><name><surname>Carolina</surname><given-names>N.</given-names></name></person-group><article-title>Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents</article-title><source>Med. Res. Rev.</source><year>2016</year><volume>35</volume><fpage>1</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1002/med.21319</pub-id></element-citation></ref><ref id="B69-pharmaceuticals-14-00157"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardalani</surname><given-names>H.</given-names></name><name><surname>Avan</surname><given-names>A.</given-names></name><name><surname>Ghayour-mobarhan</surname><given-names>M.</given-names></name></person-group><article-title>Podophyllotoxin: A novel potential natural anticancer agent</article-title><source>Avicenna J. Phytomed.</source><year>2017</year><volume>7</volume><fpage>285</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">28884079</pub-id></element-citation></ref><ref id="B70-pharmaceuticals-14-00157"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicenas</surname><given-names>J.</given-names></name><name><surname>Kalyan</surname><given-names>K.</given-names></name><name><surname>Sorokinas</surname><given-names>A.</given-names></name><name><surname>Stankunas</surname><given-names>E.</given-names></name><name><surname>Levy</surname><given-names>J.</given-names></name><name><surname>Meskinyte</surname><given-names>I.</given-names></name><name><surname>Stankevicius</surname><given-names>V.</given-names></name><name><surname>Kaupinis</surname><given-names>A.</given-names></name><name><surname>Valius</surname><given-names>M.</given-names></name></person-group><article-title>Roscovitine in cancer and other diseases</article-title><source>Ann. Transl. Med.</source><year>2015</year><volume>3</volume><fpage>135</fpage><pub-id pub-id-type="pmid">26207228</pub-id></element-citation></ref><ref id="B71-pharmaceuticals-14-00157"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delehouz&#x000e9;</surname><given-names>C.</given-names></name><name><surname>Godl</surname><given-names>K.</given-names></name><name><surname>Loa&#x000eb;c</surname><given-names>N.</given-names></name><name><surname>Bruy&#x000e8;re</surname><given-names>C.</given-names></name><name><surname>Desban</surname><given-names>N.</given-names></name><name><surname>Oumata</surname><given-names>N.</given-names></name><name><surname>Galons</surname><given-names>H.</given-names></name><name><surname>Roumeliotis</surname><given-names>T.I.</given-names></name><name><surname>Giannopoulou</surname><given-names>E.G.</given-names></name><name><surname>Grenet</surname><given-names>J.</given-names></name><etal/></person-group><article-title>CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells</article-title><source>Oncogene</source><year>2014</year><volume>33</volume><fpage>5675</fpage><lpage>5687</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.513</pub-id><pub-id pub-id-type="pmid">24317512</pub-id></element-citation></ref><ref id="B72-pharmaceuticals-14-00157"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>H.S.</given-names></name><name><surname>Mitev</surname><given-names>V.</given-names></name><name><surname>Vlaykova</surname><given-names>T.</given-names></name><name><surname>Cavicchi</surname><given-names>L.</given-names></name><name><surname>Zhelev</surname><given-names>N.</given-names></name></person-group><article-title>Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance</article-title><source>J. Biotechnol.</source><year>2015</year><volume>202</volume><fpage>40</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">25747275</pub-id></element-citation></ref><ref id="B73-pharmaceuticals-14-00157"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodoropoulou</surname><given-names>M.</given-names></name><name><surname>Reincke</surname><given-names>M.</given-names></name></person-group><article-title>Tumor-Directed Therapeutic Targets in Cushing Disease</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2019</year><volume>104</volume><fpage>925</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1210/jc.2018-02080</pub-id><?supplied-pmid 30535260?><pub-id pub-id-type="pmid">30535260</pub-id></element-citation></ref><ref id="B74-pharmaceuticals-14-00157"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gary</surname><given-names>C.</given-names></name><name><surname>Hajek</surname><given-names>M.</given-names></name><name><surname>Biktasova</surname><given-names>A.</given-names></name><name><surname>Bellinger</surname><given-names>G.</given-names></name><name><surname>Wendell</surname><given-names>G.</given-names></name></person-group><article-title>Selective antitumor activity of roscovitine in head and neck cancer</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>38598</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.9560</pub-id><?supplied-pmid 27233076?><pub-id pub-id-type="pmid">27233076</pub-id></element-citation></ref><ref id="B75-pharmaceuticals-14-00157"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipolla</surname><given-names>B.G.</given-names></name><name><surname>Mandron</surname><given-names>E.</given-names></name><name><surname>Marc Lefort</surname><given-names>J.</given-names></name><name><surname>Coadou</surname><given-names>Y.</given-names></name><name><surname>Della Negra</surname><given-names>E.</given-names></name><name><surname>Corbel</surname><given-names>L.</given-names></name><name><surname>Le Scodan</surname><given-names>R.</given-names></name><name><surname>Rahmene Azzouzi</surname><given-names>A.</given-names></name><name><surname>Mottet</surname><given-names>N.</given-names></name></person-group><article-title>Effect of sulforaphane in men with biochemical recurrence after radical prostatectomy</article-title><source>Cancer Prev. Res.</source><year>2015</year><volume>8</volume><fpage>712</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-14-0459</pub-id><?supplied-pmid 25968598?><pub-id pub-id-type="pmid">25968598</pub-id></element-citation></ref><ref id="B76-pharmaceuticals-14-00157"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alumkal</surname><given-names>J.J.</given-names></name><name><surname>Slottke</surname><given-names>R.</given-names></name><name><surname>Schwartzman</surname><given-names>J.</given-names></name><name><surname>Cherala</surname><given-names>G.</given-names></name><name><surname>Munar</surname><given-names>M.</given-names></name><name><surname>Graff</surname><given-names>J.N.</given-names></name><name><surname>Beer</surname><given-names>T.M.</given-names></name><name><surname>Ryan</surname><given-names>C.W.</given-names></name><name><surname>Koop</surname><given-names>D.R.</given-names></name><name><surname>Gibbs</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer</article-title><source>Investig. New Drugs</source><year>2015</year><volume>33</volume><fpage>480</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1007/s10637-014-0189-z</pub-id><pub-id pub-id-type="pmid">25431127</pub-id></element-citation></ref><ref id="B77-pharmaceuticals-14-00157"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Yi</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Yuan</surname><given-names>C.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name></person-group><article-title>Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells</article-title><source>Cancer Lett.</source><year>2020</year><volume>493</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2020.08.041</pub-id><?supplied-pmid 32891712?><pub-id pub-id-type="pmid">32891712</pub-id></element-citation></ref><ref id="B78-pharmaceuticals-14-00157"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howells</surname><given-names>L.M.</given-names></name><name><surname>Berry</surname><given-names>D.P.</given-names></name><name><surname>Elliott</surname><given-names>P.J.</given-names></name><name><surname>Jacobson</surname><given-names>E.W.</given-names></name><name><surname>Hoffmann</surname><given-names>E.</given-names></name><name><surname>Hegarty</surname><given-names>B.</given-names></name><name><surname>Brown</surname><given-names>K.</given-names></name><name><surname>Steward</surname><given-names>W.P.</given-names></name><name><surname>Gescher</surname><given-names>A.J.</given-names></name></person-group><article-title>Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases&#x02014;Safety, pharmacokinetics, and pharmacodynamics</article-title><source>Cancer Prev. Res.</source><year>2011</year><volume>4</volume><fpage>1419</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-11-0148</pub-id></element-citation></ref><ref id="B79-pharmaceuticals-14-00157"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Qin</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Rottinghaus</surname><given-names>G.E.</given-names></name><name><surname>Chen</surname><given-names>Y.C.</given-names></name><name><surname>Kliethermes</surname><given-names>B.</given-names></name><name><surname>Sauter</surname><given-names>E.R.</given-names></name></person-group><article-title>Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer</article-title><source>Nutr. Cancer</source><year>2012</year><volume>64</volume><fpage>393</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1080/01635581.2012.654926</pub-id><pub-id pub-id-type="pmid">22332908</pub-id></element-citation></ref><ref id="B80-pharmaceuticals-14-00157"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paller</surname><given-names>C.J.</given-names></name><name><surname>Rudek</surname><given-names>M.A.</given-names></name><name><surname>Zhou</surname><given-names>X.C.</given-names></name><name><surname>Wagner</surname><given-names>W.</given-names></name><name><surname>Hudson</surname><given-names>T.S.</given-names></name><name><surname>Anders</surname><given-names>N.</given-names></name><name><surname>Hammers</surname><given-names>H.</given-names></name><name><surname>Dowling</surname><given-names>D.</given-names></name><name><surname>King</surname><given-names>S.</given-names></name><name><surname>Antoranakis</surname><given-names>E.</given-names></name><etal/></person-group><article-title>A Phase I Study of Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: Safety, Tolerability, and Dose Determination</article-title><source>Prostate</source><year>2015</year><volume>75</volume><fpage>1518</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1002/pros.23024</pub-id><pub-id pub-id-type="pmid">26012728</pub-id></element-citation></ref><ref id="B81-pharmaceuticals-14-00157"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paller</surname><given-names>C.J.</given-names></name><name><surname>Zhou</surname><given-names>X.C.</given-names></name><name><surname>Heath</surname><given-names>E.I.</given-names></name><name><surname>Taplin</surname><given-names>M.E.</given-names></name><name><surname>Mayer</surname><given-names>T.M.</given-names></name><name><surname>Stein</surname><given-names>M.N.</given-names></name><name><surname>Bubley</surname><given-names>G.J.</given-names></name><name><surname>Pili</surname><given-names>R.</given-names></name><name><surname>Hudson</surname><given-names>T.S.</given-names></name><name><surname>Kakarla</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo- Controlled Clinical Trial</article-title><source>Clin. Cancer Res.</source><year>2018</year><volume>24</volume><fpage>306</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-1100</pub-id><pub-id pub-id-type="pmid">29113986</pub-id></element-citation></ref><ref id="B82-pharmaceuticals-14-00157"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastorelli</surname><given-names>D.</given-names></name><name><surname>Fabricio</surname><given-names>A.S.C.</given-names></name><name><surname>Giovanis</surname><given-names>P.</given-names></name><name><surname>D&#x02019;Ippolito</surname><given-names>S.</given-names></name><name><surname>Fiduccia</surname><given-names>P.</given-names></name><name><surname>Sold&#x000e0;</surname><given-names>C.</given-names></name><name><surname>Buda</surname><given-names>A.</given-names></name><name><surname>Sperti</surname><given-names>C.</given-names></name><name><surname>Bardini</surname><given-names>R.</given-names></name><name><surname>Da Dalt</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial</article-title><source>Pharmacol. Res.</source><year>2018</year><volume>132</volume><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.03.013</pub-id><pub-id pub-id-type="pmid">29614381</pub-id></element-citation></ref><ref id="B83-pharmaceuticals-14-00157"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saghatelyan</surname><given-names>T.</given-names></name><name><surname>Tananyan</surname><given-names>A.</given-names></name><name><surname>Janoyan</surname><given-names>N.</given-names></name><name><surname>Tadevosyan</surname><given-names>A.</given-names></name><name><surname>Petrosyan</surname><given-names>H.</given-names></name><name><surname>Hovhannisyan</surname><given-names>A.</given-names></name><name><surname>Hayrapetyan</surname><given-names>L.</given-names></name><name><surname>Arustamyan</surname><given-names>M.</given-names></name><name><surname>Arnhold</surname><given-names>J.</given-names></name><name><surname>Rotmann</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial</article-title><source>Phytomedicine</source><year>2020</year><volume>70</volume><fpage>153218</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2020.153218</pub-id><pub-id pub-id-type="pmid">32335356</pub-id></element-citation></ref><ref id="B84-pharmaceuticals-14-00157"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekstr&#x000f6;m</surname><given-names>A.M.</given-names></name><name><surname>Serafini</surname><given-names>M.</given-names></name><name><surname>Nyr&#x000e9;n</surname><given-names>O.</given-names></name><name><surname>Wolk</surname><given-names>A.</given-names></name><name><surname>Bosetti</surname><given-names>C.</given-names></name><name><surname>Bellocco</surname><given-names>R.</given-names></name></person-group><article-title>Dietary quercetin intake and risk of gastric cancer: Results from a population-based study in Sweden</article-title><source>Ann. Oncol.</source><year>2011</year><volume>22</volume><fpage>438</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq390</pub-id><pub-id pub-id-type="pmid">20688844</pub-id></element-citation></ref><ref id="B85-pharmaceuticals-14-00157"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citronberg</surname><given-names>J.</given-names></name><name><surname>Bostick</surname><given-names>R.</given-names></name><name><surname>Ahearn</surname><given-names>T.</given-names></name><name><surname>Turgeon</surname><given-names>D.K.</given-names></name><name><surname>Ruf</surname><given-names>M.T.</given-names></name><name><surname>Djuric</surname><given-names>Z.</given-names></name><name><surname>Sen</surname><given-names>A.</given-names></name><name><surname>Brenner</surname><given-names>D.E.</given-names></name><name><surname>Zick</surname><given-names>S.M.</given-names></name></person-group><article-title>Effects of Ginger Supplementation on Cell-Cycle Biomarkers in the Normal-Appearing Colonic Mucosa of Patients at Increased Risk for Colorectal Cancer: Results from a Pilot, Randomized, and Controlled Trial</article-title><source>Cancer Pre.</source><year>2013</year><volume>6</volume><fpage>271</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-12-0327</pub-id></element-citation></ref><ref id="B86-pharmaceuticals-14-00157"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danwilai</surname><given-names>K.</given-names></name><name><surname>Konmun</surname><given-names>J.</given-names></name><name><surname>Sripanidkulchai</surname><given-names>B.</given-names></name><name><surname>Subongkot</surname><given-names>S.</given-names></name></person-group><article-title>Antioxidant activity of ginger extract as a daily supplement in cancer patients receiving adjuvant chemotherapy: a pilot study</article-title><source>Cancer Manag. Res.</source><year>2017</year><volume>9</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S124016</pub-id><pub-id pub-id-type="pmid">28203106</pub-id></element-citation></ref><ref id="B87-pharmaceuticals-14-00157"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konmun</surname><given-names>J.</given-names></name><name><surname>Danwilai</surname><given-names>K.</given-names></name><name><surname>Ngamphaiboon</surname><given-names>N.</given-names></name><name><surname>Sripanidkulchai</surname><given-names>B.</given-names></name><name><surname>Sookprasert</surname><given-names>A.</given-names></name><name><surname>Subongkot</surname><given-names>S.</given-names></name></person-group><article-title>A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy</article-title><source>Med. Oncol.</source><year>2017</year><volume>34</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s12032-017-0931-4</pub-id><?supplied-pmid 28349496?><pub-id pub-id-type="pmid">27889880</pub-id></element-citation></ref><ref id="B88-pharmaceuticals-14-00157"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gates</surname><given-names>M.A.</given-names></name><name><surname>Tworoger</surname><given-names>S.S.</given-names></name><name><surname>Hecht</surname><given-names>J.L.</given-names></name><name><surname>De Vivo</surname><given-names>I.</given-names></name><name><surname>Rosner</surname><given-names>B.</given-names></name><name><surname>Hankinson</surname><given-names>S.E.</given-names></name></person-group><article-title>A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer</article-title><source>Int. J. Cancer</source><year>2007</year><volume>121</volume><fpage>2225</fpage><lpage>2232</lpage><pub-id pub-id-type="doi">10.1002/ijc.22790</pub-id><?supplied-pmid 17471564?><pub-id pub-id-type="pmid">17471564</pub-id></element-citation></ref><ref id="B89-pharmaceuticals-14-00157"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000f6;thlings</surname><given-names>U.</given-names></name><name><surname>Murphy</surname><given-names>S.P.</given-names></name><name><surname>Wilkens</surname><given-names>L.R.</given-names></name><name><surname>Henderson</surname><given-names>B.E.</given-names></name><name><surname>Kolonel</surname><given-names>L.N.</given-names></name></person-group><article-title>Flavonols and pancreatic cancer risk: The multiethnic cohort study</article-title><source>Am. J. Epidemiol.</source><year>2007</year><volume>166</volume><fpage>924</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1093/aje/kwm172</pub-id><?supplied-pmid 17690219?><pub-id pub-id-type="pmid">17690219</pub-id></element-citation></ref><ref id="B90-pharmaceuticals-14-00157"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>151</volume><fpage>482</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.04.011</pub-id><pub-id pub-id-type="pmid">29649743</pub-id></element-citation></ref><ref id="B91-pharmaceuticals-14-00157"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghawanmeh</surname><given-names>A.A.</given-names></name><name><surname>Chong</surname><given-names>K.F.</given-names></name><name><surname>Sarkar</surname><given-names>S.M.</given-names></name><name><surname>Bakar</surname><given-names>M.A.</given-names></name><name><surname>Othaman</surname><given-names>R.</given-names></name><name><surname>Khalid</surname><given-names>R.M.</given-names></name></person-group><article-title>Colchicine prodrugs and codrugs: Chemistry and bioactivities</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>144</volume><fpage>229</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.12.029</pub-id><pub-id pub-id-type="pmid">29274490</pub-id></element-citation></ref><ref id="B92-pharmaceuticals-14-00157"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majcher</surname><given-names>U.</given-names></name><name><surname>Klejborowska</surname><given-names>G.</given-names></name><name><surname>Kaik</surname><given-names>M.</given-names></name><name><surname>Maj</surname><given-names>E.</given-names></name><name><surname>Wietrzyk</surname><given-names>J.</given-names></name><name><surname>Barl</surname><given-names>F.</given-names></name><name><surname>Predo</surname><given-names>J.</given-names></name><name><surname>Tuszynski</surname><given-names>J.A.</given-names></name><name><surname>Huczynski</surname><given-names>A.</given-names></name></person-group><article-title>Antiproliferative Activity and Molecular Docking of Novel Double-Modified Colchicine Derivatives</article-title><source>Cells</source><year>2018</year><volume>7</volume><elocation-id>192</elocation-id><pub-id pub-id-type="doi">10.3390/cells7110192</pub-id></element-citation></ref><ref id="B93-pharmaceuticals-14-00157"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majcher</surname><given-names>U.</given-names></name><name><surname>Klejborowska</surname><given-names>G.</given-names></name><name><surname>Kaik</surname><given-names>M.</given-names></name><name><surname>Maj</surname><given-names>E.</given-names></name><name><surname>Wietrzyk</surname><given-names>J.</given-names></name><name><surname>Moshari</surname><given-names>M.</given-names></name><name><surname>Predo</surname><given-names>J.</given-names></name><name><surname>Tuszynski</surname><given-names>J.A.</given-names></name><name><surname>Huczynski</surname><given-names>A.</given-names></name></person-group><article-title>Synthesis and Biological Evaluation of Novel Triple-Modified Colchicine Derivatives as Potent Tubulin-Targeting</article-title><source>Cells</source><year>2018</year><volume>7</volume><elocation-id>216</elocation-id><pub-id pub-id-type="doi">10.3390/cells7110216</pub-id></element-citation></ref><ref id="B94-pharmaceuticals-14-00157"><label>94.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Akhtar</surname><given-names>M.S.</given-names></name><name><surname>Swammy</surname><given-names>M.K.</given-names></name></person-group><source>Anticancer Plants: Clinical Trials and Nanotechnology</source><publisher-name>Springer</publisher-name><publisher-loc>Singapore</publisher-loc><year>2017</year><volume>Volume 3</volume></element-citation></ref><ref id="B95-pharmaceuticals-14-00157"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chartoumpekis</surname><given-names>D.V.</given-names></name><name><surname>Ziros</surname><given-names>P.G.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Groopman</surname><given-names>J.D.</given-names></name><name><surname>Kensler</surname><given-names>T.W.</given-names></name><name><surname>Sykiotis</surname><given-names>G.P.</given-names></name></person-group><article-title>Broccoli sprout beverage is safe for thyroid hormonal and autoimmune status: results of a 12-week randomized trial</article-title><source>Food Chem. Toxicol.</source><year>2020</year><volume>126</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2019.02.004</pub-id></element-citation></ref><ref id="B96-pharmaceuticals-14-00157"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuran</surname><given-names>D.</given-names></name><name><surname>Pogorzelska</surname><given-names>A.</given-names></name></person-group><article-title>Breast Cancer Prevention-Is there a Future for Sulforaphane and Its Analogs?</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><elocation-id>1559</elocation-id><pub-id pub-id-type="doi">10.3390/nu12061559</pub-id><?supplied-pmid 32471217?><pub-id pub-id-type="pmid">32471217</pub-id></element-citation></ref><ref id="B97-pharmaceuticals-14-00157"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soundararajan</surname><given-names>P.</given-names></name><name><surname>Kim</surname><given-names>J.S.</given-names></name></person-group><article-title>Vegetables and Their Antagonistic Effects on Prevention of Cancers</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>2983</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23112983</pub-id><?supplied-pmid 30445746?><pub-id pub-id-type="pmid">30445746</pub-id></element-citation></ref><ref id="B98-pharmaceuticals-14-00157"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahey</surname><given-names>J.W.</given-names></name><name><surname>Wade</surname><given-names>K.L.</given-names></name><name><surname>Wehage</surname><given-names>S.L.</given-names></name><name><surname>Holtzclaw</surname><given-names>W.D.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Talalay</surname><given-names>P.</given-names></name><name><surname>Fuchs</surname><given-names>E.</given-names></name><name><surname>Stephenson</surname><given-names>K.K.</given-names></name></person-group><article-title>Stabilized sulforaphane for clinical use: Phytochemical delivery efficiency</article-title><source>Mol. Nutr. Food Res.</source><year>2017</year><volume>61</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201600766</pub-id></element-citation></ref><ref id="B99-pharmaceuticals-14-00157"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Meng</surname><given-names>L.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Xin</surname><given-names>Y.</given-names></name></person-group><article-title>Anticancer activity of sulforaphane: The epigenetic mechanisms and the Nrf2 signaling pathway</article-title><source>Oxid. Med. Cell. Longev.</source><year>2018</year><volume>2018</volume><fpage>5438179</fpage><pub-id pub-id-type="doi">10.1155/2018/5438179</pub-id><pub-id pub-id-type="pmid">29977456</pub-id></element-citation></ref><ref id="B100-pharmaceuticals-14-00157"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leone</surname><given-names>A.</given-names></name><name><surname>Diorio</surname><given-names>G.</given-names></name><name><surname>Sexton</surname><given-names>W.</given-names></name><name><surname>Schell</surname><given-names>M.</given-names></name><name><surname>Alexandrow</surname><given-names>M.</given-names></name><name><surname>Fahey</surname><given-names>J.W.</given-names></name><name><surname>Kumar</surname><given-names>N.B.</given-names></name></person-group><article-title>Sulforaphane for the chemoprevention of bladder cancer: Molecular mechanism targeted approach</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>35412</fpage><lpage>35424</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16015</pub-id><pub-id pub-id-type="pmid">28423681</pub-id></element-citation></ref><ref id="B101-pharmaceuticals-14-00157"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabbarzadeh</surname><given-names>P.</given-names></name><name><surname>Afzalipour</surname><given-names>M.</given-names></name><name><surname>Mohammadi</surname><given-names>M.</given-names></name></person-group><article-title>Targets and mechanisms of sulforaphane derivatives obtained from cruciferous plants with special focus on breast cancer&#x02014;Contradictory effects and future perspectives</article-title><source>Biomed. Pharmacother.</source><year>2020</year><volume>121</volume><fpage>109635</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2019.109635</pub-id><?supplied-pmid 31739165?><pub-id pub-id-type="pmid">31739165</pub-id></element-citation></ref><ref id="B102-pharmaceuticals-14-00157"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>H.U.A.</given-names></name><name><surname>Lee</surname><given-names>E.D.</given-names></name><name><surname>Grandis</surname><given-names>J.R.</given-names></name><name><surname>Bauman</surname><given-names>J.E.</given-names></name><name><surname>Johnson</surname><given-names>D.E.</given-names></name></person-group><article-title>Gene targets of sulforaphane in head and neck squamous cell carcinoma</article-title><source>Mol. Med. Rep.</source><year>2019</year><fpage>5335</fpage><lpage>5344</lpage><pub-id pub-id-type="doi">10.3892/mmr.2019.10766</pub-id></element-citation></ref><ref id="B103-pharmaceuticals-14-00157"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scarano</surname><given-names>A.</given-names></name><name><surname>Chieppa</surname><given-names>M.</given-names></name><name><surname>Santino</surname><given-names>A.</given-names></name></person-group><article-title>Plant polyphenols-biofortified foods as a novel tool for the prevention of human gut diseases</article-title><source>Antioxidants</source><year>2020</year><volume>9</volume><elocation-id>1225</elocation-id><pub-id pub-id-type="doi">10.3390/antiox9121225</pub-id></element-citation></ref><ref id="B104-pharmaceuticals-14-00157"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heim</surname><given-names>K.E.</given-names></name><name><surname>Tagliaferro</surname><given-names>A.R.</given-names></name><name><surname>Bobilya</surname><given-names>D.J.</given-names></name></person-group><article-title>Flavonoid antioxidants: Chemistry, metabolism and structure-activity relationships</article-title><source>J. Nutr. Biochem.</source><year>2002</year><volume>13</volume><fpage>572</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/S0955-2863(02)00208-5</pub-id><pub-id pub-id-type="pmid">12550068</pub-id></element-citation></ref><ref id="B105-pharmaceuticals-14-00157"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravishankar</surname><given-names>D.</given-names></name><name><surname>Rajora</surname><given-names>A.K.</given-names></name><name><surname>Greco</surname><given-names>F.</given-names></name><name><surname>Osborn</surname><given-names>H.M.I.</given-names></name></person-group><article-title>Flavonoids as prospective compounds for anti-cancer therapy</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2013</year><volume>45</volume><fpage>2821</fpage><lpage>2831</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2013.10.004</pub-id><pub-id pub-id-type="pmid">24128857</pub-id></element-citation></ref><ref id="B106-pharmaceuticals-14-00157"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>F.</given-names></name><name><surname>Yan</surname><given-names>W.J.</given-names></name><name><surname>Du</surname><given-names>Y.T.</given-names></name><name><surname>Bao</surname><given-names>X.Z.</given-names></name><name><surname>Li</surname><given-names>X.Z.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name></person-group><article-title>Structural basis, chemical driving forces and biological implications of flavones as Cu(II) ionophores</article-title><source>Free Radic. Biol. Med.</source><year>2017</year><volume>108</volume><fpage>554</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2017.04.023</pub-id><pub-id pub-id-type="pmid">28431962</pub-id></element-citation></ref><ref id="B107-pharmaceuticals-14-00157"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tungmunnithum</surname><given-names>D.</given-names></name><name><surname>Thongboonyou</surname><given-names>A.</given-names></name><name><surname>Pholboon</surname><given-names>A.</given-names></name><name><surname>Yangsabai</surname><given-names>A.</given-names></name></person-group><article-title>Flavonoids and Other Phenolic Compounds from Medicinal Plants for Pharmaceutical and Medical Aspects: An Overview</article-title><source>Medicines</source><year>2018</year><volume>5</volume><elocation-id>93</elocation-id><pub-id pub-id-type="doi">10.3390/medicines5030093</pub-id><?supplied-pmid 30149600?><pub-id pub-id-type="pmid">30149600</pub-id></element-citation></ref><ref id="B108-pharmaceuticals-14-00157"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proch&#x000e1;zkov&#x000e1;</surname><given-names>D.</given-names></name><name><surname>Bou&#x00161;ov&#x000e1;</surname><given-names>I.</given-names></name><name><surname>Wilhelmov&#x000e1;</surname><given-names>N.</given-names></name></person-group><article-title>Antioxidant and prooxidant properties of flavonoids</article-title><source>Fitoterapia</source><year>2011</year><volume>82</volume><fpage>513</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2011.01.018</pub-id><pub-id pub-id-type="pmid">21277359</pub-id></element-citation></ref><ref id="B109-pharmaceuticals-14-00157"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>L.</given-names></name></person-group><article-title>Influence of resveratrol on the immune response</article-title><source>Nutrients</source><year>2019</year><volume>11</volume><elocation-id>946</elocation-id><pub-id pub-id-type="doi">10.3390/nu11050946</pub-id></element-citation></ref><ref id="B110-pharmaceuticals-14-00157"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czop</surname><given-names>M.</given-names></name><name><surname>Bogucka-Kocka</surname><given-names>A.</given-names></name><name><surname>Kubrak</surname><given-names>T.</given-names></name><name><surname>Knap-Czop</surname><given-names>K.</given-names></name><name><surname>Makuch-Kocka</surname><given-names>A.</given-names></name><name><surname>Galkowski</surname><given-names>D.</given-names></name><name><surname>Wawer</surname><given-names>J.</given-names></name><name><surname>Kocki</surname><given-names>T.</given-names></name><name><surname>Kocki</surname><given-names>J.</given-names></name></person-group><article-title>Imaging flow cytometric analysis of stilbene-dependent apoptosis in drug resistant human leukemic cell lines</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>1896</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24101896</pub-id></element-citation></ref><ref id="B111-pharmaceuticals-14-00157"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name></person-group><article-title>Resveratrol inhibits TGF-&#x003b2;1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis</article-title><source>Toxicology</source><year>2013</year><volume>303</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2012.09.017</pub-id><?supplied-pmid 23146760?><pub-id pub-id-type="pmid">23146760</pub-id></element-citation></ref><ref id="B112-pharmaceuticals-14-00157"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name></person-group><article-title>Resveratrol modulates the apoptosis and autophagic death of human lung adenocarcinoma A549 cells via a p53-dependent pathway: Integrated bioinformatics analysis and experimental validation</article-title><source>Int. J. Oncol.</source><year>2020</year><volume>57</volume><fpage>926</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.3892/ijo.2020.5107</pub-id></element-citation></ref><ref id="B113-pharmaceuticals-14-00157"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganapathy</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Singh</surname><given-names>K.P.</given-names></name><name><surname>Shankar</surname><given-names>S.</given-names></name><name><surname>Srivastava</surname><given-names>R.K.</given-names></name></person-group><article-title>Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>15627</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0015627</pub-id><?supplied-pmid 21209944?><pub-id pub-id-type="pmid">21209944</pub-id></element-citation></ref><ref id="B114-pharmaceuticals-14-00157"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>G.</given-names></name><name><surname>Mishra</surname><given-names>S.</given-names></name><name><surname>Suman</surname><given-names>S.</given-names></name><name><surname>Shukla</surname><given-names>Y.</given-names></name></person-group><article-title>Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight</article-title><source>Phytomedicine</source><year>2016</year><volume>23</volume><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2015.12.020</pub-id><?supplied-pmid 26969377?><pub-id pub-id-type="pmid">26969377</pub-id></element-citation></ref><ref id="B115-pharmaceuticals-14-00157"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Dai</surname><given-names>S.</given-names></name><name><surname>Qian</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Gong</surname><given-names>Z.</given-names></name></person-group><article-title>Targeting autophagy to sensitive glioma to temozolomide treatment</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2016</year><volume>35</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1186/s13046-016-0303-5</pub-id><pub-id pub-id-type="pmid">26728266</pub-id></element-citation></ref><ref id="B116-pharmaceuticals-14-00157"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patra</surname><given-names>S.</given-names></name><name><surname>Pradhan</surname><given-names>B.</given-names></name><name><surname>Nayak</surname><given-names>R.</given-names></name><name><surname>Behera</surname><given-names>C.</given-names></name><name><surname>Rout</surname><given-names>L.</given-names></name><name><surname>Jena</surname><given-names>M.</given-names></name><name><surname>Efferth</surname><given-names>T.</given-names></name><name><surname>Bhutia</surname><given-names>S.K.</given-names></name></person-group><article-title>Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics</article-title><source>Semin. Cancer Biol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.semcancer.2020.10.010</pub-id><?supplied-pmid 33152486?><pub-id pub-id-type="pmid">33152486</pub-id></element-citation></ref><ref id="B117-pharmaceuticals-14-00157"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregoriou</surname><given-names>Y.</given-names></name><name><surname>Gregoriou</surname><given-names>G.</given-names></name><name><surname>Yilmaz</surname><given-names>V.</given-names></name><name><surname>Kapnisis</surname><given-names>K.</given-names></name><name><surname>Prokopi</surname><given-names>M.</given-names></name></person-group><article-title>Resveratrol loaded polymeric micelles for theranostic targeting of breast cancer cells</article-title><source>Nanotheranostics</source><year>2021</year><volume>5</volume><fpage>113</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.7150/ntno.51955</pub-id><?supplied-pmid 33391978?><pub-id pub-id-type="pmid">33391978</pub-id></element-citation></ref><ref id="B118-pharmaceuticals-14-00157"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>P.</given-names></name><name><surname>Huang</surname><given-names>Y.-W.</given-names></name><name><surname>Oshima</surname><given-names>K.</given-names></name><name><surname>Martha Yearsley</surname><given-names>J.Z.</given-names></name><name><surname>Arnold</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>L.-S.</given-names></name></person-group><article-title>The Immunomodulatory Potential of Natural Compounds in Tumor-Bearing Mice and Humans</article-title><source>Crit. Rev. Food Sci. Nutr.</source><year>2019</year><volume>59</volume><fpage>992</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">30795687</pub-id></element-citation></ref><ref id="B119-pharmaceuticals-14-00157"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>G.</given-names></name><name><surname>Mittal</surname><given-names>S.</given-names></name><name><surname>Sak</surname><given-names>K.</given-names></name><name><surname>Tuli</surname><given-names>H.S.</given-names></name></person-group><article-title>Molecular mechanisms underlying chemopreventive potential of curcumin: Current challenges and future perspectives</article-title><source>Life Sci.</source><year>2016</year><volume>148</volume><fpage>313</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2016.02.022</pub-id><?supplied-pmid 26876915?><pub-id pub-id-type="pmid">26876915</pub-id></element-citation></ref><ref id="B120-pharmaceuticals-14-00157"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourhanifeh</surname><given-names>M.H.</given-names></name><name><surname>Darvish</surname><given-names>M.</given-names></name><name><surname>Tabatabaeian</surname><given-names>J.</given-names></name><name><surname>Fard</surname><given-names>M.R.</given-names></name><name><surname>Mottaghi</surname><given-names>R.</given-names></name><name><surname>Azadchehr</surname><given-names>M.J.</given-names></name><name><surname>Jahanshahi</surname><given-names>M.</given-names></name><name><surname>Sahebkar</surname><given-names>A.</given-names></name><name><surname>Mirzaei</surname><given-names>H.</given-names></name></person-group><article-title>Therapeutic role of curcumin and its novel formulations in gynecological cancers</article-title><source>J. Ovarian Res.</source><year>2020</year><volume>13</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1186/s13048-020-00731-7</pub-id><?supplied-pmid 33148295?><pub-id pub-id-type="pmid">33148295</pub-id></element-citation></ref><ref id="B121-pharmaceuticals-14-00157"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Curcumin suppresses migration and invasion of human endometrial carcinoma cells</article-title><source>Oncol. Lett.</source><year>2015</year><volume>10</volume><fpage>1297</fpage><lpage>1302</lpage><pub-id pub-id-type="doi">10.3892/ol.2015.3478</pub-id><pub-id pub-id-type="pmid">26622667</pub-id></element-citation></ref><ref id="B122-pharmaceuticals-14-00157"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuelli</surname><given-names>L.</given-names></name><name><surname>Benvenuto</surname><given-names>M.</given-names></name><name><surname>Di Stefano</surname><given-names>E.</given-names></name><name><surname>Mattera</surname><given-names>R.</given-names></name><name><surname>Fantini</surname><given-names>M.</given-names></name><name><surname>De Feudis</surname><given-names>G.</given-names></name><name><surname>De Smaele</surname><given-names>E.</given-names></name><name><surname>Tresoldi</surname><given-names>I.</given-names></name><name><surname>Giganti</surname><given-names>M.G.</given-names></name><name><surname>Modesti</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>34405</fpage><lpage>34422</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.14907</pub-id><pub-id pub-id-type="pmid">28159921</pub-id></element-citation></ref><ref id="B123-pharmaceuticals-14-00157"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taverna</surname><given-names>S.</given-names></name><name><surname>Giallombardo</surname><given-names>M.</given-names></name><name><surname>Pucci</surname><given-names>M.</given-names></name><name><surname>Flugy</surname><given-names>A.</given-names></name><name><surname>Manno</surname><given-names>M.</given-names></name><name><surname>Raccosta</surname><given-names>S.</given-names></name><name><surname>Rolfo</surname><given-names>C.</given-names></name><name><surname>De Leo</surname><given-names>G.</given-names></name><name><surname>Alessandro</surname><given-names>R.</given-names></name></person-group><article-title>Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: A possible role for exosomal disposal of miR-21</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>21918</fpage><lpage>21933</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4204</pub-id><?supplied-pmid 26116834?><pub-id pub-id-type="pmid">26116834</pub-id></element-citation></ref><ref id="B124-pharmaceuticals-14-00157"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koohpar</surname><given-names>Z.K.</given-names></name><name><surname>Entezari</surname><given-names>M.</given-names></name><name><surname>Movafagh</surname><given-names>A.</given-names></name><name><surname>Hashemi</surname><given-names>M.</given-names></name></person-group><article-title>Anticancer activity of curcumin on human breast adenocarcinoma: Role of Mcl-1 gene</article-title><source>Int. J. Cancer Manag.</source><year>2015</year><volume>8</volume><fpage>2331</fpage><pub-id pub-id-type="doi">10.17795/ijcp2331</pub-id></element-citation></ref><ref id="B125-pharmaceuticals-14-00157"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bimonte</surname><given-names>S.</given-names></name><name><surname>Barbieri</surname><given-names>A.</given-names></name><name><surname>Leongito</surname><given-names>M.</given-names></name><name><surname>Piccirillo</surname><given-names>M.</given-names></name><name><surname>Giudice</surname><given-names>A.</given-names></name><name><surname>Pivonello</surname><given-names>C.</given-names></name><name><surname>De Angelis</surname><given-names>C.</given-names></name><name><surname>Granata</surname><given-names>V.</given-names></name><name><surname>Palaia</surname><given-names>R.</given-names></name><name><surname>Izzo</surname><given-names>F.</given-names></name></person-group><article-title>Curcumin anticancer studies in pancreatic cancer</article-title><source>Nutrients</source><year>2016</year><volume>8</volume><elocation-id>433</elocation-id><pub-id pub-id-type="doi">10.3390/nu8070433</pub-id></element-citation></ref><ref id="B126-pharmaceuticals-14-00157"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Pu</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Mo</surname><given-names>J.</given-names></name></person-group><article-title>Curcumin: A calixarene derivative micelle potentiates anti-breast cancer stem cells effects in xenografted, triple-negative breast cancer mouse models</article-title><source>Drug Deliv.</source><year>2017</year><volume>24</volume><fpage>1470</fpage><lpage>1481</lpage><pub-id pub-id-type="doi">10.1080/10717544.2017.1381198</pub-id><pub-id pub-id-type="pmid">28956452</pub-id></element-citation></ref><ref id="B127-pharmaceuticals-14-00157"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>G.S.</given-names></name><name><surname>Mohanty</surname><given-names>S.</given-names></name><name><surname>Hossain</surname><given-names>D.M.S.</given-names></name><name><surname>Bhattacharyya</surname><given-names>S.</given-names></name><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Chakraborty</surname><given-names>J.</given-names></name><name><surname>Saha</surname><given-names>S.</given-names></name><name><surname>Ray</surname><given-names>P.</given-names></name><name><surname>Bhattacharjee</surname><given-names>P.</given-names></name><name><surname>Mandal</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Curcumin enhances the efficacy of chemotherapy by tailoring p65NF&#x003ba;B-p300 cross-talk in favor of p53-p300 in breast cancer</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>42232</fpage><lpage>42247</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.262295</pub-id><?supplied-pmid 22013068?><pub-id pub-id-type="pmid">22013068</pub-id></element-citation></ref><ref id="B128-pharmaceuticals-14-00157"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Ju</surname><given-names>Y.</given-names></name></person-group><article-title>Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells</article-title><source>Int. J. Oncol.</source><year>2018</year><volume>53</volume><fpage>1343</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.3892/ijo.2018.4461</pub-id><?supplied-pmid 29956726?><pub-id pub-id-type="pmid">29956726</pub-id></element-citation></ref><ref id="B129-pharmaceuticals-14-00157"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dihal</surname><given-names>A.A.</given-names></name><name><surname>De Boer</surname><given-names>V.C.J.</given-names></name><name><surname>Van Der Woude</surname><given-names>H.</given-names></name><name><surname>Tilburgs</surname><given-names>C.</given-names></name><name><surname>Bruijntjes</surname><given-names>J.P.</given-names></name><name><surname>Alink</surname><given-names>G.M.</given-names></name><name><surname>Rietjens</surname><given-names>I.M.C.M.</given-names></name><name><surname>Woutersen</surname><given-names>R.A.</given-names></name><name><surname>Stierum</surname><given-names>R.H.</given-names></name></person-group><article-title>Quercetin, but not its glycosidated conjugate rutin, inhibits azoxymethane-induced colorectal carcinogenesis in F344 rats</article-title><source>J. Nutr.</source><year>2006</year><volume>136</volume><fpage>2862</fpage><lpage>2867</lpage><pub-id pub-id-type="doi">10.1093/jn/136.11.2862</pub-id><?supplied-pmid 17056814?><pub-id pub-id-type="pmid">17056814</pub-id></element-citation></ref><ref id="B130-pharmaceuticals-14-00157"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>S.M.</given-names></name><name><surname>Deng</surname><given-names>X.T.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Q.P.</given-names></name><name><surname>Ge</surname><given-names>X.X.</given-names></name><name><surname>Miao</surname><given-names>L.</given-names></name></person-group><article-title>Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects</article-title><source>Biomed. Pharmacother.</source><year>2020</year><volume>121</volume><fpage>109604</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2019.109604</pub-id><pub-id pub-id-type="pmid">31733570</pub-id></element-citation></ref><ref id="B131-pharmaceuticals-14-00157"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khursheed</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>S.K.</given-names></name><name><surname>Wadhwa</surname><given-names>S.</given-names></name><name><surname>Gulati</surname><given-names>M.</given-names></name><name><surname>Awasthi</surname><given-names>A.</given-names></name></person-group><article-title>Enhancing the potential preclinical and clinical benefits of quercetin through novel drug delivery systems</article-title><source>Drug Discov. Today</source><year>2020</year><volume>25</volume><fpage>209</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2019.11.001</pub-id><pub-id pub-id-type="pmid">31707120</pub-id></element-citation></ref><ref id="B132-pharmaceuticals-14-00157"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duo</surname><given-names>J.</given-names></name><name><surname>Ying</surname><given-names>G.G.</given-names></name><name><surname>Wang</surname><given-names>G.W.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation</article-title><source>Mol. Med. Rep.</source><year>2012</year><volume>5</volume><fpage>1453</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.3892/mmr.2012.845</pub-id><?supplied-pmid 22447039?><pub-id pub-id-type="pmid">22447039</pub-id></element-citation></ref><ref id="B133-pharmaceuticals-14-00157"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>S.Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>D.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Ge</surname><given-names>J.F.</given-names></name></person-group><article-title>Anticancer effect and apoptosis induction by quercetin in the human lung cancer cell line A-549</article-title><source>Mol. Med. Rep.</source><year>2012</year><volume>5</volume><fpage>822</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.3892/mmr.2011.726</pub-id><?supplied-pmid 22200874?><pub-id pub-id-type="pmid">22200874</pub-id></element-citation></ref><ref id="B134-pharmaceuticals-14-00157"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albrecht</surname><given-names>C.</given-names></name><name><surname>Cittadini</surname><given-names>M.C.</given-names></name><name><surname>Soria</surname><given-names>E.A.</given-names></name></person-group><article-title>Pharmacological Activity of Quercetin and 5 caffeoylquinic Acid Oral Intake in Male Balb/c Mice with Lung Adenocarcinoma</article-title><source>Arch. Med. Res.</source><year>2020</year><volume>51</volume><fpage>8</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2019.11.006</pub-id><?supplied-pmid 32086110?><pub-id pub-id-type="pmid">32086110</pub-id></element-citation></ref><ref id="B135-pharmaceuticals-14-00157"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calgarotto</surname><given-names>A.K.</given-names></name><name><surname>Maso</surname><given-names>V.</given-names></name><name><surname>Junior</surname><given-names>G.C.F.</given-names></name><name><surname>Nowill</surname><given-names>A.E.</given-names></name><name><surname>Filho</surname><given-names>P.L.</given-names></name><name><surname>Vassallo</surname><given-names>J.</given-names></name><name><surname>Saad</surname><given-names>S.T.O.</given-names></name></person-group><article-title>Antitumor activities of Quercetin and Green Tea in xenografts of human leukemia HL60 cells</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41598-018-21516-5</pub-id><pub-id pub-id-type="pmid">29311550</pub-id></element-citation></ref><ref id="B136-pharmaceuticals-14-00157"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Yin</surname><given-names>X.</given-names></name><name><surname>Zan</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name></person-group><article-title>Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction</article-title><source>Life Sci.</source><year>2018</year><volume>208</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2018.07.027</pub-id><pub-id pub-id-type="pmid">30025823</pub-id></element-citation></ref><ref id="B137-pharmaceuticals-14-00157"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>C.S.</given-names></name><name><surname>Hou</surname><given-names>Y.C.</given-names></name><name><surname>Pai</surname><given-names>M.H.</given-names></name><name><surname>Lin</surname><given-names>M.T.</given-names></name><name><surname>Yeh</surname><given-names>S.L.</given-names></name></person-group><article-title>Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies</article-title><source>J. Nutr. Biochem.</source><year>2018</year><volume>51</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2017.09.011</pub-id><pub-id pub-id-type="pmid">29125991</pub-id></element-citation></ref><ref id="B138-pharmaceuticals-14-00157"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shitole</surname><given-names>A.A.</given-names></name><name><surname>Sharma</surname><given-names>N.</given-names></name><name><surname>Giram</surname><given-names>P.</given-names></name><name><surname>Khandwekar</surname><given-names>A.</given-names></name><name><surname>Baruah</surname><given-names>M.</given-names></name><name><surname>Garnaik</surname><given-names>B.</given-names></name><name><surname>Koratkar</surname><given-names>S.</given-names></name></person-group><article-title>LHRH-conjugated, PEGylated, poly-lactide-co-glycolide nanocapsules for targeted delivery of combinational chemotherapeutic drugs Docetaxel and Quercetin for prostate cancer</article-title><source>Mater. Sci. Eng. C</source><year>2020</year><volume>114</volume><fpage>111035</fpage><pub-id pub-id-type="doi">10.1016/j.msec.2020.111035</pub-id><?supplied-pmid 32994029?><pub-id pub-id-type="pmid">32994029</pub-id></element-citation></ref><ref id="B139-pharmaceuticals-14-00157"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kooshyar</surname><given-names>M.M.</given-names></name><name><surname>Mozafari</surname><given-names>P.M.</given-names></name><name><surname>Amirchaghmaghi</surname><given-names>M.</given-names></name><name><surname>Pakfetrat</surname><given-names>A.</given-names></name><name><surname>Karoos</surname><given-names>P.</given-names></name><name><surname>Mohasel</surname><given-names>M.R.</given-names></name><name><surname>Orafai</surname><given-names>H.</given-names></name><name><surname>Azarian</surname><given-names>A.A.</given-names></name></person-group><article-title>A randomized placebo- controlled double blind clinical trial of quercetin in the prevention and treatment of chemotherapy-induced oral mucositis</article-title><source>J. Clin. Diagnostic Res.</source><year>2017</year><volume>11</volume><fpage>ZC46</fpage><lpage>ZC50</lpage><pub-id pub-id-type="doi">10.7860/JCDR/2017/23975.9571</pub-id><?supplied-pmid 28511508?><pub-id pub-id-type="pmid">28511508</pub-id></element-citation></ref><ref id="B140-pharmaceuticals-14-00157"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>J.C.</given-names></name><name><surname>Syu</surname><given-names>J.J.</given-names></name><name><surname>Chen</surname><given-names>J.C.</given-names></name><name><surname>Wang</surname><given-names>T.J.</given-names></name><name><surname>Chang</surname><given-names>P.Y.</given-names></name><name><surname>Chen</surname><given-names>C.Y.</given-names></name><name><surname>Jian</surname><given-names>Y.T.</given-names></name><name><surname>Jian</surname><given-names>Y.J.</given-names></name><name><surname>Lin</surname><given-names>Y.W.</given-names></name></person-group><article-title>Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells</article-title><source>Basic Clin. Pharmacol. Toxicol.</source><year>2015</year><volume>117</volume><fpage>383</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1111/bcpt.12425</pub-id><?supplied-pmid 26046675?><pub-id pub-id-type="pmid">26046675</pub-id></element-citation></ref><ref id="B141-pharmaceuticals-14-00157"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Lima</surname><given-names>R.M.T.</given-names></name><name><surname>dos Reis</surname><given-names>A.C.</given-names></name><name><surname>de Menezes</surname><given-names>A.A.P.M.</given-names></name><name><surname>Santos</surname><given-names>J.V.</given-names></name><name><surname>Filho</surname><given-names>J.W.G.D.O.</given-names></name><name><surname>Ferreira</surname><given-names>J.R.D.O.</given-names></name><name><surname>de Alencar</surname><given-names>M.V.O.B.</given-names></name><name><surname>da Mata</surname><given-names>A.M.O.F.</given-names></name><name><surname>Khan</surname><given-names>I.N.</given-names></name><name><surname>Islam</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Protective and therapeutic potential of ginger (Zingiber officinale) extract and [6]-gingerol in cancer: A comprehensive review</article-title><source>Phyther. Res.</source><year>2018</year><volume>32</volume><fpage>1885</fpage><lpage>1907</lpage><pub-id pub-id-type="doi">10.1002/ptr.6134</pub-id></element-citation></ref><ref id="B142-pharmaceuticals-14-00157"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Lima</surname><given-names>R.M.T.</given-names></name><name><surname>dos Reis</surname><given-names>A.C.</given-names></name><name><surname>de Oliveira Santos</surname><given-names>J.V.</given-names></name><name><surname>de Oliveira Ferreira</surname><given-names>J.R.</given-names></name><name><surname>de Oliveira Filho</surname><given-names>J.W.G.</given-names></name><name><surname>Dias</surname><given-names>A.C.S.</given-names></name><name><surname>de Menezes</surname><given-names>A.A.P.M.</given-names></name><name><surname>da Mata</surname><given-names>A.M.O.</given-names></name><name><surname>Ferreira</surname></name><name><surname>de Alencar</surname><given-names>M.V.O.B.</given-names></name><etal/></person-group><article-title>Antitumoral effects of [6]-gingerol [(S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl) -3-decanone] in sarcoma 180 cells through cytogenetic mechanisms</article-title><source>Biomed. Pharmacother.</source><year>2020</year><volume>126</volume><fpage>110004</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2020.110004</pub-id><pub-id pub-id-type="pmid">32145583</pub-id></element-citation></ref><ref id="B143-pharmaceuticals-14-00157"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Lima</surname><given-names>R.M.T.</given-names></name><name><surname>dos Reis</surname><given-names>A.C.</given-names></name><name><surname>de Oliveira Santos</surname><given-names>J.V.</given-names></name><name><surname>de Oliveira Ferreira</surname><given-names>J.R.</given-names></name><name><surname>de Oliveira Filho</surname><given-names>J.W.G.</given-names></name><name><surname>de Menezes</surname><given-names>A.A.P.M.</given-names></name><name><surname>da Mata</surname><given-names>A.M.O.F.</given-names></name><name><surname>de Alencar</surname><given-names>M.V.O.B.</given-names></name><name><surname>Rodrigues</surname><given-names>D.C.N.</given-names></name><name><surname>Ferreira</surname><given-names>P.M.P.</given-names></name><etal/></person-group><article-title>Toxic, cytogenetic and antitumor evaluations of [6] -gingerol in non-clinical in vitro studies</article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>115</volume><fpage>108873</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2019.108873</pub-id><pub-id pub-id-type="pmid">31003079</pub-id></element-citation></ref><ref id="B144-pharmaceuticals-14-00157"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>A.C.B.M.</given-names></name><name><surname>Fuzer</surname><given-names>A.M.</given-names></name><name><surname>Becceneri</surname><given-names>A.B.</given-names></name><name><surname>Almada</surname><given-names>J.</given-names></name><name><surname>Tomasin</surname><given-names>R.</given-names></name><name><surname>Denoyer</surname><given-names>D.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Mcintyre</surname><given-names>K.A.</given-names></name><name><surname>Pearson</surname><given-names>H.B.</given-names></name><name><surname>Yeo</surname><given-names>B.</given-names></name><etal/></person-group><article-title>[10]-gingerol induces apoptosis and inhibits metastatic dissemination of triple negative breast cancer in vivo</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>72260</fpage><lpage>72271</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.20139</pub-id><pub-id pub-id-type="pmid">29069785</pub-id></element-citation></ref><ref id="B145-pharmaceuticals-14-00157"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>A.C.B.M.</given-names></name><name><surname>Tomasin</surname><given-names>R.</given-names></name><name><surname>Luna-Dulcey</surname><given-names>L.</given-names></name><name><surname>Graminha</surname><given-names>A.E.</given-names></name><name><surname>Naves</surname><given-names>M.A.</given-names></name><name><surname>Teles</surname><given-names>R.H.G.</given-names></name><name><surname>da Silva</surname><given-names>V.D.</given-names></name><name><surname>da Silva</surname><given-names>J.A.</given-names></name><name><surname>Vieira</surname><given-names>P.C.</given-names></name><name><surname>Annabi</surname><given-names>B.</given-names></name><etal/></person-group><article-title>[10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models</article-title><source>Cell. Oncol.</source><year>2020</year><volume>43</volume><fpage>915</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1007/s13402-020-00539-z</pub-id><?supplied-pmid 32761561?><pub-id pub-id-type="pmid">32761561</pub-id></element-citation></ref><ref id="B146-pharmaceuticals-14-00157"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Zha</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>C.</given-names></name><name><surname>Zhuang</surname><given-names>X.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Qiao</surname><given-names>T.</given-names></name></person-group><article-title>[6]-Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via PI3K/AKT signaling pathway</article-title><source>Phyther. Res.</source><year>2019</year><volume>33</volume><fpage>1353</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1002/ptr.6325</pub-id></element-citation></ref><ref id="B147-pharmaceuticals-14-00157"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Wei</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Shi</surname><given-names>F.</given-names></name><name><surname>Tong</surname><given-names>S.S.</given-names></name><name><surname>Feng</surname><given-names>C.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A novel formulation of [6] -gingerol: Proliposomes with enhanced oral bioavailability and antitumor effect</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>535</volume><fpage>308</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.11.006</pub-id><?supplied-pmid 29126908?><pub-id pub-id-type="pmid">29126908</pub-id></element-citation></ref><ref id="B148-pharmaceuticals-14-00157"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Niu</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name></person-group><article-title>Formulation, Characterization, and Pharmacokinetic Studies of 6-Gingerol-Loaded Nanostructured Lipid Carriers</article-title><source>AAPS PharmSciTech</source><year>2018</year><volume>19</volume><fpage>3661</fpage><lpage>3669</lpage><pub-id pub-id-type="doi">10.1208/s12249-018-1165-2</pub-id><pub-id pub-id-type="pmid">30324361</pub-id></element-citation></ref><ref id="B149-pharmaceuticals-14-00157"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Firempong</surname><given-names>C.K.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Omari-Siaw</surname><given-names>E.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Pu</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name></person-group><article-title>Enhanced oral bioavailability of [6]-Gingerol-SMEDDS: Preparation, in vitro and in vivo evaluation</article-title><source>J. Funct. Foods</source><year>2016</year><volume>27</volume><fpage>703</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1016/j.jff.2016.10.007</pub-id></element-citation></ref><ref id="B150-pharmaceuticals-14-00157"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>A.Y.</given-names></name><name><surname>Chen</surname><given-names>Y.C.</given-names></name></person-group><article-title>A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention</article-title><source>Food Chem.</source><year>2013</year><volume>138</volume><fpage>2099</fpage><lpage>2107</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2012.11.139</pub-id><pub-id pub-id-type="pmid">23497863</pub-id></element-citation></ref><ref id="B151-pharmaceuticals-14-00157"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajendran</surname><given-names>P.</given-names></name><name><surname>Rengarajan</surname><given-names>T.</given-names></name><name><surname>Nandakumar</surname><given-names>N.</given-names></name><name><surname>Palaniswami</surname><given-names>R.</given-names></name><name><surname>Nishigaki</surname><given-names>Y.</given-names></name><name><surname>Nishigaki</surname><given-names>I.</given-names></name></person-group><article-title>Kaempferol, a potential cytostatic and cure for inflammatory disorders</article-title><source>Eur. J. Med. Chem.</source><year>2014</year><volume>86</volume><fpage>103</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2014.08.011</pub-id><?supplied-pmid 25147152?><pub-id pub-id-type="pmid">25147152</pub-id></element-citation></ref><ref id="B152-pharmaceuticals-14-00157"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashyap</surname><given-names>D.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>H.</given-names></name><name><surname>Sak</surname><given-names>K.</given-names></name><name><surname>Punia</surname><given-names>S.</given-names></name><name><surname>Mukherjee</surname><given-names>T.K.</given-names></name></person-group><article-title>Kaempferol&#x02014;A dietary anticancer molecule with multiple mechanisms of action: Recent trends and advancements</article-title><source>J. Funct. Foods</source><year>2017</year><volume>30</volume><fpage>203</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.jff.2017.01.022</pub-id><?supplied-pmid 32288791?><pub-id pub-id-type="pmid">32288791</pub-id></element-citation></ref><ref id="B153-pharmaceuticals-14-00157"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Lee</surname><given-names>I.M.</given-names></name><name><surname>Zhang</surname><given-names>S.M.</given-names></name><name><surname>Blumberg</surname><given-names>J.B.</given-names></name><name><surname>Buring</surname><given-names>J.E.</given-names></name><name><surname>Sesso</surname><given-names>H.D.</given-names></name></person-group><article-title>Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women</article-title><source>Am. J. Clin. Nutr.</source><year>2009</year><volume>89</volume><fpage>905</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.3945/ajcn.2008.26913</pub-id><?supplied-pmid 19158208?><pub-id pub-id-type="pmid">19158208</pub-id></element-citation></ref><ref id="B154-pharmaceuticals-14-00157"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gates</surname><given-names>M.A.</given-names></name><name><surname>Vitonis</surname><given-names>A.F.</given-names></name><name><surname>Tworoger</surname><given-names>S.S.</given-names></name><name><surname>Rosner</surname><given-names>B.</given-names></name><name><surname>Titus-Ernstoff</surname><given-names>L.</given-names></name><name><surname>Hankinson</surname><given-names>S.E.</given-names></name><name><surname>Cramer</surname><given-names>D.W.</given-names></name></person-group><article-title>Flavonoid intake and ovarian cancer risk in a population-based case-control study</article-title><source>Int. J. Cancer</source><year>2009</year><volume>124</volume><fpage>1918</fpage><lpage>1925</lpage><pub-id pub-id-type="doi">10.1002/ijc.24151</pub-id><pub-id pub-id-type="pmid">19117058</pub-id></element-citation></ref><ref id="B155-pharmaceuticals-14-00157"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adebamowo</surname><given-names>C.A.</given-names></name><name><surname>Cho</surname><given-names>E.</given-names></name><name><surname>Sampson</surname><given-names>L.</given-names></name><name><surname>Katan</surname><given-names>M.B.</given-names></name><name><surname>Spiegelman</surname><given-names>D.</given-names></name><name><surname>Willett</surname><given-names>W.C.</given-names></name><name><surname>Holmes</surname><given-names>M.D.</given-names></name></person-group><article-title>Dietary flavonols and flavonol-rich foods intake and the risk of breast cancer</article-title><source>Int. J. Cancer</source><year>2005</year><volume>114</volume><fpage>628</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1002/ijc.20741</pub-id><pub-id pub-id-type="pmid">15609322</pub-id></element-citation></ref><ref id="B156-pharmaceuticals-14-00157"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thangavel</surname><given-names>P.</given-names></name><name><surname>Viswanath</surname><given-names>B.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis and characterization of kaempferol-based ruthenium (II) complex: A facile approach for superior anticancer application</article-title><source>Mater. Sci. Eng. C</source><year>2018</year><volume>89</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2018.03.020</pub-id><?supplied-pmid 29752123?><pub-id pub-id-type="pmid">29752123</pub-id></element-citation></ref><ref id="B157-pharmaceuticals-14-00157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pecere</surname><given-names>T.</given-names></name><name><surname>Gazzola</surname><given-names>M.V.</given-names></name><name><surname>Mucignat</surname><given-names>C.</given-names></name><name><surname>Parolin</surname><given-names>C.</given-names></name><name><surname>Vecchia</surname><given-names>F.D.</given-names></name><name><surname>Cavaggioni</surname><given-names>A.</given-names></name><name><surname>Basso</surname><given-names>G.</given-names></name><name><surname>Diaspro</surname><given-names>A.</given-names></name><name><surname>Salvato</surname><given-names>B.</given-names></name><name><surname>Carli</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors</article-title><source>Cancer Res.</source><year>2000</year><volume>60</volume><fpage>2800</fpage><lpage>2804</lpage><?supplied-pmid 10850417?><pub-id pub-id-type="pmid">10850417</pub-id></element-citation></ref><ref id="B158-pharmaceuticals-14-00157"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>J.Y.</given-names></name><name><surname>Song</surname><given-names>G.P.</given-names></name><name><surname>Deng</surname><given-names>J.P.</given-names></name><name><surname>Jiang</surname><given-names>L.Z.</given-names></name><name><surname>Xiong</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>B.J.</given-names></name><name><surname>Liu</surname><given-names>S.S.</given-names></name></person-group><article-title>Antitumor effects and mechanism of novel emodin rhamnoside derivatives against human cancer cells in vitro</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>144781</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0144781</pub-id></element-citation></ref><ref id="B159-pharmaceuticals-14-00157"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slezakova</surname><given-names>S.</given-names></name><name><surname>Ruda-Kucerova</surname><given-names>J.</given-names></name></person-group><article-title>Anticancer Activity of Artemisinin and its Derivatives</article-title><source>Anticancer Res.</source><year>2017</year><volume>37</volume><fpage>5995</fpage><lpage>6003</lpage><pub-id pub-id-type="pmid">29061778</pub-id></element-citation></ref><ref id="B160-pharmaceuticals-14-00157"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efferth</surname><given-names>T.</given-names></name><name><surname>Dunstan</surname><given-names>H.</given-names></name><name><surname>Sauerbrey</surname><given-names>A.</given-names></name><name><surname>Miyachi</surname><given-names>H.</given-names></name><name><surname>Chitambar</surname><given-names>C.R.</given-names></name></person-group><article-title>The anti-malarial artesunate is also active against cancer</article-title><source>Int. J. Oncol.</source><year>2001</year><volume>18</volume><fpage>767</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.3892/ijo.18.4.767</pub-id><pub-id pub-id-type="pmid">11251172</pub-id></element-citation></ref><ref id="B161-pharmaceuticals-14-00157"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukhari</surname><given-names>S.N.A.</given-names></name><name><surname>Kumar</surname><given-names>G.B.</given-names></name><name><surname>Revankar</surname><given-names>H.M.</given-names></name><name><surname>Qin</surname><given-names>H.L.</given-names></name></person-group><article-title>Development of combretastatins as potent tubulin polymerization inhibitors</article-title><source>Bioor. Chem.</source><year>2017</year><volume>72</volume><fpage>130</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2017.04.007</pub-id></element-citation></ref><ref id="B162-pharmaceuticals-14-00157"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.M.</given-names></name><name><surname>Gravett</surname><given-names>A.M.</given-names></name><name><surname>Dalgleish</surname><given-names>A.G.</given-names></name></person-group><article-title>The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies</article-title><source>Int. J. Cancer</source><year>2011</year><volume>128</volume><fpage>1471</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1002/ijc.25707</pub-id><pub-id pub-id-type="pmid">20886599</pub-id></element-citation></ref><ref id="B163-pharmaceuticals-14-00157"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faujan</surname><given-names>N.H.</given-names></name><name><surname>Alitheen</surname><given-names>N.B.</given-names></name><name><surname>Yeap</surname><given-names>S.K.</given-names></name><name><surname>Ali</surname><given-names>A.M.</given-names></name><name><surname>Muhajir</surname><given-names>A.H.</given-names></name><name><surname>Ahmad</surname><given-names>F.B.H.</given-names></name></person-group><article-title>Cytotoxic effect of betulinic acid and betulinic acid acetate isolated from <italic>Melaleuca cajuput</italic> on human myeloid leukemia (HL-60) cell line</article-title><source>African J. Biotechnol.</source><year>2010</year><volume>9</volume><fpage>6387</fpage><lpage>6396</lpage><pub-id pub-id-type="doi">10.5897/AJB09.1049</pub-id></element-citation></ref><ref id="B164-pharmaceuticals-14-00157"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surowiak</surname><given-names>P.</given-names></name><name><surname>Drag</surname><given-names>M.</given-names></name><name><surname>Materna</surname><given-names>V.</given-names></name><name><surname>Dietel</surname><given-names>M.</given-names></name><name><surname>Lage</surname><given-names>H.</given-names></name></person-group><article-title>Betulinic acid exhibits stronger cytotoxic activity on the normal melanocyte NHEM-neo cell line than on drug-resistant and drug-sensitive MeWo melanoma cell lines</article-title><source>Mol. Med. Rep.</source><year>2009</year><volume>2</volume><fpage>543</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.3892/mmr</pub-id><?supplied-pmid 21475863?><pub-id pub-id-type="pmid">21475863</pub-id></element-citation></ref><ref id="B165-pharmaceuticals-14-00157"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damle</surname><given-names>A.A.</given-names></name><name><surname>Pawar</surname><given-names>Y.P.</given-names></name><name><surname>Narkar</surname><given-names>A.A.</given-names></name></person-group><article-title>Anticancer activity of betulinic acid on MCF-7 tumors in nude mice</article-title><source>Indian J. Exp. Biol.</source><year>2013</year><volume>51</volume><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">23898546</pub-id></element-citation></ref><ref id="B166-pharmaceuticals-14-00157"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>Betulinic acid and the pharmacological effects of tumor suppression (Review)</article-title><source>Mol. Med. Rep.</source><year>2016</year><volume>14</volume><fpage>4489</fpage><lpage>4495</lpage><pub-id pub-id-type="doi">10.3892/mmr.2016.5792</pub-id><pub-id pub-id-type="pmid">27748864</pub-id></element-citation></ref><ref id="B167-pharmaceuticals-14-00157"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kr&#x000f3;l</surname><given-names>S.K.</given-names></name><name><surname>Kie&#x00142;bus</surname><given-names>M.</given-names></name><name><surname>Rivero-M&#x000fc;ller</surname><given-names>A.</given-names></name><name><surname>Stepulak</surname><given-names>A.</given-names></name></person-group><article-title>Comprehensive review on betulin as a potent anticancer agent</article-title><source>Biomed Res. Int.</source><year>2015</year><volume>2015</volume><fpage>584189</fpage><pub-id pub-id-type="doi">10.1155/2015/584189</pub-id><pub-id pub-id-type="pmid">25866796</pub-id></element-citation></ref><ref id="B168-pharmaceuticals-14-00157"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Long</surname><given-names>Y.</given-names></name><name><surname>Ni</surname><given-names>L.</given-names></name><name><surname>Yuan</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>N.</given-names></name><name><surname>Wu</surname><given-names>R.</given-names></name><name><surname>Tao</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Anticancer effect of berberine based on experimental animal models of various cancers: A systematic review and meta-analysis</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><elocation-id>589</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-019-5791-1</pub-id><pub-id pub-id-type="pmid">31208348</pub-id></element-citation></ref><ref id="B169-pharmaceuticals-14-00157"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barzegar</surname><given-names>E.</given-names></name><name><surname>Fouladdel</surname><given-names>S.</given-names></name><name><surname>Movahhed</surname><given-names>T.K.</given-names></name><name><surname>Atashpour</surname><given-names>S.</given-names></name><name><surname>Ghahremani</surname><given-names>M.H.</given-names></name><name><surname>Ostad</surname><given-names>S.N.</given-names></name><name><surname>Azizi</surname><given-names>E.</given-names></name></person-group><article-title>Effects of berberine on proliferation, cell cycle distribution and apoptosis of human breast cancer T47D and MCF7 cell lines</article-title><source>Iran. J. Basic Med. Sci.</source><year>2015</year><volume>18</volume><fpage>334</fpage><lpage>342</lpage><?supplied-pmid 26019795?><pub-id pub-id-type="pmid">26019795</pub-id></element-citation></ref><ref id="B170-pharmaceuticals-14-00157"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babich</surname><given-names>H.</given-names></name><name><surname>Krupka</surname><given-names>M.E.</given-names></name><name><surname>Nissim</surname><given-names>H.A.</given-names></name><name><surname>Zuckerbraun</surname><given-names>H.L.</given-names></name></person-group><article-title>Differential in vitro cytotoxicity of (-)-epicatechin gallate (ECG) to cancer and normal cells from the human oral cavity</article-title><source>Toxicol. Vitr.</source><year>2005</year><volume>19</volume><fpage>231</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.tiv.2004.09.001</pub-id></element-citation></ref><ref id="B171-pharmaceuticals-14-00157"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>K.D.</given-names></name><name><surname>Lee</surname><given-names>S.G.</given-names></name><name><surname>Kim</surname><given-names>S.U.</given-names></name><name><surname>Kim</surname><given-names>S.H.</given-names></name><name><surname>Sun</surname><given-names>W.S.</given-names></name><name><surname>Cho</surname><given-names>S.J.</given-names></name><name><surname>Jeong</surname><given-names>D.H.</given-names></name></person-group><article-title>Anticancer activity of 3-O-acyl and alkyl-(-)-epicatechin derivatives</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2004</year><volume>14</volume><fpage>5189</fpage><lpage>5192</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2004.07.063</pub-id></element-citation></ref><ref id="B172-pharmaceuticals-14-00157"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G.Y.</given-names></name><name><surname>Liao</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Yurkow</surname><given-names>E.J.</given-names></name><name><surname>Yang</surname><given-names>C.S.</given-names></name></person-group><article-title>Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols</article-title><source>Carcinogenesis</source><year>1998</year><volume>19</volume><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1093/carcin/19.4.611</pub-id><pub-id pub-id-type="pmid">9600345</pub-id></element-citation></ref><ref id="B173-pharmaceuticals-14-00157"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karatoprak</surname><given-names>G.&#x0015e;.</given-names></name><name><surname>K&#x000fc;peli Akkol</surname><given-names>E.</given-names></name><name><surname>Gen&#x000e7;</surname><given-names>Y.</given-names></name><name><surname>Bardakci</surname><given-names>H.</given-names></name><name><surname>Y&#x000fc;cel</surname><given-names>&#x000c7;.</given-names></name><name><surname>Sobarzo-S&#x000e1;nchez</surname><given-names>E.</given-names></name></person-group><article-title>Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>2560</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25112560</pub-id></element-citation></ref><ref id="B174-pharmaceuticals-14-00157"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.H.</given-names></name><name><surname>Lee</surname><given-names>J.M.</given-names></name><name><surname>Kim</surname><given-names>S.C.</given-names></name><name><surname>Park</surname><given-names>C.B.</given-names></name><name><surname>Lee</surname><given-names>P.C.</given-names></name></person-group><article-title>Proposed cytotoxic mechanisms of the saffron carotenoids crocin and crocetin on cancer cell lines</article-title><source>Biochem. Cell Biol.</source><year>2014</year><volume>92</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1139/bcb-2013-0091</pub-id><?supplied-pmid 24697694?><pub-id pub-id-type="pmid">24697694</pub-id></element-citation></ref><ref id="B175-pharmaceuticals-14-00157"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hire</surname><given-names>R.R.</given-names></name><name><surname>Srivastava</surname><given-names>S.</given-names></name><name><surname>Davis</surname><given-names>M.B.</given-names></name><name><surname>Kumar Konreddy</surname><given-names>A.</given-names></name><name><surname>Panda</surname><given-names>D.</given-names></name></person-group><article-title>Antiproliferative Activity of Crocin Involves Targeting of Microtubules in Breast Cancer Cells</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/srep44984</pub-id><pub-id pub-id-type="pmid">28127051</pub-id></element-citation></ref><ref id="B176-pharmaceuticals-14-00157"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshyar</surname><given-names>R.</given-names></name><name><surname>Mollaei</surname><given-names>H.</given-names></name></person-group><article-title>A comprehensive review on anticancer mechanisms of the main carotenoid of saffron, crocin</article-title><source>J. Pharm. Pharmacol.</source><year>2017</year><volume>69</volume><fpage>1419</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1111/jphp.12776</pub-id><?supplied-pmid 28675431?><pub-id pub-id-type="pmid">28675431</pub-id></element-citation></ref><ref id="B177-pharmaceuticals-14-00157"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Cui</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Anticancer activity of safranal against colon carcinoma is due to induction of apoptosis and G2/M cell cycle arrest mediated by suppression of mTOR/PI3K/Akt pathway</article-title><source>J. B.U.ON.</source><year>2018</year><volume>23</volume><fpage>574</fpage><lpage>578</lpage></element-citation></ref><ref id="B178-pharmaceuticals-14-00157"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahlhut</surname><given-names>M.</given-names></name><name><surname>Bertelsen</surname><given-names>M.</given-names></name><name><surname>H&#x000f8;yer-Hansen</surname><given-names>M.</given-names></name><name><surname>Zibert</surname><given-names>J.R.</given-names></name></person-group><article-title>Ingenol Mebutate-Induced Cell Death Patterns in Normal and Cancer Epithelial Cells</article-title><source>J. Drugs Dermatol.</source><year>2012</year><volume>11</volume><fpage>707</fpage><lpage>712</lpage></element-citation></ref><ref id="B179-pharmaceuticals-14-00157"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>V.A.O.</given-names></name><name><surname>Rosa</surname><given-names>M.N.</given-names></name><name><surname>Martinho</surname><given-names>O.</given-names></name><name><surname>Tanuri</surname><given-names>A.</given-names></name><name><surname>Lima</surname><given-names>J.P.</given-names></name><name><surname>Pianowski</surname><given-names>L.F.</given-names></name><name><surname>Reis</surname><given-names>R.M.</given-names></name></person-group><article-title>Modified ingenol semi-synthetic derivatives from <italic>Euphorbia tirucalli</italic> induce cytotoxicity on a large panel of human cancer cell lines</article-title><source>Investig. New Drugs</source><year>2019</year><volume>37</volume><fpage>1029</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1007/s10637-019-00728-0</pub-id><pub-id pub-id-type="pmid">30706338</pub-id></element-citation></ref><ref id="B180-pharmaceuticals-14-00157"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Qin</surname><given-names>Z.</given-names></name><name><surname>Liang</surname><given-names>X.</given-names></name><name><surname>Tian</surname><given-names>G.</given-names></name></person-group><article-title>Geniposide exhibits anticancer activity to medulloblastoma cells by downregulating microRNA-373</article-title><source>J. Biochem. Mol. Toxicol.</source><year>2020</year><volume>34</volume><pub-id pub-id-type="doi">10.1002/jbt.22471</pub-id></element-citation></ref><ref id="B181-pharmaceuticals-14-00157"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanmugam</surname><given-names>M.K.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>F.R.</given-names></name><name><surname>Arfuso</surname><given-names>F.</given-names></name><name><surname>Rajesh</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Kumar</surname><given-names>A.P.</given-names></name><name><surname>Bian</surname><given-names>J.</given-names></name><name><surname>Goh</surname><given-names>B.C.</given-names></name><name><surname>Bishayee</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Potential role of genipin in cancer therapy</article-title><source>Pharmacol. Res.</source><year>2018</year><volume>133</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.05.007</pub-id><?supplied-pmid 29758279?><pub-id pub-id-type="pmid">29758279</pub-id></element-citation></ref><ref id="B182-pharmaceuticals-14-00157"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>J.S.</given-names></name><name><surname>Bi</surname><given-names>W.C.</given-names></name><name><surname>Chan</surname><given-names>G.K.L.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>C.W.</given-names></name><name><surname>Zhou</surname><given-names>Z.Y.</given-names></name><name><surname>Wang</surname><given-names>H.Y.</given-names></name><name><surname>Yao</surname><given-names>P.</given-names></name><name><surname>Dong</surname><given-names>T.T.X.</given-names></name><name><surname>Tsim</surname><given-names>K.W.K.</given-names></name></person-group><article-title>Ginkgetin induces autophagic cell death through p62/SQSTM1- mediated autolysosome formation and redox setting in nonsmall cell lung cancer</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>93131</fpage><lpage>93148</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.21862</pub-id><pub-id pub-id-type="pmid">29190983</pub-id></element-citation></ref><ref id="B183-pharmaceuticals-14-00157"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>Y.J.</given-names></name><name><surname>Jung</surname><given-names>S.N.</given-names></name><name><surname>Yun</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>C.W.</given-names></name><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>Y.J.</given-names></name><name><surname>Han</surname><given-names>D.C.</given-names></name><name><surname>Kwon</surname><given-names>B.M.</given-names></name></person-group><article-title>Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity</article-title><source>Cancer Sci.</source><year>2015</year><volume>106</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1111/cas.12608</pub-id><pub-id pub-id-type="pmid">25611086</pub-id></element-citation></ref><ref id="B184-pharmaceuticals-14-00157"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>Y.</given-names></name><name><surname>Woo</surname><given-names>S.H.</given-names></name><name><surname>Seo</surname><given-names>S.K.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Noh</surname><given-names>W.C.</given-names></name><name><surname>Lee</surname><given-names>J.K.</given-names></name><name><surname>Kwon</surname><given-names>B.M.</given-names></name><name><surname>Min</surname><given-names>K.N.</given-names></name><name><surname>Choe</surname><given-names>T.B.</given-names></name><name><surname>Park</surname><given-names>I.C.</given-names></name></person-group><article-title>Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor</article-title><source>Oncol. Lett.</source><year>2017</year><volume>14</volume><fpage>5027</fpage><lpage>5033</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.6742</pub-id><pub-id pub-id-type="pmid">29085516</pub-id></element-citation></ref><ref id="B185-pharmaceuticals-14-00157"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Xia</surname><given-names>Z.M.</given-names></name><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Rui</surname><given-names>W.J.</given-names></name><name><surname>Dong</surname><given-names>J.X.</given-names></name><name><surname>Xiao</surname><given-names>F.J.</given-names></name></person-group><article-title>Anticancer effects of five biflavonoids from ginkgo biloba l. Male flowers in vitro</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>1496</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24081496</pub-id></element-citation></ref><ref id="B186-pharmaceuticals-14-00157"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.S.</given-names></name><name><surname>Thakur</surname><given-names>K.</given-names></name><name><surname>Hussain</surname><given-names>S.S.</given-names></name><name><surname>Zhang</surname><given-names>J.G.</given-names></name><name><surname>Xiao</surname><given-names>G.R.</given-names></name><name><surname>Wei</surname><given-names>Z.J.</given-names></name></person-group><article-title>Licochalcone A from licorice root, an inhibitor of human hepatoma cell growth via induction of cell apoptosis and cell cycle arrest</article-title><source>Food Chem. Toxicol.</source><year>2018</year><volume>120</volume><fpage>407</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2018.07.044</pub-id><?supplied-pmid 30055311?><pub-id pub-id-type="pmid">30055311</pub-id></element-citation></ref><ref id="B187-pharmaceuticals-14-00157"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S.J.</given-names></name><name><surname>Cho</surname><given-names>I.A.</given-names></name><name><surname>Kang</surname><given-names>K.R.</given-names></name><name><surname>Jung</surname><given-names>Y.R.</given-names></name><name><surname>Cho</surname><given-names>S.S.</given-names></name><name><surname>Yoon</surname><given-names>G.</given-names></name><name><surname>Oh</surname><given-names>J.S.</given-names></name><name><surname>You</surname><given-names>J.S.</given-names></name><name><surname>Seo</surname><given-names>Y.S.</given-names></name><name><surname>Lee</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Licochalcone-E induces caspase-dependent death of human pharyngeal squamous carcinoma cells through the extrinsic and intrinsic apoptotic signaling pathways</article-title><source>Oncol. Lett.</source><year>2017</year><volume>13</volume><fpage>3662</fpage><lpage>3668</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.5865</pub-id><pub-id pub-id-type="pmid">28521469</pub-id></element-citation></ref><ref id="B188-pharmaceuticals-14-00157"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Preparative isolation of four new and two known flavonoids from the leaf of <italic>Patrinia villosa</italic> Juss. by counter-current chromatography and evaluation of their anticancer activities in vitro</article-title><source>J. Chromatogr. A</source><year>2006</year><volume>1115</volume><fpage>103</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.chroma.2006.02.079</pub-id><?supplied-pmid 16545824?><pub-id pub-id-type="pmid">16545824</pub-id></element-citation></ref><ref id="B189-pharmaceuticals-14-00157"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhury</surname><given-names>D.</given-names></name><name><surname>Ganguli</surname><given-names>A.</given-names></name><name><surname>Dastidar</surname><given-names>D.G.</given-names></name><name><surname>Acharya</surname><given-names>B.R.</given-names></name><name><surname>Das</surname><given-names>A.</given-names></name><name><surname>Chakrabarti</surname><given-names>G.</given-names></name></person-group><article-title>Apigenin shows synergistic anticancer activity with curcumin by binding at different sites of tubulin</article-title><source>Biochimie</source><year>2013</year><volume>95</volume><fpage>1297</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2013.02.010</pub-id><pub-id pub-id-type="pmid">23485682</pub-id></element-citation></ref><ref id="B190-pharmaceuticals-14-00157"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Dabbagh</surname><given-names>B.</given-names></name><name><surname>Elhaty</surname><given-names>I.A.</given-names></name><name><surname>Elhaw</surname><given-names>M.</given-names></name><name><surname>Murali</surname><given-names>C.</given-names></name><name><surname>Al Mansoori</surname><given-names>A.</given-names></name><name><surname>Awad</surname><given-names>B.</given-names></name><name><surname>Amin</surname><given-names>A.</given-names></name></person-group><article-title>Antioxidant and anticancer activities of chamomile (<italic>Matricaria recutita</italic> L.)</article-title><source>BMC Res. Notes</source><year>2019</year><volume>12</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.1186/s13104-018-3960-y</pub-id><?supplied-pmid 30602390?><pub-id pub-id-type="pmid">30602390</pub-id></element-citation></ref><ref id="B191-pharmaceuticals-14-00157"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>J.K.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name></person-group><article-title>Antiproliferative and apoptotic effects of chamomile extract in various human cancer cells</article-title><source>J. Agric. Food Chem.</source><year>2007</year><volume>55</volume><fpage>9470</fpage><lpage>9478</lpage><pub-id pub-id-type="doi">10.1021/jf071953k</pub-id><pub-id pub-id-type="pmid">17939735</pub-id></element-citation></ref><ref id="B192-pharmaceuticals-14-00157"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.L.</given-names></name><name><surname>Wang</surname><given-names>C.Z.</given-names></name><name><surname>Mehendale</surname><given-names>S.R.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Yuan</surname><given-names>C.S.</given-names></name></person-group><article-title>Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells</article-title><source>Cancer Chemother. Pharmacol.</source><year>2009</year><volume>64</volume><fpage>1097</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1007/s00280-009-0966-0</pub-id><pub-id pub-id-type="pmid">19277659</pub-id></element-citation></ref><ref id="B193-pharmaceuticals-14-00157"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Duan</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>Anticancer effects of ginsenoside Rg3 (Review)</article-title><source>Int. J. Mol. Med.</source><year>2017</year><volume>39</volume><fpage>507</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2017.2857</pub-id><?supplied-pmid 28098857?><pub-id pub-id-type="pmid">28098857</pub-id></element-citation></ref><ref id="B194-pharmaceuticals-14-00157"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>M.</given-names></name><name><surname>Reddy</surname><given-names>P.</given-names></name><name><surname>Rawat</surname><given-names>D.</given-names></name></person-group><article-title>Noscapine and its analogues as anti- cancer agents</article-title><source>Chem. Biol. Interface</source><year>2014</year><volume>4</volume><fpage>1</fpage><lpage>22</lpage></element-citation></ref><ref id="B195-pharmaceuticals-14-00157"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falodun</surname><given-names>A.</given-names></name><name><surname>Engel</surname><given-names>N.</given-names></name><name><surname>Kragl</surname><given-names>U.</given-names></name><name><surname>Nebe</surname><given-names>B.</given-names></name><name><surname>Langer</surname><given-names>P.</given-names></name></person-group><article-title>Novel anticancer alkene lactone from Persea americana</article-title><source>Pharm. Biol.</source><year>2013</year><volume>51</volume><fpage>700</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.3109/13880209.2013.764326</pub-id><?supplied-pmid 23570517?><pub-id pub-id-type="pmid">23570517</pub-id></element-citation></ref><ref id="B196-pharmaceuticals-14-00157"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>C.X.</given-names></name><name><surname>Zuo</surname><given-names>Z.L.</given-names></name><name><surname>Xiong</surname><given-names>B.</given-names></name><name><surname>Ma</surname><given-names>J.G.</given-names></name><name><surname>Geng</surname><given-names>M.Y.</given-names></name><name><surname>Lin</surname><given-names>L.P.</given-names></name><name><surname>Jiang</surname><given-names>H.L.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name></person-group><article-title>Salvicine functions as novel topoisomerase II poison by binding to ATP pocket</article-title><source>Mol. Pharmacol.</source><year>2006</year><volume>70</volume><fpage>1593</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1124/mol.106.027714</pub-id><?supplied-pmid 16914642?><pub-id pub-id-type="pmid">16914642</pub-id></element-citation></ref><ref id="B197-pharmaceuticals-14-00157"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>L.H.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name></person-group><article-title>Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation</article-title><source>Acta Pharmacol. Sin.</source><year>2007</year><volume>28</volume><fpage>1460</fpage><lpage>1465</lpage><pub-id pub-id-type="doi">10.1111/j.1745-7254.2007.00698.x</pub-id><pub-id pub-id-type="pmid">17723179</pub-id></element-citation></ref><ref id="B198-pharmaceuticals-14-00157"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>F.</given-names></name><name><surname>Lu</surname><given-names>J.J.</given-names></name><name><surname>Liu</surname><given-names>H.Y.</given-names></name><name><surname>Lin</surname><given-names>L.P.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.S.</given-names></name></person-group><article-title>Synthesis and antitumor activity of novel salvicine analogues</article-title><source>Chinese Chem. Lett.</source><year>2011</year><volume>22</volume><fpage>25</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.cclet.2010.07.009</pub-id></element-citation></ref><ref id="B199-pharmaceuticals-14-00157"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.F.</given-names></name><name><surname>Klauck</surname><given-names>S.M.</given-names></name><name><surname>Efferth</surname><given-names>T.</given-names></name></person-group><article-title>Anticancer activity of cryptotanshinone on acute lymphoblastic leukemia cells</article-title><source>Arch. Toxicol.</source><year>2016</year><volume>90</volume><fpage>2275</fpage><lpage>2286</lpage><pub-id pub-id-type="doi">10.1007/s00204-015-1616-4</pub-id><pub-id pub-id-type="pmid">26564229</pub-id></element-citation></ref><ref id="B200-pharmaceuticals-14-00157"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>H.J.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.S.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo</article-title><source>Mol. Med. Rep.</source><year>2014</year><volume>9</volume><fpage>2447</fpage><lpage>2452</lpage><pub-id pub-id-type="doi">10.3892/mmr.2014.2093</pub-id><?supplied-pmid 24682389?><pub-id pub-id-type="pmid">24682389</pub-id></element-citation></ref><ref id="B201-pharmaceuticals-14-00157"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Hong</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name></person-group><article-title>Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling</article-title><source>Cancer Biol. Ther.</source><year>2015</year><volume>16</volume><fpage>176</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.4161/15384047.2014.962960</pub-id><pub-id pub-id-type="pmid">25482936</pub-id></element-citation></ref><ref id="B202-pharmaceuticals-14-00157"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>T.</given-names></name><name><surname>Rasul</surname><given-names>A.</given-names></name><name><surname>Sarfraz</surname><given-names>A.</given-names></name><name><surname>Sarfraz</surname><given-names>I.</given-names></name><name><surname>Hussain</surname><given-names>G.</given-names></name><name><surname>Anwar</surname><given-names>H.</given-names></name><name><surname>Riaz</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Wei</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Salvianolic acid A &#x00026; B: Potential cytotoxic polyphenols in battle against cancer via targeting multiple signaling pathways</article-title><source>Int. J. Biol. Sci.</source><year>2019</year><volume>15</volume><fpage>2256</fpage><lpage>2264</lpage><pub-id pub-id-type="pmid">31592132</pub-id></element-citation></ref><ref id="B203-pharmaceuticals-14-00157"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deep</surname><given-names>G.</given-names></name><name><surname>Oberlies</surname><given-names>N.H.</given-names></name><name><surname>Kroll</surname><given-names>D.J.</given-names></name><name><surname>Agarwal</surname><given-names>R.</given-names></name></person-group><article-title>Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells</article-title><source>Carcinogenesis</source><year>2007</year><volume>28</volume><fpage>1533</fpage><lpage>1542</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgm069</pub-id><?supplied-pmid 17389612?><pub-id pub-id-type="pmid">17389612</pub-id></element-citation></ref><ref id="B204-pharmaceuticals-14-00157"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhanalakshmi</surname><given-names>S.</given-names></name><name><surname>Agarwal</surname><given-names>C.</given-names></name><name><surname>Singh</surname><given-names>R.P.</given-names></name><name><surname>Agarwal</surname><given-names>R.</given-names></name></person-group><article-title>Silibinin up-regulates DNA-protein kinase-dependent p53 activation to enhance UVB-induced apoptosis in mouse epithelial JB6 cells</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>20375</fpage><lpage>20383</lpage><pub-id pub-id-type="doi">10.1074/jbc.M414640200</pub-id><pub-id pub-id-type="pmid">15792956</pub-id></element-citation></ref><ref id="B205-pharmaceuticals-14-00157"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scambia</surname><given-names>G.</given-names></name><name><surname>De Vincenzo</surname><given-names>R.</given-names></name><name><surname>Ranelletti</surname><given-names>F.O.</given-names></name><name><surname>Panici</surname><given-names>P.B.</given-names></name><name><surname>Ferrandina</surname><given-names>G.</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>G.</given-names></name><name><surname>Fattorossi</surname><given-names>A.</given-names></name><name><surname>Bombardelli</surname><given-names>E.</given-names></name><name><surname>Mancuso</surname><given-names>S.</given-names></name></person-group><article-title>Antiproliferative effect of silybin on gynaecological malignancies: Synergism with cisplatin and doxorubicin</article-title><source>Eur. J. Cancer</source><year>1996</year><volume>32</volume><fpage>877</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1016/0959-8049(96)00011-1</pub-id></element-citation></ref><ref id="B206-pharmaceuticals-14-00157"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramasamy</surname><given-names>K.</given-names></name><name><surname>Agarwal</surname><given-names>R.</given-names></name></person-group><article-title>Multitargeted therapy of cancer by silymarin</article-title><source>Cancer Lett.</source><year>2008</year><volume>269</volume><fpage>352</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.03.053</pub-id><?supplied-pmid 18472213?><pub-id pub-id-type="pmid">18472213</pub-id></element-citation></ref><ref id="B207-pharmaceuticals-14-00157"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zi</surname><given-names>X.</given-names></name><name><surname>Feyes</surname><given-names>D.K.</given-names></name><name><surname>Agarwal</surname><given-names>R.</given-names></name></person-group><article-title>Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: Induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins</article-title><source>Clin. Cancer Res.</source><year>1998</year><volume>4</volume><fpage>1055</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">9563902</pub-id></element-citation></ref><ref id="B208-pharmaceuticals-14-00157"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shukla</surname><given-names>Y.</given-names></name><name><surname>Singh</surname><given-names>M.</given-names></name></person-group><article-title>Cancer preventive properties of ginger: A brief review</article-title><source>Food Chem. Toxicol.</source><year>2007</year><volume>45</volume><fpage>683</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2006.11.002</pub-id><pub-id pub-id-type="pmid">17175086</pub-id></element-citation></ref><ref id="B209-pharmaceuticals-14-00157"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Abbasi</surname><given-names>F.A.</given-names></name><name><surname>Alghamdi</surname><given-names>E.A.</given-names></name><name><surname>Baghdadi</surname><given-names>M.A.</given-names></name><name><surname>Alamoudi</surname><given-names>A.J.</given-names></name><name><surname>El-Halawany</surname><given-names>A.M.</given-names></name><name><surname>El-Bassossy</surname><given-names>H.M.</given-names></name><name><surname>Aseeri</surname><given-names>A.H.</given-names></name><name><surname>Al-Abd</surname><given-names>A.M.</given-names></name></person-group><article-title>Gingerol synergizes the cytotoxic effects of doxorubicin against liver cancer cells and protects from its vascular toxicity</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>886</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21070886</pub-id></element-citation></ref><ref id="B210-pharmaceuticals-14-00157"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Warin</surname><given-names>R.F.</given-names></name><name><surname>Soroka</surname><given-names>D.N.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Sang</surname><given-names>S.</given-names></name></person-group><article-title>Metabolites of Ginger Component [6]-Shogaol Remain Bioactive in Cancer Cells and Have Low Toxicity in Normal Cells: Chemical Synthesis and Biological Evaluation</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>54677</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0054677</pub-id><?supplied-pmid 23382939?><pub-id pub-id-type="pmid">23382939</pub-id></element-citation></ref><ref id="B211-pharmaceuticals-14-00157"><label>211.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jafri</surname><given-names>A.</given-names></name><name><surname>Amjad</surname><given-names>S.</given-names></name><name><surname>Bano</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Serajuddin</surname><given-names>M.</given-names></name><name><surname>Arshad</surname><given-names>M.</given-names></name></person-group><article-title>Efficacy of Nano-phytochemicals Over Pure Phytochemicals Against Various Cancers: Current Trends and Future Prospects</article-title><source>Nanomaterials and Environmental Biotechnology</source><person-group person-group-type="editor"><name><surname>Bhushan</surname><given-names>I.</given-names></name><name><surname>Singh</surname><given-names>V.K.</given-names></name><name><surname>Tripathi</surname><given-names>D.K.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2020</year><fpage>407</fpage><lpage>424</lpage></element-citation></ref><ref id="B212-pharmaceuticals-14-00157"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>V.K.</given-names></name><name><surname>Arora</surname><given-names>D.</given-names></name><name><surname>Ansari</surname><given-names>M.I.</given-names></name><name><surname>Sharma</surname><given-names>P.K.</given-names></name></person-group><article-title>Phytochemicals based chemopreventive and chemotherapeutic strategies and modern technologies to overcome limitations for better clinical applications</article-title><source>Phyther. Res.</source><year>2019</year><volume>33</volume><fpage>3064</fpage><lpage>3089</lpage><pub-id pub-id-type="doi">10.1002/ptr.6508</pub-id></element-citation></ref><ref id="B213-pharmaceuticals-14-00157"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Koay</surname><given-names>E.J.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Wen</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name></person-group><article-title>A hindsight reflection on the clinical studies of poly(l-glutamic acid)-paclitaxel</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2018</year><volume>10</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1002/wnan.1497</pub-id></element-citation></ref><ref id="B214-pharmaceuticals-14-00157"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagoa</surname><given-names>R.</given-names></name><name><surname>Silva</surname><given-names>J.</given-names></name><name><surname>Rui</surname><given-names>J.</given-names></name><name><surname>Bishayee</surname><given-names>A.</given-names></name></person-group><article-title>Advances in phytochemical delivery systems for improved anticancer activity</article-title><source>Biotechnol. Adv.</source><year>2020</year><volume>38</volume><fpage>107382</fpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2019.04.004</pub-id><?supplied-pmid 30978386?><pub-id pub-id-type="pmid">30978386</pub-id></element-citation></ref><ref id="B215-pharmaceuticals-14-00157"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manjili</surname><given-names>H.K.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Tavaddod</surname><given-names>S.</given-names></name><name><surname>Mashhadikhan</surname><given-names>M.</given-names></name></person-group><article-title>D, L-Sulforaphane Loaded Fe3O4@ Gold Core Shell Nanoparticles: A Potential Sulforaphane Delivery System</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0151344</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0151344</pub-id><pub-id pub-id-type="pmid">26982588</pub-id></element-citation></ref><ref id="B216-pharmaceuticals-14-00157"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Dutta</surname><given-names>S.</given-names></name><name><surname>Sarkar</surname><given-names>A.</given-names></name><name><surname>Kundu</surname><given-names>M.</given-names></name><name><surname>Sil</surname><given-names>P.C.</given-names></name></person-group><article-title>Targeted delivery of curcumin in breast cancer cells via hyaluronic acid modified mesoporous silica nanoparticle to enhance anticancer efficiency</article-title><source>Colloids Surf. B Biointerfaces</source><year>2021</year><volume>197</volume><fpage>111404</fpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.111404</pub-id><pub-id pub-id-type="pmid">33142257</pub-id></element-citation></ref><ref id="B217-pharmaceuticals-14-00157"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Seto</surname><given-names>S.W.</given-names></name><name><surname>Chang</surname><given-names>D.</given-names></name><name><surname>Kiat</surname><given-names>H.</given-names></name><name><surname>Razmovski-Naumovski</surname><given-names>V.</given-names></name><name><surname>Chan</surname><given-names>K.</given-names></name><name><surname>Bensoussan</surname><given-names>A.</given-names></name></person-group><article-title>Synergistic effects of Chinese herbal medicine: A comprehensive review of methodology and current research</article-title><source>Front. Pharmacol.</source><year>2016</year><volume>7</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.3389/fphar.2016.00201</pub-id><pub-id pub-id-type="pmid">26858644</pub-id></element-citation></ref><ref id="B218-pharmaceuticals-14-00157"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>B.</given-names></name><name><surname>Kanwar</surname><given-names>S.S.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name></person-group><article-title>Lead phytochemicals for anticancer drug development</article-title><source>Front. Plant Sci.</source><year>2016</year><volume>7</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.3389/fpls.2016.01667</pub-id><pub-id pub-id-type="pmid">26858731</pub-id></element-citation></ref><ref id="B219-pharmaceuticals-14-00157"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Radacsi</surname><given-names>N.</given-names></name></person-group><article-title>New tricks of old drugs: Repurposing non-chemo drugs and dietary phytochemicals as adjuvants in anti-tumor therapies</article-title><source>J. Control. Release</source><year>2021</year><volume>329</volume><fpage>96</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.11.047</pub-id><pub-id pub-id-type="pmid">33259852</pub-id></element-citation></ref><ref id="B220-pharmaceuticals-14-00157"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aung</surname><given-names>T.N.</given-names></name><name><surname>Qu</surname><given-names>Z.</given-names></name><name><surname>Kortschak</surname><given-names>R.D.</given-names></name><name><surname>Adelson</surname><given-names>D.L.</given-names></name></person-group><article-title>Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>656</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18030656</pub-id><?supplied-pmid 28304343?><pub-id pub-id-type="pmid">28304343</pub-id></element-citation></ref><ref id="B221-pharmaceuticals-14-00157"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X.Q.</given-names></name><name><surname>Bi</surname><given-names>H.</given-names></name><name><surname>Feng</surname><given-names>J.Q.</given-names></name><name><surname>Cao</surname><given-names>J.G.</given-names></name></person-group><article-title>Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR</article-title><source>Acta Pharmacol. Sin.</source><year>2005</year><volume>26</volume><fpage>1009</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1111/j.1745-7254.2005.00149.x</pub-id><pub-id pub-id-type="pmid">16038636</pub-id></element-citation></ref><ref id="B222-pharmaceuticals-14-00157"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganta</surname><given-names>S.</given-names></name><name><surname>Amiji</surname><given-names>M.</given-names></name></person-group><article-title>Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells</article-title><source>Mol. Pharm.</source><year>2009</year><volume>6</volume><fpage>928</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1021/mp800240j</pub-id><pub-id pub-id-type="pmid">19278222</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceuticals-14-00157-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Main causes involved in the development of cancer, according to WHO.</p></caption><graphic xlink:href="pharmaceuticals-14-00157-g001"/></fig><fig id="pharmaceuticals-14-00157-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Schematic process for the development of anticancer drugs based on plant-derived compounds.</p></caption><graphic xlink:href="pharmaceuticals-14-00157-g002"/></fig><fig id="pharmaceuticals-14-00157-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Main mechanisms of phytochemical compounds employed in cancer therapy.</p></caption><graphic xlink:href="pharmaceuticals-14-00157-g003"/></fig><table-wrap id="pharmaceuticals-14-00157-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00157-t001_Table 1</object-id><label>Table 1</label><caption><p>Anticancer compounds employed in clinical treatment of cancer [<xref rid="B41-pharmaceuticals-14-00157" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceuticals-14-00157" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-14-00157" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceuticals-14-00157" ref-type="bibr">44</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compounds</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source-Extraction</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Development</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Commercial Name</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vinca alkaloids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Catharanthus roseu</italic> (Leaves)<break/>Isolated by semi-synthetic routes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit the tubulin polymerization of tumor cells and also cause mitotic spindle destruction</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical use; combination trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vinorelbine, Vincristine, Vinblastine, Vindesine, Vinflunine, Vincamine, Vintafolide</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paclitaxel, docetaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Taxus</italic> spp. (Bark)<break/>Synthesis, semi-synthesis, and plant cell culture</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stabilization of microtubules and inhibition of depolymerization into tubulin, which stops the cell cycle in the G2/M phase leading to cell death</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In clinical use; Phase I-III clinical trials; early treatment settings; non-small lung cancer, breast cancer, ovarian cancer, Kaposi sarcoma. Research and development in alternative drug administration using nanoparticles, naocochealtes and nanoliposomes.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Taxol<sup>&#x000ae;</sup>, Taxotere<sup>&#x000ae;</sup>, Abraxane<sup>&#x000ae;</sup>, Jevtana<sup>&#x000ae;</sup>, Taxoprexin<sup>&#x000ae;</sup>, Xytotax<sup>&#x000ae;</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Camptotecin, irinotecan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Camptotheca acuminata</italic><break/>(leaves)<break/>Water extraction</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Binding to the TOP1 cleavage complex, leading to an accumulation of DNA strand breaks upon replication, causing apoptosis during the S phase of the cell cycle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian, lung, colorectal and pediatric cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topotecan, irinotecan, belotecan</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Podophyllotoxin and analogues</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Podophyllum</italic> spp.<break/>(rhizome, roots)<break/>Alcohol extraction</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blockage of cell division metaphase of mitosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphomas and testicular cancer trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No rentable</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roscovitine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Raphanus sativus</italic> (Radish)<break/>Chloroform extraction</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of cyclin dependent kinases; reduction of cell cycle progression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II clinical trials in Europe</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Roscovitine, seliciclib</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceuticals-14-00157-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00157-t002_Table 2</object-id><label>Table 2</label><caption><p>Examples of clinical trials carried out with the selected phytochemical compounds.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Cancer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Results</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sulforaphane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction of prostate-specific antigen after prostatectomy/Lengthening of the on-treatment prostate-specific antigen doubling time. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-pharmaceuticals-14-00157" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceuticals-14-00157" ref-type="bibr">76</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved efficacy of doxorubicin, without any cytotoxic effect.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-pharmaceuticals-14-00157" ref-type="bibr">77</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Resveratrol</td><td align="center" valign="middle" rowspan="1" colspan="1">Colorectal</td><td align="center" valign="middle" rowspan="1" colspan="1">Induction of apoptosis in malignant cells in hepatic metastasis.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B78-pharmaceuticals-14-00157" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" rowspan="1" colspan="1">Reduction of DNA methylation of RASSF-1&#x003b1; and prostaglandin E2 expression.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B79-pharmaceuticals-14-00157" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prostate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction of cancer recurrence.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-pharmaceuticals-14-00157" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceuticals-14-00157" ref-type="bibr">81</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Curcumin</td><td align="center" valign="middle" rowspan="1" colspan="1">Pancreas</td><td align="center" valign="middle" rowspan="1" colspan="1">Improved efficacy of gemcitabine, without any cytotoxic effect.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B82-pharmaceuticals-14-00157" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved efficacy of paclitaxel, without any cytotoxic effect.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-pharmaceuticals-14-00157" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastric</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High dietary intake is inversely related to the risk of cancer development.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-pharmaceuticals-14-00157" ref-type="bibr">84</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Gingerol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorectal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction of the risk of cancer development.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-pharmaceuticals-14-00157" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid tumor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced antioxidant status of patients receiving chemotherapy/Improvement of general quality of cancer patients receiving chemotherapy. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-pharmaceuticals-14-00157" ref-type="bibr">86</xref>,<xref rid="B87-pharmaceuticals-14-00157" ref-type="bibr">87</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kaempferol</td><td align="center" valign="middle" rowspan="1" colspan="1">Ovarian</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduction of the risk of cancer development.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B88-pharmaceuticals-14-00157" ref-type="bibr">88</xref>,<xref rid="B89-pharmaceuticals-14-00157" ref-type="bibr">89</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancreatic</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceuticals-14-00157-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00157-t003_Table 3</object-id><label>Table 3</label><caption><p>Anticancer compounds obtained from plants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Plant</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Structure</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results (IC<sub>50</sub> &#x000b5;M)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Aloe vera</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emodin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i001.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast (8.6); Lung (19.6); Liver (12.8) <break/>Induction of apoptosis, specific energy-dependent pathway of drug incorporation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B157-pharmaceuticals-14-00157" ref-type="bibr">157</xref>,<xref rid="B158-pharmaceuticals-14-00157" ref-type="bibr">158</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic>Artemisia annua</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Artemisinin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i002.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Lung (0.9)<break/>Production of reactive oxygen species, inhibition of cell cycle in G0/G1 phase, induction of apoptosis, inhibition of angiogenesis.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B159-pharmaceuticals-14-00157" ref-type="bibr">159</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artesunate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i003.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast (2.3); colon (1.9); lung (9.8); leukemia (2); ovarian (15.0)<break/>Antiangiogenic effect; inhibition of VEGF expression.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B160-pharmaceuticals-14-00157" ref-type="bibr">160</xref>,<xref rid="B161-pharmaceuticals-14-00157" ref-type="bibr">161</xref>,<xref rid="B162-pharmaceuticals-14-00157" ref-type="bibr">162</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Betula</italic> sp.</td><td align="center" valign="middle" rowspan="1" colspan="1">Betulinic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i004.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Human leukemia (2.6); murine leukemia (2.1); cervix (2.5); colon (10.0); lung (4.3); skin (8.0); gastric (13.0) <italic>In vivo:</italic> (mice): Breast (13.5)<break/>Activation of extrinsic apoptosis pathway via up regulation of DR4, DR5 and PARP cleavage.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B163-pharmaceuticals-14-00157" ref-type="bibr">163</xref>,<xref rid="B164-pharmaceuticals-14-00157" ref-type="bibr">164</xref>,<xref rid="B165-pharmaceuticals-14-00157" ref-type="bibr">165</xref>,<xref rid="B166-pharmaceuticals-14-00157" ref-type="bibr">166</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Betulin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i005.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast (30.7); colon (45.2); lung (45.2); leukemia (14.5); skin (6.8); prostate (17.9)<break/>Synergistic effect with chemotherapeutic drugs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B167-pharmaceuticals-14-00157" ref-type="bibr">167</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Berberis vulgaris</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Berberine</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i006.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Breast (25)/In vivo: Breast (25.0); colon (25.0)<break/>Induction of cell cycle arrest, synergistic effect with drugs/Reduction of tumor volume and angiogensis in a dose-dependent manner.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B168-pharmaceuticals-14-00157" ref-type="bibr">168</xref>,<xref rid="B169-pharmaceuticals-14-00157" ref-type="bibr">169</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
<italic>Camellia sinensis</italic>
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Epicatechin gallate</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i007.jpg"/>
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">In vitro: Breast (350.0); colon (1000); lung (78.0)<break/>Induce apoptosis of cancer cell lines.</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[<xref rid="B170-pharmaceuticals-14-00157" ref-type="bibr">170</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Epicatechin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i008.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Colon (60); prostate (8.9); ovarian (7.9)<break/>Growth inhibition.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B171-pharmaceuticals-14-00157" ref-type="bibr">171</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epigallocatechin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i009.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast (22.0); colon (75.0); lung (70.0)<break/>Growth inhibition.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B172-pharmaceuticals-14-00157" ref-type="bibr">172</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Combretum caffrum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combretastatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i010.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo (mice): Breast (80-190); colon (8.4;) lung (7.1); leukemia (1.9)<break/>&#x003b2;-tubulin binding, causing the destabilization of the microtubules.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B161-pharmaceuticals-14-00157" ref-type="bibr">161</xref>,<xref rid="B173-pharmaceuticals-14-00157" ref-type="bibr">173</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic>Crocus sativus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Crocetin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i011.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Colon (0.2); lung (0.4); liver (0.6)<break/>Activation of Nrf2, reduction of lactate dehydrogenase A expression.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B174-pharmaceuticals-14-00157" ref-type="bibr">174</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Crocin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i012.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of cancer cells&#x02019; proliferation or/and induction of apoptosis, both in vitro and in vivo studies.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B174-pharmaceuticals-14-00157" ref-type="bibr">174</xref>,<xref rid="B175-pharmaceuticals-14-00157" ref-type="bibr">175</xref>,<xref rid="B176-pharmaceuticals-14-00157" ref-type="bibr">176</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safranal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i013.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Colon (20.0)<break/>Apoptosis and G2/M cell cycle arrest mediated by suppression of mTOR/PI3K/Akt pathway.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B177-pharmaceuticals-14-00157" ref-type="bibr">177</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Euphorbia peplus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ingenol mebutate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i014.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast (23.9); colon (22.2); lung (15.2); skin (200.0); prostate (29.8)<break/>Necrotic mechanism.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B178-pharmaceuticals-14-00157" ref-type="bibr">178</xref>,<xref rid="B179-pharmaceuticals-14-00157" ref-type="bibr">179</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic>Gardenia jasminoides</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Geniposide</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i015.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Lung (351.5); medullobalstome (293.5)<break/>Activation of mitochondrial execution pathway by Caspase-9 and -3; increase levels of Bax in response to p38MAPK signaling initiation of the mitochondrial death cascade.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B161-pharmaceuticals-14-00157" ref-type="bibr">161</xref>,<xref rid="B180-pharmaceuticals-14-00157" ref-type="bibr">180</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genipin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i016.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibitor of mitochondrial uncoupling protein 2, induction caspase-dependent apoptosis in vitro and in in vivo models. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B181-pharmaceuticals-14-00157" ref-type="bibr">181</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic>Ginkgo biloba</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Ginkgetin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i017.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vivo (mouse): Breast 10.0; colon 5.0; lung 10.0; prostate 5.0<break/>p62/SQSTM1-mediated autolysosome formation and redox setting; inhibition of signal transducer and activator of transcription 3 activity.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B182-pharmaceuticals-14-00157" ref-type="bibr">182</xref>,<xref rid="B183-pharmaceuticals-14-00157" ref-type="bibr">183</xref>,<xref rid="B184-pharmaceuticals-14-00157" ref-type="bibr">184</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bilobetin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i018.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Breast 57.6; lung 36.4; leukemia 46.0<break/>Arresting the G2/M phase of the cell cycle.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B185-pharmaceuticals-14-00157" ref-type="bibr">185</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isoginkgetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i019.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast 91.2; lung 43.0; skin 18.8<break/>Arresting the G2/M phase of the cell cycle.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B185-pharmaceuticals-14-00157" ref-type="bibr">185</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic>Glycyrrhiza glabra</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Licochalcone</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i020.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Lung (30.0); skin (50.0); liver (44.13); gastric (42)<break/>Increased mRNA expression of DR3, DR5, caspases-3, caspases-8, caspases-10, Fas, Bad, Bax, Bcl-2, Bak, and PUMA; decreased level of PKC&#x003b5;, p70S6K, Akt.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B186-pharmaceuticals-14-00157" ref-type="bibr">186</xref>,<xref rid="B187-pharmaceuticals-14-00157" ref-type="bibr">187</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Licoagrochalcone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i021.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast (28.6;) colon (25.4); leukemia (12.2); kidney (35.21)<break/>Induction of apoptosis, inhibition of proliferation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B188-pharmaceuticals-14-00157" ref-type="bibr">188</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic>Matricaria chamomilla</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Apigenin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i022.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Breast (100;) lung (93.7); liver (38.9)<break/>Up-regulation of DR5 pathway.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B189-pharmaceuticals-14-00157" ref-type="bibr">189</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chamomillol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i023.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast (300.0); colon (165.0); prostate (200.0); liver (300.0)<break/>Regulation angiogenesis by down regulating expression proteins.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B190-pharmaceuticals-14-00157" ref-type="bibr">190</xref>,<xref rid="B191-pharmaceuticals-14-00157" ref-type="bibr">191</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic>Panax ginseng</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Panaxadiol</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i024.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Colon (25.0); liver (1.2)<break/>Regulation of cell cycle transition and the induction of apoptotic cells.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B192-pharmaceuticals-14-00157" ref-type="bibr">192</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ginsenoside</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i025.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast (30.0); colon (100.0); lung (50.0); skin (25&#x02013;100)<break/>Induction of apoptosis, inhibition of proliferation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B193-pharmaceuticals-14-00157" ref-type="bibr">193</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Papaver somniferum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Noscapine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i026.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo (mice): Breast (45.0); lung (73.0); leukemia (20.0); pancreas (70.0)<break/>Activating multiple signaling pathways including apoptosis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B194-pharmaceuticals-14-00157" ref-type="bibr">194</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Persea americana</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Borbonol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i027.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast (20.5)<break/>Inhibition of proliferation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B195-pharmaceuticals-14-00157" ref-type="bibr">195</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic>Salvia prionitis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Salvicine</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i028.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Breast (1.4); leukemia (3.6); stomach (1.8)<break/>Breaks two strands of DNA by facilitating TOP2 activity; inhibits re-ligation</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B196-pharmaceuticals-14-00157" ref-type="bibr">196</xref>,<xref rid="B197-pharmaceuticals-14-00157" ref-type="bibr">197</xref>,<xref rid="B198-pharmaceuticals-14-00157" ref-type="bibr">198</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cryptotanshinone</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i029.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vivo (mice): Breast (1.1;) lung (20.0); leukemia (4.8)<break/>Multispecific modes of actions: G2/M arrest, apoptosis, inhibition of cellular movement. Inhibition of NF&#x003ba;B orchestrates all these mechanisms.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B199-pharmaceuticals-14-00157" ref-type="bibr">199</xref>,<xref rid="B200-pharmaceuticals-14-00157" ref-type="bibr">200</xref>,<xref rid="B201-pharmaceuticals-14-00157" ref-type="bibr">201</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Salvianolic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i030.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro studies.<break/>Prompting apoptosis, disturbance of cell cycle and adjourning metastasis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B202-pharmaceuticals-14-00157" ref-type="bibr">202</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic>Silybum marianum</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Silibinin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i031.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Breast (24.0); skin (100.0); prostate (55.6); ovarian (25.0)<break/>Induction of apoptosis and cell cycle arrest. </td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B203-pharmaceuticals-14-00157" ref-type="bibr">203</xref>,<xref rid="B204-pharmaceuticals-14-00157" ref-type="bibr">204</xref>,<xref rid="B205-pharmaceuticals-14-00157" ref-type="bibr">205</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silymarin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i032.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast (75); prostate (67.9)<break/>Interference with expressions of cell cycle regulators and proteins involved in apoptosis; induction of cell cycle arrest.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B203-pharmaceuticals-14-00157" ref-type="bibr">203</xref>,<xref rid="B206-pharmaceuticals-14-00157" ref-type="bibr">206</xref>,<xref rid="B207-pharmaceuticals-14-00157" ref-type="bibr">207</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic>Zingiber officinale</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Paradol</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i033.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">In vitro: Breast (20.4;) colon (10.4); leukemia (100); liver (&#x0003e;100).<break/>Reduction of cell viability.</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B208-pharmaceuticals-14-00157" ref-type="bibr">208</xref>,<xref rid="B209-pharmaceuticals-14-00157" ref-type="bibr">209</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shogaol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-14-00157-i034.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro: Breast (24.4); colon (3.1); lung (25.8); liver (18.7)<break/>Inhibitory activity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B209-pharmaceuticals-14-00157" ref-type="bibr">209</xref>,<xref rid="B210-pharmaceuticals-14-00157" ref-type="bibr">210</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>